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ABSTRACT 
 
LET -7 MIRNAS PROGRAM THE FATE OF CD8 T CELLS 
 
MAY 2019 
 
ALEXANDRIA WELLS, B.A., NEW COLLEGE OF FLORIDA 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Dr. Leonid A. Pobezinsky 
 
CD8 T cells are the cytotoxic effectors of the adaptive immune response, clearing 
virally infected and cancerous cells within the host. CD8 T cells acquire their cytotoxic 
function by differentiating into cytotoxic T lymphocytes (CTLs). Once the CTLs have 
cleared the antigen, the majority of responding cells will die during contraction; however, 
a small population of the antigen-specific responders will remain, differentiating into long-
lived memory cells that provide potent protection to the host upon re-encounter with the 
antigen. These differentiation programs often become disturbed in cases of chronic 
infection and cancer. Instead, CD8 T cells are subverted into the so-called exhausted state, 
in which cells become functionally inert. As such, the ability to program the differentiation 
of CD8 T cells into a particular fate is an important therapeutic strategy. We have identified 
a global post-transcriptional mechanism that determines the fate of differentiating CD8 T 
cells. Specifically, we have found that the let-7 family of miRNAs is abundantly expressed 
in naïve CD8 T cells, and that this expression is downregulated upon T cell receptor 
signaling. The expression of let-7 in naïve CD8 T cells was demonstrated to be necessary 
and sufficient to maintain the quiescent state of naïve cells. Accordingly, the down-
regulation of let-7 is necessary for the differentiation of naïve CD8 T cells into cytotoxic 
T lymphocytes in vitro. However, let-7 expression had paradoxical effects on CD8 T cell 
 viii 
 
function in vitro and in vivo. Specifically, loss of let-7 expression drives the differentiation 
of terminal effector CD8 T cells, which in immunosuppressive environments in vivo, are 
diverted into the exhausted state. Accordingly, maintaining let-7 expression restrained 
terminal effector differentiation, and programmed CD8 T cells to differentiate into highly 
protective memory cells. These findings may have important implications for the 
improvement of current immunotherapies targeting CD8 T cell fate.   
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 1 
CHAPTER 1 
INTRODUCTION 
 
1.1 The immune system 
 The immune system protects the body against infection and cancer. In vertebrates, 
there are two branches of the immune system that mediate such responses: the innate 
immune system, and the adaptive immune system. The innate immune system is a relic of 
evolution from lower organisms and cells of this branch rely on the expression of germline-
encoded receptors to recognize conserved molecular patterns associated with multiple 
pathogens. Cells of the innate immune system respond within minutes of pathogen 
detection, and contribute to inflammatory responses by producing chemokines and 
cytokines, and help eliminate pathogens by phagocytosis. Although innate immune 
responses are essential for the early control of pathogens, the specificity, magnitude, and 
duration of these responses is limited. On the other hand, the adaptive immune system 
mounts highly specific, and robust responses that yield lifelong protection to the host 
(Figure 1.1) (Punt et al., 2019). In fact, the innate immune system is critical in ‘alarming’ 
the adaptive immune system to the presence of pathogen to ensure effective clearance of 
the pathogen. Adaptive immune responses are mediated by B and T cells. B cells mature 
in the bone marrow, and mediate humoral immunity through the production of antibodies. 
T cells, following maturation in the thymus, aid in pathogen elimination. The function of 
mature T cells is determined in part by their expression of either the CD4 or CD8 
coreceptor. An important function of CD4 T cells is to provide help in the form of cytokine 
production which contributes to the activation and differentiation of CD8 T cells (Murphy 
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et al., 2017). CD8 T cells are responsible for the rapid clearance of virally infected and 
cancerous cells, and store immunological ‘memory’ of these encounters to provide lifelong 
immunity to the organism. Prior to antigen exposure during such challenges, CD8 T cells 
are naïve, and lack effector function. Thus, successful protection relies on the appropriate 
activation and differentiation of CD8 T cells. 
 
1.2 CD8 T cell differentiation  
1.2.1 Naive CD8 T cells must be activated to exit the quiescent state 
 Upon egress from the thymus into secondary lymphoid organs, CD8 T cells are 
mature, but naïve. Naïve CD8 T cells are maintained in a quiescent state that is 
characterized by very low rates of proliferation, a ‘quiet’ transcriptional landscape, with no 
expression of effector molecules, and consequently no cytotoxic function (Surh and Sprent, 
2008). Accordingly, these cells have very low metabolic demands, and energy is generated 
primarily through oxidative phosphorylation (O’Neill et al., 2016). As a direct result of this 
quiescence, naïve CD8 T cells are small, and round lymphocytes with a nearly absent 
cytoplasm. The importance of preserving the quiescent state is two-fold; it prevents 
unsolicited effector activity and maintains a stable population of healthy CD8 T cells in 
homeostasis. Maintenance of naïve CD8 T cells is achieved through low rates of 
homeostatic proliferation which is induced in part by the cytokines interleukin-7 (IL-7), 
and IL-15 (Schluns et al., 2000; Tan et al., 2001; Kimura et al., 2013). IL-7 and IL-15 both 
signal through heterodimeric cytokine receptors, one subunit of which is the common 
gamma chain (CD132), while the second subunit is specific to the signaling cytokine. 
Whereas IL-7 signals exclusively through its own alpha chain (CD127), IL-15 can signal 
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either through its alpha chain, or the low affinity IL-2 beta chain (CD122) (Sprent and 
Surh, 2011). 
Three signals are required for the activation of naïve CD8 T cells: 1) engagement 
of the T cell receptor (TCR) with peptide:major histocompatibility class I (MHC-I) 
complex; 2) co-stimulation; and 3) cytokine signaling. Specifically, CD8 T cells recognize 
endogenous peptides that are processed, and presented in the context of MHC class I 
(MHC-I). The CD8 co-receptor binds to an invariant domain on MHC-I, which may serve 
to stabilize the interaction between the TCR and peptide:MHC complex (Wooldridge et 
al., 2005). More importantly, this interaction also places the cytoplasmic tail of CD8, which 
is bound by the kinase Lck, within reach of the immunoreceptor tyrosine-based activation 
motifs (ITAMs) of CD3, the signaling component of the TCR complex (Marth et al., 1985; 
Janeway, 1992). Phosphorylation of the CD3 ITAMs by Lck initiates an effective TCR 
signal. The CD28 co-stimulatory receptor, upon binding of either the B7.1 or B7.2 (CD80 
or CD86) ligand, is also phosphorylated by Lck to generate a successful co-stimulation 
signal (Ledbetter et al., 1990; Holdorf et al., 1999). Several cytokines are important 
throughout T cell differentiation, with IL-2 being the most critical during the early 
activation and effector stage of CD8 T cell differentiation (Boyman and Sprent, 2012). This 
is best exemplified by CD28-mediated upregulation of the high affinity IL-2 receptor 
(CD25) upon activation (Boyman and Sprent, 2012). Moreover, the distinct signals 
produced by the TCR and co-stimulation result in the convergence of several transcription 
factors on the IL-2 promoter to initiate its transcription and production (Jain et al., 1995). 
Three important transcription factors involved in the very early activation of CD8 
T cells are NF-kB, NFAT, and AP-1 (Karin et al., 1997; Macian, 2005; Hayden et al., 
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2006). As these transcription factors are required to drive transcription of genes 
immediately after TCR engagement, they must be expressed in naïve cells in an inactive 
state. Thus, upon CD8 T cell activation, they can be activated and rapidly execute their 
transcriptional programs. Specifically, NF-kB is retained in the cytoplasm when bound by 
its inhibitor, IkB. TCR signaling results in the phosphorylation of IkB, which leads to its 
degradation, freeing NF-kB to translocate to the nucleus and drive transcription of target 
genes (Hayden et al., 2006). NFAT is also retained in the cytoplasm by phosphorylation of 
various serine/threonine residues. Influx of calcium, which is an important signaling event 
upon TCR engagement, activates calmodulin. Calmodulin then binds and activates 
calcineurin, a phosphatase that dephosphorylates NFAT, allowing its translocation into the 
nucleus (Macian, 2005). Finally, MAPK signaling results in the phosphorylation of c-Jun, 
one subunit of AP-1, in the nucleus. This phosphorylation allows c-Jun to bind its partner 
c-Fos, thus forming a functional AP-1 complex that can bind DNA and drive transcription 
(Karin et al., 1997). Importantly, NFAT partners with AP-1 to further amplify T cell 
activation signals (Jain et al., 1995; Macian, 2005). These transcription factors are 
responsible for the expression of many other genes needed for T cell activation, in addition 
to IL-2. Proper regulation of the expression and function of these transcription factors is 
essential to coordinate productive T cell responses. Some of the consequences of their 
dysregulation will be discussed later. 
 
1.2.2 CD8 T cell blastogenesis and clonal expansion 
The coordinated effects of these three signals result in global changes to the 
morphology, metabolism, proliferation, and transcriptional activity of the activated CD8 T 
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cell. The process of acquiring these changes is referred to as blastogenesis. Upon 
activation, CD8 T cells initiate a growth program that results in the accumulation of cell 
biomass, particularly in the expanding cytoplasm (Wang et al., 2011). Activation also 
permits entrance into the cell cycle, which not only facilitates this cell growth, but also 
rapid proliferation to generate the large numbers of antigen-specific CD8 T cells needed to 
clear the antigen (Iritani et al., 2002). This proliferative burst is termed clonal expansion, 
as a responding cell which expresses a TCR specific to a given epitope of the antigen, will 
only give rise to daughter cells which express the same TCR with the same specificity 
(Zarozinski and Welsh, 1997; Murali-Krishna et al., 1998). The immediate initiation of cell 
growth and proliferation programs elicits a dramatic increase in bioenergetic and metabolic 
demands. To meet these demands, CD8 T cell activation triggers a metabolic switch from 
oxidative phosphorylation to glycolysis. Although glycolysis is much less efficient than 
oxidative phosphorylation in terms of ATP production, it results in a high abundance of 
the biomacromolecular intermediates that are used for DNA and protein synthesis, cell 
growth and division, and myriad other cellular processes (Warburg, 1956).  
The initiation of glycolysis, cell growth, and proliferation is a highly coordinated 
event, and is mediated largely by the activation of Myc. Myc expression is fully induced 
by four hours after CD8 T cell activation (Nie et al., 2012), through both TCR and CD28 
co-stimulation (Wang et al., 2011, Grzes et al., 2017). Moreover, its expression can be 
boosted by IL-2 signaling later in blastogenesis (Chou et al., 2014). Myc has previously 
been demonstrated to direct progression of the cell cycle from the G1 to S phase by 
inducing expression of G1 cyclins, cyclin dependent kinases, and E2F transcription factors, 
while simultaneously antagonizing the activity of cell cycle inhibitors (Bretones et al., 
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2014). In addition, the expression of glucose transporters, enzymes involved in glycolysis, 
and protein synthesis enzymes is directly controlled by Myc. While Myc is critical for 
proliferation and metabolic reprogramming, sustained expression can be toxic to cells 
(Chang et al., 2000). Thus, Myc expression is transient, and is downregulated by 72 hours 
after initial TCR stimulation; however, its effects are long-lasting (Chou et al., 2014). This 
is in part due to the induction of AP-4, a transcription factor that sustains protein synthesis, 
metabolism, and proliferation, to support the subsequent differentiation into cytotoxic T 
lymphocytes (CTLs), and the corresponding acquisition of effector function (Chou et al., 
2014). 
 
1.2.3 Terminal effector differentiation and the acquisition of cytotoxic function 
The majority of CD8 T cells generated during the primary response to antigen will 
differentiate into cytotoxic T lymphocytes (CTLs), and have fully acquired the ability to 
kill target cells. CTLs produce cytotoxic granules, which are modified lysosomes that 
contain effector molecules, primarily perforin, granzyme A, and granzyme B. TCR 
recognition of the peptide:MHC-I complex presented on the surface of infected or 
transformed cells will trigger the release of these proteins from the CTL to the target cell. 
In the CTL, these proteins are contained within modified lysosomes referred to as granules. 
Restructuring of the secretory machinery in the CTL upon TCR engagement facilitates the 
transport of these granules directly to the target cell (Stinchombe and Griffiths, 2007). 
Upon degranulation, perforin generates pores in the membrane of the target cell, allowing 
the entrance of granzymes. Once inside the target cell, the serine proteases Granzyme A 
and Granzyme B initiate apoptosis. Granzyme B initiates the intrinsic apoptotic pathway 
 7 
in two ways: direct cleavage of pro-caspase 3 to activate the proteolytic caspase cascade, 
and by disrupting the mitochondrial membrane to release cytochrome c. The exact 
mechanism of Granzyme A-mediated apoptosis is unclear, but likely involves caspase-
independent mitochondrial damage (Chowdury and Lieberman, 2008). CTLs also produce 
cytokines that contribute to the clearance of antigen, namely interferon-gamma (IFN-) and 
tumor necrosis factor- alpha (TNF-) (Kaech and Wherry, 2007). During viral infection, 
IFN- not only directly prevents viral replication, but also increases expression of MHC-I 
on target cells to increase detection of infected cells. TNF- is a pro-inflammatory cytokine 
that aids in the recruitment and activation of other immune cells to the site of infection to 
support the CD8 T cell response. If uncontrolled, the CTL response can be extremely 
devastating. To prevent hyperactivation of the CTL response, activated T cells upregulate 
the expression of several co-inhibitory receptors, including PD-1, Tim-3, CD160 and 2B4 
(Wherry et al., 2007; Blackburn et al., 2009). Although it is known that engagement of 
these receptors dampens CTL responses, the precise mechanisms of inhibition carried out 
by each receptor are not fully understood.  
The peak of the effector CTL response occurs by seven days post-activation, at 
which point the majority of the antigen has been cleared (Figure 1.2). In the process of 
acquiring their effector function, the cells that most efficiently cleared the antigen also 
acquired several irreversible epigenetic changes which prevents them from differentiating 
any further. Accordingly, these cells are referred to as terminal effector cells. The 
resolution of inflammation is characterized by not only the clearance of antigen, but also 
effector cytokines such as IL-2, and leads to contraction, a massive apoptotic event in 
which the majority (90-95%) of CTLs die (Kaech and Cui, 2012). Specifically, the cells 
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cleared during contraction are the terminal effector cells, as they no longer serve a 
protective purpose to the host. This is another mechanism used to prevent unwarranted 
inflammation from CTLs which could cause harm to the host if uncontrolled. 
 
1.2.4 Transcriptional regulation of terminal effector differentiation 
The magnitude of the terminal effector response is scaled to the severity of the 
infection (Kaech and Wherry, 2007). Thus, the regulation of terminal effector 
differentiation and the acquisition of effector function involves a complex transcriptional 
network that integrates multiple signals to ‘translate’ the degree of inflammation into an 
appropriate effector response (Kaech and Cui, 2012; Best et al., 2013). The T-box 
transcription factors T-bet (encoded by Tbx21) and Eomesodermin (Eomes), were two of 
the first transcription factors discovered to regulate effector differentiation (Szabo et al., 
2000; Pearce et al., 2003). T-bet and Eomes facilitate the acquisition of effector function 
by coordinated upregulation of the effector molecules IFN-g, granzyme B, and perforin. 
While this is accomplished through partially redundant mechanisms, T-bet and Eomes also 
control discrete stages of effector differentiation, and thus their expression is somewhat 
reciprocal (Intlekofer et al., 2007; Kaech and Cui, 2012). T-bet expression peaks early 
during effector differentiation and is downregulated as CTL differentiation progresses, 
while Eomes expression peaks later, and is downregulated closer to contraction (Joshi et 
al., 2011; Kakaradov et al., 2017). This is likely due to TCR-mediated induction of T-bet, 
while Eomes expression is dependent on IL-2 signaling, and the transcription factor Runx3 
(Cruz-Guilloty, 2009; Pipkin et al., 2010). Importantly, the levels of Eomes and T-bet 
expression are modulated by cytokine signaling, which has important consequences for the 
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fate of differentiating CD8 T cells. IL-2 signaling amplifies both T-bet and Eomes 
expression to support CTL differentiation and the acquisition of effector function (Kalia et 
al., 2009; Pipkin et al., 2010). Alternatively, IL-12 amplifies T-bet and represses Eomes 
expression to drive cells into the terminal effector state (Takemoto et al., 2006; Joshi et al., 
2007). This is accomplished by IL-12-mediated enhancement of mTOR (mammalian target 
of rapamycin) activity (Rao et al., 2010).  
Other transcriptional regulators also make important contributions to terminal 
effector differentiation. In addition to upregulating Eomes, Runx3 directly regulates 
granzyme B expression, and synergizes with Eomes and T-bet to promote IFN-g and 
perforin expression (Cruz-Guilloty et al., 2009). The transcriptional repressor, Blimp-1 
(encoded by the gene Prdm1) promotes CTL migration to the site of inflammation, and 
also drives the expression of effector molecules (Kallies et al., 2009; Kaech and Cui, 2012). 
The latter role of Blimp-1 is accomplished through redundant functions with T-bet, 
although deficiencies in T-bet or Blimp-1 alone are sufficient to impair the differentiation 
of terminal effector cells (Kallies et al., 2009; Xin et al., 2016). The expression of Blimp-
1 is driven by the transcription factor IRF4 (Interferon-responsive factor 4), the expression 
and activity of which is driven by the strength of TCR signaling. Specifically, strong TCR 
signaling increases IRF4 expression and activity to promote the terminal differentiation of 
CD8 T cells (Man et al., 2013; Nayar et al., 2014).  
Notch is another critical transcriptional regulator of CTL differentiation. Notch 
expression is upregulated on CD8 T cells by TCR signaling, and by an mTOR-dependent 
mechanism driven by type I interferons produced during viral infection (Cho et al., 2009; 
Backer et al., 2014). IL-2 signaling can further amplify Notch expression. Notch-1 was 
 10 
demonstrated to induce T-bet expression, which in turn further upregulates Notch-1 in a 
positive feedforward loop that drives transcription of effector molecules (Backer et al., 
2014).  Additionally, inhibitor of DNA binding 2 (Id2), which functions primarily by 
preventing E protein transcription factors from binding DNA, promotes terminal effector 
differentiation by supporting the survival of differentiating cells (Cannarile et al., 2006; 
Yang et al., 2011; Knell et al., 2013). Consistent with a role in supporting survival, Id2 
expression is induced later during the terminal effector differentiation program by IL-2, 
IL-12, and IL-21 cytokine signaling (Yang et al., 2011). Thus, increased production of 
these cytokines during the immune response will lead to sustained CTL responses through 
induction of Id2 (Yang et al., 2011). 
In addition to cytokine signaling and mTOR, access to target gene promoters is 
another important determinant of transcription factor activity, and consequently, 
expression. In fact, dynamic changes are made to the chromatin landscape of differentiating 
CD8 T cells and play an important role in modulating the CD8 T cell response (Scott-
Browne et al., 2016). What signals determine the extent of the epigenetic changes made 
during CD8 T cell differentiation remain to be determined. In general, the mechanisms that 
modulate transcription factor expression and activity to titrate the magnitude of the CTL 
response according to the demands of the infection are not fully understood. As such, 
identifying a global regulatory mechanism that ‘translates’ the degree of inflammation by 
tuning the expression of these transcription factors will be important for better 
understanding terminal effector differentiation and for identifying new therapeutic targets.  
 
1.2.5 Memory CD8 T cells 
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Although roughly 90% of responding CD8 T cells die during contraction, 
approximately 5-10% survive to form the memory CD8 T cell population (Figure 1.2). 
Memory CD8 T cells are incredibly important as they provide life-long protection to the 
host (Williams and Bevan, 2007). Accordingly, memory CD8 T cells express high levels 
of anti-apoptotic proteins, such as Bcl-2, to support both survival through contraction and 
longevity. These cells ‘remember’ the initial encounter with antigen, such that upon 
subsequent re-encounter, they will respond with a greater magnitude and more quickly, 
than cells encountering the antigen for the first time.  
The CD8 T cells that will survive contraction to populate the memory pool can be 
identified during the effector phase of the CD8 T cell response, and are referred to as 
memory precursor effector cells (MPECs) as they have not yet fully differentiated into 
memory cells. MPECs are identified by low expression of the terminal effector marker 
KLRG1, and high expression of the IL-7 receptor (Joshi et al., 2007), as memory cells are 
dependent on IL-7 signaling to survive. MPECs acquire several molecular, metabolic, and 
functional alterations as they transition into the memory state. Although all memory cells 
are characterized by a return to quiescence, the changes acquired are not uniform amongst 
the differentiating MPECs. The memory CD8 T cell pool is heterogenous and is comprised 
of four subsets of memory CD8 T cells that can be classified by their anatomic localization, 
proliferative capacity, effector function, and retained differentiation potential (Gebhardt et 
al., 2009; Masopust et al., 2010). The most differentiated subset of memory CD8 T cells 
are tissue resident memory cells which, as their name implies, reside in non-lymphoid 
peripheral tissues, such as the skin, liver, lung, and white adipose tissue (Masopust et al., 
2001). As these cells populate tissues, they serve as a first line of defense and thus retain 
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high expression of transcripts encoding effector molecules (Gebhardt et al., 2009). 
Although they proliferate very minimally in homeostasis, they proliferate very rapidly 
upon restimulation (Schenkel and Masopust, 2014). The least differentiated memory 
subset, stem cell memory cells, display features of stemness. They have relatively high 
proliferative capacity, increased self-renewal potential, and importantly, the ability to seed 
all memory subsets (Gattinoni et al., 2011; Gattinoni et al., 2017).  
The two remaining subsets of memory CD8 T cells, effector memory CD8 T cells 
and central memory CD8 T cells, lie somewhere in between, with effector memory cells 
being more differentiated, and central memory being less differentiated. These two 
populations are the best characterized, and their features are broadly used to identify and 
study memory cells. Accordingly, these two populations, will be the primary focus herein. 
Consistent with their name, effector memory cells retain higher expression of effector 
molecules than central memory cells (Sallusto et al., 1999). While effector memory cells 
circulate throughout the bloodstream, central memory cells home back to secondary 
lymphoid organs. Thus, central memory cells highly express L-selectin (CD62L) which 
mediates rolling along the high endothelial venules that lead back to lymph nodes, and the 
chemokine receptor CCR7, which facilitates lymphocyte migration into, and subsequent 
retention in secondary lymphoid organs. Although central memory cells have a higher 
proliferative potential than effector memory cells, both populations undergo low levels of 
homeostatic proliferation and rely on IL-7 and IL-15 signaling for long term survival 
(Schluns et al., 2000; Surh et al., 2006). Moreover, both populations of cells will switch 
their metabolism back to oxidative phosphorylation as there is now a significant decrease 
in bioenergetic demands, and instead a need to maintain quiescence (van der Windt et al., 
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2012). In addition, glutaminolysis has recently been demonstrated to improve the survival 
of memory precursor cells during the transition into mature memory cells, and their 
function upon antigen re-encounter (Geiger et al., 2016). Several in vitro studies have 
suggested that memory CD8 T cells also rely on fatty acid beta-oxidation, although it is 
controversial whether this is consistent in vivo (Pearce et al., 2009; van der Windt et al., 
2012; Raud et al., 2017).  
Despite the many differences between these subsets of memory CD8 T cells, the 
successful differentiation and maintenance of each population is important for sustaining 
life-long immunity, yet very little is known regarding this process. 
 
1.2.6 Proposed mechanisms of memory differentiation 
In general, all naïve CD8 T cells are considered to have the same potential to 
become a memory cell, and that memory cells are less differentiated than effector cells 
(Sallusto et al., 2004; Joshi et al., 2007; Gattinoni et al., 2011). Accordingly, it is likely that 
over the course of CD8 T cell differentiation, memory potential is lost, rather than gained 
(Joshi et al., 2007; Kaech and Cui, 2012; Chang et al., 2014; Chen et al., 2018). Although 
the latter has been proposed to occur through the ‘de-differentiation’ of effector cells, this 
has only been demonstrated in a limited subset of ‘permissive’ effector cells, and fails to 
account for the heterogeneity of the memory pool (Akondy et al., 2017; Youngblood et al., 
2017). Thus, the two prevailing models of memory CD8 T cell differentiation support the 
concept that memory potential is lost during CD8 T cell differentiation (Figure 1.3). The 
first model accounts for the effects compounding signals have on the differentiating CD8 
T cell, while the second model accounts for the strength of these signals. The first model 
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is the progressive differentiation model, and proposes that the accumulation of signals a 
CD8 T cell receives, either antigenic or cytokine-derived, during differentiation gradually 
pushes cells into a more terminal effector state, thus diminishing memory potential (Joshi 
et al., 2007; Sarkar et al., 2008; Gray et al., 2017). Studies in support of this model 
demonstrate that reducing antigen exposure time drives memory formation (Sarkar et al., 
2008), although this could also indicate that the duration of TCR signaling is an important 
determinant of memory potential. More recently, the importance of signal strength during 
priming has been incorporated into this model (Figure 1.3) (Daniels and Teixeiro, 2015). 
The second model proposes that both an effector and a memory cell are generated 
simultaneously from a single primed CD8 T cell via asymmetric division of this cell 
(Figure 1.3). Upon stimulation by an antigen presenting cell, a T cell will give rise to two 
daughter cells. The asymmetric division model suggests the daughter cell proximal to the 
antigen presenting cell is fated to become a terminal effector, as it receives stronger TCR 
stimulation. The distal daughter cell retains its memory potential, as it receives weaker 
TCR stimulation (Chang et al., 2007; Chang et al., 2011; Verbist et al., 2016). This model 
is consistent with reports demonstrating strength of TCR signaling can determine CD8 T 
cell fate (Chen et al., 2018).  
An important discrepancy between these models is whether the timing of signaling, 
in addition to the accumulation and strength of signal, is relevant to the differentiation of 
memory CD8 T cells. The progressive differentiation model suggests signaling throughout 
differentiation is relevant, whereas the asymmetric division model suggests the initial 
priming event is when the memory fate is specified. However, both models indicate TCR 
signaling is an important determinant of memory potential, and in reality, there is likely to 
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be some combination of these proposed mechanisms involved in the generation of such a 
heterogeneous memory pool.  
 
1.2.7 Transcriptional regulation of memory differentiation 
Despite controversy in how and when the memory fate is specified, significant 
progress has been made in understanding the transcriptional network that is involved in the 
differentiation and maintenance of CD8 T cell memory. Of particular importance is the 
transcription factor Tcf1 (encoded by the gene Tcf7), which is a downstream component of 
Wnt signaling. Tcf1 is highly expressed in naïve cells, downregulated upon activation, and 
then partially re-expressed in memory CD8 T cells (Zhou et al., 2010). The first evidence 
of a role for Tcf1 in memory cells was demonstrated by constitutive activation of the Wnt 
signaling pathway, which enhanced memory CD8 T cell differentiation (Gattinoni et al., 
2011; Zhou et al., 2010). It was subsequently demonstrated that loss of Tcf1 expression in 
mature CD8 T cells impaired the maintenance of the memory compartment as a result of 
diminished CD122 and Bcl-2 expression, and compromised homing to secondary 
lymphoid organs (Zhou et al., 2010). Tcf1 expression is in part controlled by Foxo1, which 
also helps drive expression of the genes Cd127, Bcl-2, Sell (encodes CD62L), and Ccr7.  
Another important function of both Tcf1 and Foxo1 is to promote expression of 
Eomes. In fact, in addition to its role in effector differentiation, Eomes is critical to the 
generation of memory cells. Eomes directly upregulates expression of CD122, to support 
memory CD8 T cell survival. Accordingly, while Eomes-deficient mice generate memory 
precursor cells in response to viral challenge, they fail to form a mature memory population 
(Kaech and Cui, 2012). Eomes is not the only transcription factor involved in both effector 
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and memory differentiation. In fact, Runx3 has also been demonstrated to drive memory 
formation early during CD8 T cell differentiation (Wang et al., 2018). Although Eomes 
and Runx3 appear to have dual roles in CD8 T cell differentiation, the majority of 
transcription regulators involved in terminal differentiation must be actively repressed to 
generate memory cells. Transcription factors, such as Bcl-6 and Id2, are upregulated in 
memory cells in part to suppress expression of Blimp-1 and Id3, respectively. Expression 
of Bcl-6, and Eomes, are upregulated in a STAT3-dependent mechanism downstream of 
cytokine signaling in the effector to memory transition during contraction (Cui et al., 2011), 
supporting models in which the memory fate is specified throughout differentiation.  
The epigenetic landscape is an additional level of regulation that determines the 
transcriptional activity during memory CD8 T cell differentiation. Moreover, the enhanced 
responses of memory cells are proposed to be a result of epigenetic ‘re-wiring’ during the 
primary response that keeps cells poised to proliferate and produce effector molecules upon 
antigen re-encounter (Scott-Browne et al., 2016; Akondy et al., 2017; Gray et al., 2017; 
Youngblood et al., 2017; Yu et al. 2017). However, the transcription factors involved in 
establishing and maintaining the chromatin landscape of memory CD8 T cells are only 
beginning to be identified (Pace et al., 2018; Wang et al., 2018). Notably, one of these 
factors, Runx3, exerts its effects by establishing a chromatin landscape associated with 
memory cells during TCR stimulation to prevent terminal effector differentiation (Wang 
et al., 2018), in support of models in which the memory cell fate is programmed during 
TCR stimulation.  
Although the transcriptional regulation of memory differentiation has been well-
studied, it is not fully understood. As some of these results suggest, a better understanding 
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of the transcriptional control of memory differentiation may provide insight into how and 
when the memory fate is specified.  
 
1.2.8 CD8 T cell exhaustion 
 The proper differentiation of terminal effector and memory CD8 T cells is 
intrinsically tied to the ability of these cells to effectively clear the antigen. In cases of 
chronic infection and cancer, when the antigen fails to be cleared, CD8 T cells are diverted 
into a compromised state, termed exhaustion (Zajac et al., 1998; Gallimore et al., 1998; 
Schietinger et al., 2016). Broadly, exhaustion is defined as the loss of effector function, 
which occurs in a hierarchical manner. First, effector CTLs lose the ability to produce IL-
2, proliferate at high rates, and kill target cells, followed by loss of IFN-g and TNF-a 
production, and the ability to degranulate, with the most severe form of exhaustion leading 
to the death of the CD8 T cell (Figure 1.4) Wherry et al., 2003; Wherry, 2011). 
 Exhaustion is established by the chronic TCR stimulation that results from 
persistent antigen exposure (Schietinger et al., 2016). This continual TCR signaling drives 
the upregulation of co-inhibitory receptors, including PD-1, Tim-3, CD160 and 2B4 
(Schietinger et al., 2016). Engagement of these inhibitory receptors in immunosuppressive 
environments maintains exhausted cells in a dysfunctional state (Schietinger and 
Greenberg, 2014). The best characterized of these receptors is PD-1. The importance of 
PD-1 in suppressing T cell function was first demonstrated by the spontaneous induction 
of autoimmunity in PD-1 deficient mice (Nishimura et al., 1996; Nishimura et al., 1998). 
The ligands for PD-1, PD-L1 and PD-L2, are expressed on a variety of immune and non-
immune cells, including cancer cells, in response to interferons produced during the 
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immune response (Sun et al., 2018). Binding of PD-L1 or PD-L2 to PD-1 was demonstrated 
in vitro to cluster PD-1 with the TCR and Lck, and to recruit the phosphatases SHP-1 and 
SHP-2 to bind a conserved motif in the intracellular tail of PD-1 (Chemnitz et al., 2004; 
Sheppard et al., 2004; Yokosuka et al., 2012). This combination of events was thought to 
bring SHP-1 and SHP-2 into contact with TCR signaling components to dephosphorylate 
the TCR, and suppress Lck activity, thus dampening TCR signaling (Sheppard et al., 2004; 
Yokosuka et al., 2012). It has also been suggested that PD-1 signaling not only dampens 
TCR signals, but also co-stimulatory signaling (Hui et al., 2017; Kamphorst et al., 2017). 
However, the recent generation of SHP-2-deficient mice demonstrated that SHP-2 is 
dispensable for PD-1- mediated suppression of T cell responses in vivo (Rota et al., 2018). 
Thus, the exact molecular events driven by PD-1, as well as the other inhibitory receptors, 
remain to be elucidated. 
In addition to inhibitory receptor engagement, the cytokine milieu of the 
inflammatory environments associated with chronic viral infections and cancer also 
suppresses terminal effector cell function. TGF- and IL-10 are the most prominent 
cytokines to be implicated in suppressing T cell function. In fact, TGF--deficient mice die 
from uncontrolled inflammation in vital organs (Diebold et al., 1995). TGF- is produced 
by several cells in the immunosuppressive environment, including antigen presenting cells 
and T cells (Flavell et al., 2010; Caja and Vannucci, 2015), and directly inhibits the 
proliferation and cytotoxic function of CD8 T cells (Thomas and Massague, 2005; Stephen 
et al., 2014). Innate immune responses are also dampened by TGF- which can additionally 
contribute to weakened CD8 T cell responses in the presence of this cytokine (Flavell et 
al., 2010). Similar to TGF-, IL-10 is produced by multiple immune cells, including 
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antigen presenting cells and T cells (Blackburn and Wherry, 2007; Filippi and von Herrath, 
2008). IL-10 negatively regulates several features of the CD8 T cell immune response, 
such that depletion of IL-10 restores CD8 T cell function during chronic infection (Brooks 
et al., 2006; Ejrnaes et al., 2006). Specifically, IL-10 indirectly contributes to CD8 T cell 
dysfunction by reducing MHC-II expression on antigen presenting cells to limit CD4 T cell 
help, and directly by restraining CD8 T cell proliferation and cytokine production (Brooks 
et al., 2006; Ejrnaes et al., 2006). Interestingly, IL-10 production is increased in exhausted 
T cells, suggesting that these cells may contribute to their own immunosuppression. It has 
been hypothesized this may be a preventative mechanism to protect against tissue damage 
during prolonged immune responses against chronic infection (Blackburn and Wherry, 
2007). 
The decided impact of inhibitory receptors and suppressive cytokines on the 
function of CD8 T cells has led to a concerted effort to develop therapies that can overcome 
these negative signals to revive CD8 T cell function in cancer and chronic infection. The 
most successful of these so-called immunotherapies are primarily targeted against the 
inhibitory receptor, PD-1, and its ligand, PD-L1 (Weber, 2010; Brahmer et al., 2012; 
Topalian et al., 2012). The therapeutic targeting of the PD-1-PD-L1 axis is achieved by 
blocking antibodies which prevent the receptor-ligand interactions, and is referred to as 
checkpoint blockade inhibition (CBI) (Weber, 2010; Brahmer et al., 2012; Topalian et al., 
2012; Sharma and Allison, 2015). The therapeutic success of CBI against PD-1 guaranteed 
the two scientists who discovered PD-1 and developed this therapy, Tasuku Honjo and 
James Allison, the 2018 Nobel Prize in Physiology or Medicine. 
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However, positive CD8 T cell responses to CBI are not guaranteed, and are not 
uniform amongst responding CD8 T cells (Blackburn et al., 2008; Paley et al., 2012). It has 
become evident that the exhausted CD8 T cell pool is not homogenous (Blackburn et al., 
2008; Blackburn et al., 2009; Paley et al., 2012). In fact, there are distinct populations of 
exhausted cells which retain different degrees of effector function, and the potential to be 
‘revitalized’ through checkpoint blockade inhibition (Im et al., 2016, Utzschneider et al., 
2016; Siddiqui, et al., 2019; Kurtulus et al., 2019). These are likely cells that are at different 
stages in the gradual acquisition of exhaustion. Moreover, the pattern of inhibitory receptor 
expression is not uniform across exhausted CD8 T cells, and can group exhausted cells into 
clusters with different effector functions (Jin et al., 2010; Blackburn et al., 2009; Singer et 
al., 2016; Chihara et al., 2018). As such, expression of inhibitory receptors does not 
preclude CD8 T cells to exhaustion, although it is certainly a driving force. Consequently, 
the better characterizing the distinctions between the terminal effector and exhaustion 
programs is an active area of research (Singer et al., 2016), and will be important for the 
improved use of CBI in the clinic.  
  
1.2.9 Transcriptional regulation of CD8 T cell exhaustion 
As the exhausted state is established as a result of chronic TCR stimulation, the 
exhaustion program is driven by dysregulation of many of the transcription factors 
involved in terminal effector differentiation. As such, two of the first transcription factors 
identified to promote the exhaustion were T-bet and Eomes (Wherry et al., 2007; Blackburn 
et al., 2008). In fact, the relative expression of these two transcription factors identified 
CD8 T cells in different stages of exhaustion (Blackburn et al., 2008; Buggert et al., 2014). 
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Specifically, high T-bet expression sustained the ‘progenitor’ population of exhausted T 
cells, and the gradual loss of T-bet expression resulted in the upregulation of Eomes, 
consequently giving rise to terminally exhausted cells (Kao et al., 2011; Paley et al., 2012; 
Doering et al., 2012). Blimp-1 was also reported to be highly expressed in exhausted cells, 
and was demonstrated directly induce inhibitory receptor expression (Shin et al., 2009).  
Additionally, upregulation of transcription factors induced by the strength and 
duration of TCR signaling, such as IRF4 and NFAT, were identified early on to drive the 
exhaustion program, and were demonstrated to increase expression of inhibitory receptors 
(Wherry et al., 2007; Martinez et al., 2015; Man et al., 2017). Importantly, in effector cells 
NFAT forms complexes with the AP-1 transcription factor complex to drive effector gene 
expression. It was reported that NFAT-AP-1 complexation is disrupted in exhausted cells, 
and that failure to form this complex allows NFAT to bind alternative regions of DNA, 
including the promoters of genes such as PD-1 (Martinez et al., 2015). In fact, it was 
recently demonstrated that in exhausted cells miR-155 targets a component of the AP-1 
complex to prevent its expression, and thus contributes to increased transcription by 
‘partnerless’ NFAT (Stelekati et al., 2018). However, such defined roles for miRNAs in 
exhaustion are extremely limited. Similarly, the epigenetic control of transcription factor 
expression and activity in driving exhaustion has only begun to be explored. As CD8 T 
cells progress further into the terminal differentiation program, their epigenetic state is 
‘rewired’ towards exhaustion (Youngblood et al., 2011). This is mediated by deposition of 
repressive marks that ‘close off’ of gene accessibility, determining transcriptional 
programs that are executed, and contributing to the gradual progression of exhaustion 
(Pauken et al., 2016; Schietinger et al., 2016; Sen et al., 2016). However, the factors which 
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mediate the epigenetic and transcriptional regulation of exhaustion have not been fully 
identified. Moreover, how these factors themselves are regulated during the transition into 
exhaustion is not completely understood. 
 
1.2.10 CD8 T cell differentiation: concluding remarks 
The transcriptional network driving CD8 T cell differentiation is clearly very 
complex and requires tight regulation, as any modification to the timing and magnitude of 
gene expression can alter the fate of the differentiating T cell. These different populations 
of CD8 T cells are maintained by distinct transcriptional profiles which are dictated by 
extracellular signals such as TCR stimulation, co-stimulation, and inflammation. As each 
CD8 T cell population has different protective capacities, being able to direct cells away 
from one fate into another has therapeutic implications. However, a major hurdle in 
implementing such an approach has been to identify global molecular hubs which can 
simultaneously integrate and translate the multiple signals a T cell receives into a 
coordinated transcriptional program to control CD8 T cell fate. One less studied 
mechanism that may provide such global control of CD8 T cell differentiation is post-
transcriptional regulation mediated by microRNAs. 
 
1.3 miRNAs and their role in CD8 T cells 
1.3.1 miRNA biogenesis and biology 
MicroRNAs (miRNAs) regulate multiple important biological processes, including cell 
differentiation, in a tissue-specific manner through a post-transcriptional mechanism that 
is based on sequence-specific inhibition of mRNA translation (Fire et al., 1998). The tissue-
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specific functions of miRNAs are in part attributed to their genomic organization (Ha and 
Kim, 2014; Treiber et al., 2018). MiRNA-encoding genes can be located in intergenic 
regions, in which the upstream promoter exclusively drives expression of the miRNA 
(Figure 1.5) (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). 
However, genes encoding miRNAs can also be intronic, in which they are located as 
introns between exons of another gene, thus sharing the promoter with the flanking gene 
(Figure 1.5) (Rodriguez, et al., 2004). In this case, the gene encoding the miRNA will be 
transcribed when the flanking gene is transcribed, and will be spliced out during mRNA 
processing (Rodriguez, et al., 2004). In both situations (intergenic and intronic) genes 
encoding miRNAs can be either monocistronic, in which a single miRNA-encoding gene 
is transcribed by a single promoter, or they can polycistronic, in which multiple miRNA-
encoding genes are clustered together to share a common promoter (Figure 1.5) (Lee et al., 
2002; Lagos-Quintana, 2003). 
Genes encoding miRNAs are first transcribed as a primary transcript by RNA PolII 
and PolIII, called primary miRNAs (pri-miRNA), which may vary in size, but are usually 
very long (Figure 1.6A) (Ha and Kim, 2014). While still in the nucleus, the pri-miRNA is 
processed into the hairpin-like 60-70 nucleotides (nt) precursor miRNA (pre-miRNA) by 
the microprocessor, a complex containing the endonuclease Drosha (Lee et al., 2002; Denli 
et al., 2004). Next, the pre-miRNA is exported from the nucleus to the cytoplasm, where 
the pre-miRNA stem loop is cleaved by the endonuclease Dicer, generating a mature 21-
24 nt double stranded miRNA (Figure 1.6B) (Ha and Kim et a., 2014). A single strand of 
this mature miRNA is then loaded into the RNA induced silencing complex (RISC), which 
can prevent protein synthesis either by stalling the ribosomal machinery or by destabilizing 
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the targeted mRNA (Ha and Kim, 2014). The sequence with which miRNAs bind their 
RNA targets is known as the “seed sequence”, is typically 6-8 nt long, and is located at the 
5’ end of the miRNA. Based on the conservation of this seed sequence, miRNAs are 
grouped into families, such that all members of one miRNA family have the same target 
mRNAs. Usually the binding site for the miRNA seed sequence is located in the 3’ 
untranslated region (UTR) of the target mRNA, although they can be located within the 
open reading frame (ORF) as well (Lai, 2002).  
 
1.3.2 miRNAs in CD8 T cells 
The importance of miRNAs in T cells was first demonstrated through the ectopic 
expression of various miRNAs during hematopoiesis (Chen et al., 2004). Later, it was 
found that miRNA depletion achieved by a T cell- specific deletion of Dicer, resulted in 
severe defects not only in T cell development (Muljo et al., 2005), but also in aberrant 
proliferation, differentiation, and function of mature peripheral T cells (Zhang and Bevan, 
2010). More recently, roles for specific miRNAs have been identified throughout CD8 T 
cell differentiation (Wu et al., 2007). miR-17-92 was demonstrated to drive CD8 T cell 
proliferation upon activation, and thus promoted memory differentiation (Wu et al., 2012; 
Steiner et al., 2011). Several miRNAs have been implicated in exhaustion, including miR-
155, and mir-31 (Gracias et al., 2013; Moffett et al., 2017). The latter was reported to 
control AP-1 expression, thus potentially driving T cell exhaustion by promoting the 
partnerless NFAT transcription program (Stelekati et al., 2018). Interestingly, NFAT was 
reported to induce the expression of miR-31 during chronic infection, resulting in the 
upregulation of several inhibitory molecules (Moffett et al., 2017). 
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Despite these important studies, the current understanding of miRNA mediated 
regulation of CD8 T cell differentiation is extremely limited. Moreover, while these studies 
demonstrate miRNA involvement in single stages of CD8 T cell differentiation, a miRNA 
family with global regulatory control of CD8 T cell differentiation has yet to identified. 
Further, the majority of these studies have focused on miRNAs that are upregulated upon 
activation, thus miRNA-mediated maintenance of naïve CD8 T cells is similarly lacking. 
 
1.4 let-7 miRNAs 
1.4.1 The let-7 miRNA family and its regulation 
Let-7 is one of the most highly conserved families of miRNAs in the animal kingdom 
(Wightman et al., 1993; Use the "Insert Citation" button to add citations to this document. 
Pasquinelli et al., 2000). Originally identified in C. elegans, the let-7 (lethal-7) miRNAs 
are so named because their deletion in C. elegans led to the death of the worm (Reinhart 
et al., 2000). Having undergone several duplications in evolution, the let-7 family is 
comprised of multiple paralog genes expressed on different chromosomes, forming the 
largest miRNA family in mammals (Roush and Slack, 2008). In fact, sequences of mature 
let-7 miRNAs are often identical although they are derived from different precursors and 
genes (Bussing et al., 2008). To indicate the differences in sequence across genes, a letter 
is placed after let-7 (i.e., let-7a, let-7b), and a number is placed after this letter to indicate 
that the same sequence of gene is expressed in multiple genomic locations (i.e., let-7c-1, 
let-7c-2). In humans, there are 10 mature let-7 family members generated from 13 
precursor sequences, and in mice there are 8 mature family members arising from 11 
precursor miRNAs (Bussing et al., 2008; Roush and Slack, 2008).  
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 It has been demonstrated that let-7 miRNAs are involved in multiple biological 
processes including differentiation, cell death, and metabolism (Bussing et al., 2008; Zhu 
et al., 2011). Specifically, let-7 miRNAs were identified as potent tumor suppressors that 
directly target mRNAs of genes involved in the cell cycle and in signal transduction 
pathways that lead to carcinogenesis (Bussing et al., 2008). Although let-7 miRNAs can 
be found in many types of cells and tissues, the expression levels vary, revealing 
complicated regulation. In fact, let-7 miRNA expression is post-transcriptionally regulated 
by multiple factors that control different stages of let-7 biogenesis. Lin28 and Lin28B are 
well studied fetal proteins, that block the generation of mature let-7 miRNAs (Piskounova 
et al., 2008). Both proteins interfere with Dicer processing by binding to a highly conserved 
sequence within the stem loop of let-7 miRNA precursors and recruiting the terminal 
uridylyl transferases (TUTases), which uridylate the immature miRNA, allowing the 
exonuclease Dis3I2 to recognize and degrade it (Heo et al., 2009; Faehnle et al., 2014). 
This particular mechanism is used to inhibit global let-7 expression during early 
embryogenesis. Therefore, Lin28-mediated modulation of let- 7 miRNA levels has been 
implicated during early embryogenesis and in establishing the immune responses of 
neonates (Bussing et al., 2008; Wang et al., 2016). 
 
1.4.2 let-7 miRNAs in the immune system 
Interestingly, it has been shown that the let-7 family of miRNAs are the most 
abundant miRNAs in T cells, and control the differentiation and function of natural killer 
T cells, an innate-like subset of T cells (Pobezinsky et al., 2015; Yuan et al., 2012). Further, 
a regulatory role has been suggested for the let-7 miRNAs in controlling the CD4 T helper 
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response (Polikepahad et al., 2010; Swaminathan et al., 2012; Guan et al., 2013), and in 
contributing to the function of Tregs (Okoye et al., 2014). A previously published miRNA 
profile of CD8 T cells reported high levels of let-7a and let-7f expression in naïve cells, 
and reduced expression in effector CD8 T cells (Wu et al., 2007). However, the extent to 
which let-7 miRNAs regulate the maintenance, proliferation, differentiation, and function 
of CD8 T cells has yet to be explored. 
 
1.5 Hypothesis and specific aims 
The central hypothesis of this dissertation is that the let-7 miRNAs act as a 
molecular control hub, regulating the fate of differentiating CD8+ T cells. First, the role of 
the let-7 miRNAs in maintaining the naïve CD8 T cell state, and promoting the 
differentiation of terminal effector CD8 T cells will be determined (Figure 1.7). Second, 
the function of let-7 miRNAs in regulating the differentiation of memory and exhausted 
CD8 T cells will be defined (Figure 1.7). The research proposed herein is expected to 
establish the let-7 miRNAs as critical regulators of CD8 T cell immune responses. The 
elucidation of the let-7-mediated mechanism regulating the maintenance of naïve CD8 T 
cell quiescence, and the differentiation of terminal effector, memory, and exhausted CD8 
T cells will offer new insights into how TCR signaling determines CD8 T cell fate and 
function. Further, if the central hypothesis is correct, it has the potential to distinguish the 
let-7 miRNAs as a novel therapeutic target capable of modulating CD8 T cell responses 
during autoimmunity, infection, and cancer. 
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Figure 1.1 Magnitude of immune responses 
Although the innate immune system responds more quickly than cells of the adaptive 
immune system, the magnitude of these responses are weaker and fixed. Conversely, the 
expression of antigen specific receptors and ability to generate immunological memory 
facilitate the more robust primary and secondary responses yielded by the adaptive 
immune system. Adapted from Kuby Immunology, 7th e. 
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Figure 1.2 Kinetics of the CD8 T cell response 
The CD8 T cell response peaks at about 8 days after infection, when the virus or target 
antigen has been cleared. Following clearance of the antigen, the majority of CD8 T cells 
die during contraction (top panel). The majority of responding cells are terminal 
effectors, which do not survive contraction, while a small population of responding cells 
differentiate into memory cells that survive long term in the host (bottom panel). Adapted 
from Kaech and Cui, 2012)  
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Figure 1.3 Memory differentiation models 
The decreasing potential model suggests that with every subsequent signal a CD8 T cell 
receives, it becomes more terminally differentiated, progressively losing memory 
potential (top panel). This model has recently been incorporated with the signal strength 
model, in which increasing strength of signal reduces memory potential by driving 
terminal effector differentiation (middle panel). The asymmetric fate model suggests that 
proximity to the antigen presenting cell (APC) determines memory fate, where the distal 
daughter retains memory potential, and the proximal daughter is fated to become an 
effector cell (bottom panel). TCM: central memory T cell; TTM: transitional memory T 
cell; TEM: effector memory T cell. Adapted from Kaech and Cui, 2012. 
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Figure 1.4 Diversion into exhaustion 
Persistent antigen exposure diverts effector CD8 T cells into an exhausted, preventing the 
formation of functional memory cells. The establishment of exhaustion is hierarchical, in 
which some exhausted cells are able to be rescued (T-bethiPD-1mid) by checkpoint 
blockade, and others have reached the terminal exhausted state (EomeshiPD-1hi), in which 
cells do not respond to checkpoint blockade and die. Adapted from Wherry and Kurachi, 
2015. 
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Figure 1.5 Genomic organization of miRNAs 
MiRNA genes are usually either intergenic or intronic. Intergenic genes use their own 
promoters, while intronic genes share promoters with the genes by which they are 
flanked. Moreover, genes encoding miRNAs can be either monocistronic, encoding a 
single miRNA, or polycistronic, where several are clustered together. Adapted from 
Olena and Patton, 2009. 
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Figure 1.6 miRNA biogenesis and processing 
MiRNA genes are transcribed in the nucleus by Polymerase II into a primary miRNA 
(pri-miRNA) which is then trimmed by Drosha into a precursor miRNA (pre-miRNA). 
The pre-miRNA is then exported by Exportin 5 into the cytoplasm where the hairpin loop 
is cleaved by Dicer to generate a mature miRNA. The mature miRNA is then loaded into 
the RNA-induced silencing complex (RISC) which brings the miRNA to its target 
transcript and bind as either a perfect match, resulting in mRNA degradation, or as an 
imperfect match, resulting in translational repression. Adapted from Ryan et al., 2015. 
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Figure 1.7 Model of specific aims to be tested 
The research proposed in this dissertation will assess the role of elt-7 miRNAs in 
regulating the quiescent state of naïve CD8 T cells, as well as in the differentiation of 
cytotoxic T lymphocytes (CTLs), memory and exhausted CD8 T cells. 
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CHAPTER 2 
MODULATION OF LET-7 MIRNAS CONTROLS THE DIFFERENTIATION OF 
EFFECTOR CD8 T CELLS 
 
2.1 Introduction 
Maintaining naïve CD8 T cells in a quiescent state is important for their long-term 
survival and for productive CD8 T cell responses throughout the lifetime of the organism. 
The maintenance of this population is dependent on very low levels of homeostatic 
proliferation driven by two signals: low affinity TCR stimulation via self-peptide:MHC-I 
complexes, and homeostatic cytokine signaling provided by IL-7 and IL-15 (Kirberg et al., 
1997; Goldrath and Bevan, 1999; Schluns et al, 2000; Tan et al., 2001). The extent to which 
cells proliferate in response to these signals must be tightly controlled, as increased rates 
of homeostatic proliferation can result in the conversion of naïve CD8 T cells 
(CD44loC122lo) into cells with a memory phenotype (CD44hiCD122hi), often referred to as 
‘virtual memory’ cells (Goldrath and Bevan, 1999; Cho et al., 2000; Hamilton et al., 2006). 
This is particularly dangerous because these cells may be cross-reactive to self-ligands, and 
result in the induction of autoimmunity (Ernst et al., 1999; Sprent and Surh, 2011). As 
such, there are several mechanisms in place that prevent spontaneous activation in naïve 
CD8 T cells receiving tonic TCR and cytokine signals. This includes retention of the 
transcription factors NF-kB, and NFAT, in the cytoplasm and transcriptional control of 
members of the AP-1 complex (Sprent and Surh, 2011). Moreover, the transcription factor 
Foxp1 has been demonstrated to play a critical role in the maintenance of quiescence (Feng 
et al., 2011). However, whether there is a post-transcriptional regulatory mechanism 
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involved in preventing the spontaneous activation of naïve CD8 T cells remains to be 
determined.  
Antigen recognition through the TCR, licenses CD8 T cells to clonally expand, and 
acquire effector function, thus differentiating into cytotoxic T lymphocytes (CTLs). It has 
been suggested that the initial strength of TCR signaling determines the magnitude of the 
resulting CTL response. Studies supporting this model have demonstrated that stronger 
TCR stimulation results in heightened proliferation, and enhanced cytotoxic function 
driven by increased transcription factor expression and activity (Chang et al., 2007; Zehn 
et al., 2009; King et al., 2012; Verbist et al., 2016). The transcription factor IRF4 is a well 
characterized interpreter of TCR signal strength. IRF4 expression increases with the 
strength of TCR stimulation, and results in increased rates of glycolysis, proliferation, and 
expression of Blimp-1 and T-bet (Man et al., 2013; Yao et al., 2013; Nayar et al., 2014; 
Nayar et al., 2015). The involvement of post-transcriptional machinery in translating TCR 
signal strength to scale effector CD8 T cell responses is not known. Further, whether there 
is conserved molecular machinery involved in both restraining the spontaneous activation 
of naïve CD8 T cells and in tuning the magnitude of the effector response remains to be 
determined. 
The pattern of high let-7a and let-7f expression in naïve cells, and reduced 
expression in effector CD8 T cells (Wu et al., 2007), suggests let-7 may regulate elements 
of naïve and effector CD8 T cells. However, no functional role for the let-7 miRNAs in 
either of these CD8 T cell populations has been demonstrated. Moreover, the temporal 
regulation of let-7 expression in the naïve to effector transition has not been addressed. As 
such, the aim of this study was to better characterize the expression of all let-7 miRNA 
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family members in naïve and activated CD8 T cells, what signal regulates this expression, 
and to identify the functional significance of let-7 expression levels in naïve and effector 
CD8 T cells. 
We found that in CD8 T cells high levels of let-7 miRNAs are necessary to maintain 
the naïve phenotype, while TCR-mediated down-regulation of let-7 levels in activated cells 
is critical for the effective differentiation and function of CTLs. In fact, experimentally 
forced let-7 expression severely impairs the proliferation and differentiation of CD8 T 
cells, while let-7 deficiency significantly enhances the cytotoxic function of CTLs, and 
consequently immune responses in vivo. Given these findings, we propose a model in 
which let-7 acts as a molecular hub by converting the strength of TCR signaling into the 
strength of CD8 T cell function. 
 
2.2 Results 
2.2.1 let-7 miRNA expression maintains the quiescent state in naïve CD8 T cells 
To explore the potential regulatory role of let-7 miRNAs in CD8 T cells, the 
expression levels of let-7 miRNA family members in naïve and activated CD8 T cells were 
determined. Two different housekeeping RNAs were used to control for the major changes 
that occur upon T cell activation. Surprisingly, the initially very high expression of let-7 
miRNAs in naïve CD8 T cells was reduced by TCR signaling, and this downregulation 
was proportional to the strength and duration of TCR-stimulation, regardless of the 
housekeeping RNA used (Figure 2.1A-C). As a specificity control, the upregulation of 
miR-17 from the miR-17-92 locus (Figure 2.1D) that is induced upon T cell activation, was 
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confirmed (Wu et al., 2012; Katz et al., 2014). Taken together, these results suggest that 
TCR-mediated signaling inhibits the expression of let-7 miRNAs during T cell activation. 
To determine the functional significance of let-7 expression in naïve CD8 
lymphocytes, we examined CD8 T cells from P14+Lin28TgRag2-/- mice. In this model, T 
cell- specific expression of the Lin28 protein blocks let-7 biogenesis (Piskounova et al., 
2011; Pobezinksy et al., 2015), inhibiting let-7 expression, and P14 is a monoclonal T cell 
receptor specific to the lymphocytic choriomeningitis virus (LCMV) peptide gp33-41, 
presented in the context of H-2Db molecules (Figure 2.2A). In comparison to the P14+ wild 
type counterparts, P14+Lin28Tg CD8 T cells were significantly larger in size, with a 
dramatically increased proportion of Ki67 positive cells (Cuylen et al., 2016) (Figure 2.2B, 
C). Consistent with the increased frequency of cells entering the cell cycle, P14+Lin28Tg 
mice had a significantly higher frequency of BrdU positive cells in both the spleen and 
lymph nodes, as compared to wild type P14+ mice (Figure 2.2D). In addition, surface 
expression of T cell activation markers, such as the IL-2 receptor beta-chain (CD122), and 
CD44 was also increased, while cells remained CD25 negative (Figure 2.2E). Thus, these 
results suggest that the expression of let-7 miRNAs may maintain the quiescence in naïve 
CD8 T cells. 
 
2.2.2 let-7 miRNA expression in CTLs affects both the anti-viral and anti-tumor 
immune responses 
TCR stimulation of naive T cells leads to a rapid loss of the quiescent state and 
differentiation into effector cells. Given that the expression of let-7 miRNAs, which is 
critical for the maintenance of naïve CD8 T cells, is inhibited by TCR signaling (Figure 
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2.1A, B), we hypothesized that the downregulation of let-7 miRNAs in response to TCR 
stimulation is necessary for the differentiation and function of effector CD8 T cells (Figure 
2.3A). To determine whether TCR-mediated downregulation of let-7 miRNAs is required 
for CD8 T cell differentiation in vivo, we analyzed the fate of P14+ CD8 T cells with forced 
let-7 expression in response to acute viral infection with LCMV Armstrong. The 
doxycycline- inducible let-7g transgene (Zhu et al., 2011) maintains let-7g miRNA 
expression in lymphocytes in the presence of doxycycline, even after TCR stimulation 
(Figure 2.3B). Donor CD45.2+CD8+ T cells from P14+ and P14+ let-7 transgenic (let-7Tg) 
mice were adoptively transferred into host congenic wild type CD45.1+ mice that were 
concurrently infected with LCMV, and the differentiation state of P14+ cells was assessed 
seven days post- injection. Interestingly, the recovery of donor CD8 T cells at the peak of 
the immune response revealed that P14+let-7Tg CD8 T cells failed to clonally expand 
(Figure 2.4A) and lacked KLRG1 expression, an established marker of terminal effector 
CTLs (Thimme et al., 2005; Joshi et al., 2007; Dominguez et al., 2015) (Figure 2.4B). 
Furthermore, let-7Tg CTLs had a reduced frequency of IFN-γ+TNF-α+ cytokine double-
producing cells, a hallmark of an effective CD8 T cell response (Kaech et al., 2002; Wherry 
et al., 2004; Williams and Bevan, 2007), while the differentiation of endogenous host-
derived CTLs was normal, suggesting a cell-intrinsic mechanism (Figure 2.4B). 
Importantly, mRNAs of the Klrg1, Ifng and Tnfa genes are not targets of let-7 miRNAs, 
therefore the reduced frequencies of effector cells generated from let-7Tg CD8 T cells is 
not simply a result of direct suppression of effector molecule expression. Thus, sustained 
let-7 expression following TCR activation severely impaired the clonal expansion and 
differentiation of CTLs in response to viral infection in vivo. 
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As the allogeneic response to foreign MHC elicits a robust CD8 T cell response, 
we used the P815 mastocytoma, an allogeneic (H-2d haplotype) tumor, to determine 
whether steady levels of let-7 in T cells would suppress the allogeneic response in vivo 
(Felix and Allen, 2007; Jankovich et al., 2002; Zhan et al., 2000). This response was 
confirmed to be CD8 T cell dependent, as P14+Rag2-/- mice without adoptive transfer of 
CD8 T cells failed to reject the tumor (Figure 2.4C). When P815 cells were injected into 
wild type or let-7Tg mice of H-2b haplotype, 60% of let-7Tg mice were unable to 
effectively respond to, and clear the tumor (Figure 2.4D). Additionally, seven days post-
injection, wild type mice retained on average 40 x106 cancer cells in the peritoneal cavity, 
while let-7Tg mice contained 115 x106 cancer cells (Figure 2.4E). Based on this failure to 
eliminate P815 tumor cells, we concluded that maintaining let-7 expression during 
stimulation and differentiation compromised the CD8 T cell response to alloantigen. Taken 
together, our results demonstrate that downregulation of let-7 expression upon TCR 
engagement is necessary for the proper proliferation and differentiation of cytotoxic CD8 
T cells in vivo. 
 
2.2.3 Expression of let-7 miRNAs in activated CD8 T cells inhibits proliferation and 
the gene expression program responsible for the metabolic switch 
To elucidate the underlying mechanisms of let-7 mediated suppression of CD8 T 
cell responses (Figure 2.4), we first analyzed the impact of let-7 microRNAs on T cell 
clonal expansion. Sorted naïve (CD44loCD25-) CD8 T cells with different levels of let-7 
expression (Figure 2.5A, B) were activated with anti-CD3 mAbs in vitro for 3 days. Let-
7Tg CD8 T cells proliferated less than their wild type counterparts, while Lin28Tg CD8 T 
 41 
cells proliferated more rapidly (Figure 2.6A), indicating that let-7 miRNAs negatively 
regulate clonal expansion of activated CD8 T cells, consistent with the previous 
observations in vivo (Figure 2.4A). Thus, we concluded that TCR-mediated 
downregulation of let-7 expression is needed for successful proliferation of activated CD8 
T cells. 
Let-7 miRNAs are well-documented tumor suppressors. It has been shown that let-
7 inhibits proliferation in cancer cells by directly targeting the mRNA of genes involved in 
the regulation of the cell cycle (Johnson et al., 2007). In fact, the expression of some let-7 
targets such as phosphatase cdc25a (cdc25a), kinase cdk6 (cdk6), and cyclin D2 (ccnd2), 
was suppressed in activated let-7Tg CD8 T cells, as compared to Lin28Tg CD8 T cells 
where it was derepressed (Figure 2.6B). Further, let-7 has been reported to regulate the 
transcription factor Myc, expression of which is upregulated upon T cell activation and is 
essential for CD8 T cell proliferation (Best et al., 2013; Iritani et al., 2002; Kim et al., 2009; 
Nie et al., 2012; Verbist et al., 2016). In fact, Myc expression was regulated by let-7 in 
activated CD8 T cells (Figure 2.6C). To demonstrate that Myc activity was suppressed by 
let-7, we also analyzed the expression of a direct transcriptional target of Myc, the 
transcription factor AP4 (Tfap4), which sustains Myc-mediated effects in CD8 T cells 
during the later stages of differentiation (Chou et al., 2014). Although mRNA of the Tfap4 
gene is not a target of let-7, the expression of Tfap4 mRNA was significantly reduced in 
let-7Tg CD8 T cells, and enhanced in Lin28Tg CD8 T cells (Figure 2.6C), suggesting that 
let-7 regulates Myc activity in CD8 T cells. 
Another important function of Myc in activated CD8 T cells is to support the 
proliferative burst through the metabolic reprogramming of lymphocytes from primarily 
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oxidative phosphorylation (resting) to glycolysis (activated), as well as through an increase 
in protein synthesis (Wang et al., 2011). To test whether let-7 miRNAs have an impact on 
the metabolic switch in activated CD8 T cells through its regulation of Myc, the expression 
of key glucose transporters, glycolytic enzymes, and protein synthesis enzymes that are 
directly controlled by Myc in activated CD8 T cells (Wang et al., 2011) was assessed. 
Strikingly, the expression of all tested targets was suppressed in let-7 transgenic CD8 T 
cells, and increased in Lin28Tg activated lymphocytes, suggesting that let-7 expression 
may influence the Myc-dependent metabolic reprogramming of activated CD8 T cells 
(Figure 2.6D). Taken together, these results demonstrate that let-7 miRNAs control the 
proliferation of activated CD8 T cells by modulating the expression and activity of genes 
involved in the regulation of the cell cycle and metabolism. 
 
2.2.4 let-7 expression regulates the function of differentiated CD8 T cells 
To identify whether let-7 mediated suppression of CD8 T cell immune responses is 
due to a failure to acquire effector function in addition to a proliferative defect, we assessed 
the cytotoxic activity of CTLs generated from P14+ wild type, P14+let-7Tg, and 
P14+Lin28Tg mice. In fact, expression of the let-7 transgene in P14+ CTLs greatly 
diminished cytotoxic activity (Figure 2.7A). Alternatively, P14+Lin28Tg CTLs exhibited 
enhanced cytotoxicity (Figure 2.7A), which could be reduced by restoring let-7 expression 
through the induction of the doxycycline-inducible let-7 transgene in P14+Let-7TgLin28Tg 
(4 Tg) CTLs (Figure 2.8A), demonstrating that let-7- deficiency, and not Lin28 
overexpression, is responsible for increased cytotoxicity. These results demonstrate that 
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TCR-mediated downregulation of let-7 microRNAs is necessary for the acquisition of 
cytotoxic function in differentiating CD8 T cells. 
To investigate how let-7 miRNA expression impacts CD8 T cell function, the 
phenotype of in vitro generated effector CTLs from wild type, let-7Tg, and Lin28Tg mice 
was further examined. Let-7Tg CTLs had less internal complexity based on the intensity 
of side scatter (SSC) than wild type cells, whereas Lin28Tg CD8 effector cells had 
significantly greater complexity (Figure 2.7B), suggesting a change in the number of 
cytotoxic granules. Indeed, let-7Tg CTLs contained fewer Granzyme A and Granzyme B 
positive granules than wild type CTLs, while Lin28Tg CTLs had more (Figure 2.7C). 
These results indicated that the expression of let-7 controls the quantity of cytotoxic 
granules produced during the differentiation of CTLs. 
Next, to determine whether let-7 expression in CTLs influences the number of 
granules by controlling the expression of effector molecules, gene expression of Granzyme 
A (Gzma), Granzyme B (Gzmb), and Perforin (Prf1), the key cytolytic factors in cytotoxic 
granules (Chowdury and Lieberman, 2008), was measured. Let-7Tg CTLs, which 
contained fewer cytotoxic granules, expressed less mRNA for Gzma, Gzmb, and Prf1, as 
compared to wild type cells, while Lin28Tg CTLs expressed higher levels of these effector 
molecules (Figure 2.7D). Moreover, the observed changes in mRNA expression of effector 
molecules, including Interferon-gamma (IFN-γ), were consistent at the protein level 
(Figure 2.7E, F). Importantly, the induction of let-7 expression in the presence of Lin28 in 
P14+Let-7TgLin28Tg (4 Tg) CTLs reduced the expression of these effector molecules 
(Figure 2.8B), again demonstrating that the Lin28Tg phenotype is due to let-7- deficiency. 
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Together, these data indicate that let-7 miRNAs negatively regulate CTL function by 
preventing the expression of important cytotoxic molecules. 
 
2.2.5 let-7 miRNAs directly target the ‘master regulator’ transcription factor, 
Eomesodermin during CTL differentiation  
To determine the mechanism through which let-7 regulates the differentiation and 
function of CTLs, we considered the possibility that let-7 miRNAs may directly control 
the expression of effector molecules. Although typical miRNA binding sites are found in 
the 3’ untranslated regions (UTRs) of mRNA transcripts (Lai et al., 2002; Reinhart et al., 
2000; Wightman et al., 1993) we analyzed the full-length mRNA of Prf1, Gzma, Gzmb, 
and Ifng, yet no let-7 binding sites were found. This suggested that let-7 may indirectly 
regulate the expression of these molecules by controlling more global regulators, such as 
transcription factors. It is known that the expression of effector molecules and cytotoxic 
function of CD8 T cells are tightly regulated by a group of transcription factors, including 
Eomesodermin (Eomes), T-bet, Zbtb32, Runx3, Notch-1 and Blimp-1 (Backer et al., 2014; 
Cho et al., 2009; Kallies et a., 2009; Pearce et al., 2003; Szabo et al., 2002; Shin et al., 
2017). To determine if these factors are regulated by let-7, expression of Eomes, Tbx21, 
Zbtb32, Prdm1, Runx3d, and Notch-1 genes was assessed in CTLs with different levels of 
let-7. The only transcription factor whose expression on both the mRNA and protein levels 
was reduced in let-7 transgenic CTLs, and enhanced in Lin28Tg CTLs, was Eomes (Figure 
2.9A-D). Furthermore, the induction of let-7 expression in the presence of Lin28 in 
P14+Let-7TgLin28Tg (4 Tg) CTLs reduced the expression of Eomes (Figure 2.9E), 
demonstrating that increased expression of Eomes in Lin28Tg CTLs is due to the Lin-28-
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mediated knockdown of let-7 miRNAs. Of note, we also found that T-bet expression was 
inversely correlated with Eomes, suggesting that an Eomes dependent mechanism may 
control T-bet expression (Figure 2.9A, B). Thus, these results demonstrate that let-7 
miRNAs negatively regulate Eomes expression.  
Next, we sought to determine whether let-7 miRNAs can target Eomes mRNA. 
Interestingly, there is no let-7 binding site located in the 3’UTR of Eomes, but rather a 
conserved binding motif within the open reading frame of Eomes mRNA was identified 
(Figure 2.10A). To determine whether this binding site is functional, the 10-nucleotide 
mouse Eomes-let-7 binding motif was cloned into a dual luciferase vector. The vector was 
then transfected into NIH 3T3 fibroblasts, which have high endogenous expression of the 
let-7 family members (Figure 2.10 B, C). This resulted in a significant decrease in 
luciferase activity, indicating that let-7 can directly bind Eomes (Figure 2.10D). When this 
sequence was mutated, disrupting the let-7 binding site, luciferase activity was restored, 
confirming that let-7 microRNAs directly target Eomes mRNA (Figure 2.10D). 
 
2.2.6 let-7 miRNAs suppress CD8 T cell function through targeting Eomes mRNA 
 To ascertain whether let-7 controlled CD8 T cell differentiation and function 
through Eomes, a loss-of-function approach to knockout Eomes expression in Lin28Tg 
CTLs was used. It was hypothesized that removal of Eomes expression would reduce the 
enhanced cytotoxicity in let-7-deficient cells. T-cell specific deletion of either one or both 
alleles of Eomes in CTLs generated from P14+CD4Cre+Eomesfl/wt Lin28Tg, and 
P14+CD4Cre+Eomesfl/flLin28Tg T cells resulted in gradually decreased levels of Eomes 
(Figure 2.11A). Any residual Eomes expression in CTLs derived from 
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CD4Cre+Eomesfl/flLin28Tg mice, was attributed to “escapees” of the conditional knockout. 
The expression of the effector molecules Gzma, and Prf1 was reduced in a manner 
consistent with the expression of Eomes, where loss of Eomes ameliorated the enhanced 
expression of these effector molecules in Lin28Tg effector cells (Figure 2.11B, C).  
Interestingly, the expression of Granzyme B was not affected by loss of Eomes expression, 
suggesting Granzyme B may be more complexly regulated through other let-7- dependent, 
but Eomes- independent mechanisms (Figure 2.11D). Ultimately, the loss of Eomes 
expression resulted in a significant reduction of cytotoxic function, even in the absence of 
let-7 microRNAs (Figure 2.11E) while restored Eomes expression completely rescued both 
the cytotoxic function and the expression of effector molecules in Eomes-deficient 
Lin28Tg CTLs (Figure 2.12A, B). Furthermore, forced expression of the mutated form of 
Eomes (lacking the let-7 binding motif) in let-7Tg CTLs also enhanced the effector 
phenotype (Figure 2.12C, D). These results demonstrate that let-7-mediated suppression of 
Eomes is in part responsible for the compromised differentiation and cytotoxic function of 
let-7Tg CTLs in vitro. 
Thus, these data suggest a model in which the let-7 miRNAs act as a molecular 
control hub that drives CD8 T cell differentiation and function, in a manner dependent on 
the magnitude of TCR stimulation (Figure 2.13). Furthermore, we propose that modulation 
of let-7 miRNA expression in CD8 T cells provides an exciting, novel therapeutic 
application to control CTL responses. 
 
2.3 Discussion 
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This study has identified a critical role for the let-7 miRNAs in regulating the 
transition between naïve and effector stages of CD8 T cells. Specifically, let-7 expression 
is high in naïve T cells and, when absent, results in increased proliferation and expression 
of activation markers, which may suggest a loss of the quiescent phenotype in CD8 
lymphocytes. Moreover, the entire family of let-7 miRNAs is downregulated upon antigen 
stimulation through the TCR, which was demonstrated to be necessary for the successful 
progression of CD8 T cell differentiation into CTLs. Therefore, these data suggest that let-
7 expression keeps CD8 T cells in a naïve state and prevents CTL differentiation, while the 
magnitude of TCR-mediated downregulation of let-7 expression guides the proliferation, 
differentiation and the acquisition of effector function of CD8 T cells. 
The importance of miRNAs in the regulation of the immune system has been 
demonstrated through the deletion of the miRNA processing enzyme, Dicer. In fact, it has 
been shown that Dicer deficiency promotes the differentiation of CD8 T cells into CTLs 
(Trifiari et al., 2013), suggesting the involvement of specific miRNAs. Let-7 microRNAs, 
the largest and most abundantly expressed family of miRNAs in CD8 T cells, have been 
shown to be important in early development, metabolism, and cancer (Zhu et al., 2011; 
Bussing et al., 2008; Roush and Slack, 2008). Recent studies have also implicated the 
importance of the let-7 miRNAs in the development, maintenance, and function of the 
immune system, including T cells (Pobezinksy et al., 2015; Yuan et al., 2012; Okoye et al., 
2014). Using both gain-of-function experiments employing the let-7Tg mouse capable of 
sustaining let-7 expression following TCR activation, and loss-of-function experiments 
using the Lin28Tg mouse, where the Lin28Tg inhibits let-7 expression, this study has 
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corroborated these earlier reports, and has identified a novel role for let-7 in CD8 T cell 
differentiation and function.  
Prior to antigen encounter, naïve CD8 T cells are maintained in a quiescent state, 
in which T cells have no effector function, are metabolically inactive and undergo minimal 
proliferation. The homeostasis of naïve T cells depends on the balance of two signals, the 
recognition of low affinity self-ligands by the TCR, and cytokine stimulation (Surh and 
Sprent, 2011; Kimura et al., 2013). Although it has become clear that the weak recognition 
of self-ligands is not enough for naïve T cells to lose the quiescent state, the molecular 
mechanism that prevents the spontaneous activation of T cells under these conditions is not 
fully understood. Here, the high expression of let-7 microRNAs was demonstrated to be 
necessary for maintaining the naïve CD8 T cell state. In fact, let-7 ablation in CD8 T cells 
led to the loss of the quiescent phenotype, as indicated by more active proliferation, an 
overall increase of cell size, and the upregulation of activation markers such as CD122, 
and CD44 (Cuylen et al., 2016; Intlekofer et al., 2005). These experiments were conducted 
using CD8 T cells from P14+Lin28TgRag2-/- mice in order to prevent bystander effects 
from IL-4- producing PLZF+ cells present in Lin28Tg mice (Pobezinsky et al., 2016; Yuan 
et al., 2012; Weinreich et al., 2010). Although further investigation is needed to distinguish 
between the let-7-dependent and let-7-independent effects of the Lin28 transgene in naïve 
CD8 T cells, it can be speculated that high expression of let-7 microRNAs prevents the 
spontaneous activation of naïve T cells. Furthermore, it will be interesting to explore the 
precise let-7-mediated regulation of transcription programs, such as Foxp1 (Feng et al., 
2011), that may contribute to the control of CD8 T cell quiescence. 
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Furthermore, we have found that the let-7 mediated “molecular brake” is released 
upon antigen stimulation, due to the profound downregulation of all members of the let-7 
microRNA family in activated CD8 T cells in response to TCR stimulation, in a manner 
proportional to its strength. Using in vivo models to assess both anti-viral and anti-tumor 
immunity, the importance of let-7 miRNAs in controlling CD8 T cell- mediated immune 
responses was demonstrated. Let-7Tg CD8 T cells failed to proliferate in response to acute 
LCMV infection, and the few let-7Tg cells that did respond exhibited a very weak effector 
phenotype, suggesting that downregulation of let-7 is critical to both the proliferative burst 
of antigen-specific CD8 T cells upon encounter with viral antigen, and the differentiation 
of these cells in vivo. These results were further bolstered by the failure of let-7Tg mice to 
reject an allogeneic tumor, the P815 mastocytoma. Altogether, these in vivo studies 
demonstrate the significance of let-7 downregulation in effector CD8 T cells, and suggest 
a novel level of control of immune responses that can be therapeutically targeted for 
treatment of infectious diseases, cancer and autoimmunity. 
Antigen stimulation of T cells results in the increased biosynthesis that is needed to 
support the clonal expansion of antigen specific lymphocytes, and ultimately the 
acquisition of effector function. The hallmark of this process is a metabolic switch from 
oxidative phosphorylation to aerobic glycolysis (Frauwirth et al., 2002), as well as a 
concomitant increase in cell size, both of which have been reported to be controlled by 
Myc (Chou et al., 2014; Wang et al., 2011), the expression of which is rapidly induced 
upon antigen stimulation of CD8 T cells (Williams and Bevan, 2007; Wang et al., 2011). 
Presumably due to the pro-apoptotic activity of Myc (Chang et al., 2000; Chou et al., 2014), 
its expression is transient, eventually receding during the later stages of CD8 T cell 
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differentiation (Best et al., 2013; Nie et al., 2012). In our study, we have shown that let-7 
suppresses the expression of Myc on the mRNA level, and consequently modulates the 
function of Myc in CD8 T cells, based on the assessment of established Myc targets, 
supporting previous reports of Myc as a non-canonical target of let-7 miRNAs in cancer 
cells (Kim et al., 2009). Our results suggest that let-7 likely regulates the metabolic switch 
in activated CD8 T cells through Myc. 
It was also found that the let-7 miRNAs may directly inhibit the proliferation of 
activated CD8 T cells by suppressing the expression of the cell cycle regulators Cdc25a, 
Ccnd2 and Cdk6, all of which are known let-7 targets (Johnson et al., 2007). Since these 
factors have also been described as transcriptional targets of Myc (Bouchard et al., 1999; 
Galaktinov et al., 1996; Hermeking et al., 2000), the possibility of more complex regulation 
in which let-7 is not solely responsible for controlling their expression cannot be ruled out.  
Moreover, it was demonstrated that let-7 mediated suppression of CD8 T cell 
immune responses is also due to modulation of effector function. The internal complexity 
of CTLs generated in vitro was diminished in the presence of forced let-7 expression, and 
it was subsequently determined that this was due to a reduction in the number of cytotoxic 
granules, as well as in the expression of effector molecules. This led to the conclusion that 
let-7 functions as a molecular rheostat that quantifies TCR signaling to direct the CTL 
response upon antigen stimulation, in a similar fashion to other miRNAs, including miR-
181 and the miR-17-92 cluster (Henao-Mejia et al., 2013; Li et al., 2007; Wu et al., 2012). 
These conclusions are supported by a recent study demonstrating that in neonatal mice the 
residual expression of Lin28B in T lymphocytes skews CD8 T cell differentiation towards 
an effector phenotype (Wang et al., 2016). 
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We further wanted to determine the molecular mechanisms through which let-7 acts 
to inhibit CTL differentiation. Eomes was found to be directly regulated by let-7 
microRNAs, which can in part explain the block in the differentiation of CD8 T cells with 
forced let-7 expression. Yet, in contrast to previous studies on the differential roles of 
Eomes and T-bet in governing CD8 T cell function, we have shown that heightened 
expression of Eomes in effector T cells may be more important for effector function than 
previously thought (Pearce et al., 2003; Intlekofer et al., 2005; Chang et al., 2014). In fact, 
let-7/ Eomes-double deficient CTLs had reduced antigen-specific cytotoxicity in vitro. 
However, this data also suggested that Eomes is only a part of this “cytotoxic program”, as 
deletion of Eomes reduced cytotoxicity to the levels exhibited by wild type CTLs, and re-
expression of Eomes in let-7Tg CTLs only marginally increased cytotoxicity. These results 
indicate that other let-7- dependent, but Eomes- independent mechanisms are involved. 
More experiments are required to elucidate these Eomes- independent mechanisms, and 
should be enlightening given the suggested redundancy of Eomes activity. Additionally, 
Granzyme A was identified as a probable target of Eomes, while Eomes-mediated control 
of Perforin, and IFN-γ expression was confirmed (Pearce et al., 2003). These results are 
consistent with the enhanced cytotoxicity exhibited by Lin28Tg CD8 T cells with increased 
Eomes expression. The previously reported reciprocal expression between T-bet and 
Eomes (Intlekofer et al., 2005; Chang et al., 2014) was also observed.  
These results strongly demonstrate that downregulation of let-7 upon TCR 
stimulation is a critical process in the determination of the magnitude of the CD8 T cell 
response in vivo, as let-7 miRNAs inhibit proliferation and differentiation by targeting cell 
cycle regulators, affecting metabolic reprogramming through the suppression of Myc, and 
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repression of effector function through Eomes dependent and independent mechanisms. 
Thus, naïve CD8 T cells require let-7 miRNAs to remain quiescent, and only upon antigen 
stimulation through the TCR can this molecular “brake” be released. Based on these results, 
we propose that let-7 miRNAs act as a molecular control hub that translates TCR signaling 
to control CD8 T cell differentiation and function. 
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Figure 2.1 let-7 expression is downregulated by TCR signaling 
(a) Quantitative RT-PCR analysis of individual let-7 miRNAs in naïve CD8 T cells 
stimulated with plate-bound anti-TCR (μg as indicated) and anti-CD28 (5 μg) for 24 hours, 
presented relative to results obtained for the small nuclear RNA (U6 control) and 
normalized to the unstimulated (0 μg) sample. (b) Quantitative RT-PCR analysis of 
individual let-7 miRNAs in naïve CD8 T cells stimulated with plate-bound anti-TCR (5μg) 
and anti-CD28 (5 μg) over increasing periods of time as indicated, presented relative to 
results obtained for the small nuclear RNA (U6 control) and normalized to the unstimulated 
(0h) sample. (c) Quantitative RT-PCR analysis of individual let-7 miRNAs in naïve CD8 
T cells stimulated with plate-bound anti-TCRβ (10μg) and anti-CD28 (5 μg) over 
increasing periods of time as indicated, presented relative to results obtained for the small 
nucleolar RNA (sno135) and normalized to the unstimulated (0h) sample. (d) Quantitative 
RT-PCR analysis of miR-17 in naïve CD8 T cells stimulated with plate-bound anti-TCRβ 
(10μg) and anti-CD28 (5 μg) over increasing periods of time as indicated, presented 
relative to results obtained for the small nuclear RNA (U6) (left) or the small nucleolar 
RNA (sno135) (right) and normalized to the unstimulated (0h) sample. *** P < 0.001, 
compared with 0 hours using two-tailed Student’s t-test (d). Data are from one experiment 
representative of two independent experiments (a, b, c, d; mean and s.e.m. of technical 
triplicates). 
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Figure 2.2 let-7 expression is necessary and sufficient to maintain the naïve phenotype 
of CD8 T cells prior to TCR stimulation 
(a) Quantitative RT-PCR analysis of individual let-7 miRNAs in naïve and effector (day 
5) TCR transgenic CD8 T cells from P14+Rag2-/-, and P14+Lin28TgRag2-/- mice. (b) Size 
analysis based on FSC (forward scatter) of naïve CD8 T cells from the spleens and lymph 
nodes of P14+ wild type and P14+Lin28Tg mice, both on Rag2-/- background, normalized 
to wild type. (c) Expression of Ki67 in naïve CD8 T cells from spleens and lymph nodes 
of P14+ wild type and P14+Lin28Tg mice, both on Rag2-/- background (left). Quantification 
of the frequency of Ki67+ cells in these populations (right). (d) Frequency of BrdU+ cells 
in naïve CD8 T cells from spleens and lymph nodes of P14+ wild type (n=6) and 
P14+Lin28Tg (n=5) mice, both on Rag2-/- background, labeled with BrdU in vivo. (e) 
Surface expression (right) and normalized MFI (left) of CD25, CD44, and CD122 on naïve 
CD8 T cells from both spleens and lymph nodes of P14+ wild type and P14+ Lin28Tg mice, 
both on Rag2-/- background. Gray indicates an isotype control for staining. n.s., not 
significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001, compared with wild 
type using two-tailed Student’s t-test (b, c, d, e) Data are from one experiment 
representative of three independent experiments (a; mean and s.e.m. of technical triplicates; 
b, c, d, e; mean and s.e.m. of three experiments). 
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Figure 2.3 Hypothesis and model to test role of let-7 expression in CD8 T cell 
responses 
(a) Schematic representation of the hypothesis that let-7 expression inhibits the 
differentiation of CD8 T cells. (a) Quantitative RT-PCR analysis of individual let-7 
miRNAs in naïve and effector (day 5) TCR transgenic CD8 T cells from P14+Rag2-/-, and 
P14+let-7TgRag2-/- mice. Data are from one experiment representative of three independent 
experiments (a; mean and s.e.m. of technical triplicates). 
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Figure 2.4 Inhibitory role of let-7 miRNA expression in CD8 T cell- mediated 
responses in vivo 
(a) Quantification of the number of donor (CD45.2+) CD8 T cells from P14+ wild type 
(n=3) or P14+let-7Tg mice (n=3) in the spleens of congenic (CD45.1+) host mice 7 days 
after cell transfer and LCMV Armstrong infection. (b) Surface expression of the activation 
marker KLRG1 on wild type host, and indicated donor cells (top). Expression of IFN-γ, 
and TNF-α in wild type host, and donor LCMV-specific CD8 T cells from the indicated 
mice, as determined by re-stimulation with the gp33 peptide, and subsequent intracellular 
staining (middle). Quantification of the frequency of KLRG1+, and IFN-γ+, TNF-α+ 
populations in wild type host, and donor cells from the indicated mice (bottom). (c) 
Analysis of the survival of Rag2-/- mice injected i.p. with 30X106 P815 cells, which 
received i.v. adoptive transfer of 10X106 naïve purified CD8 T cells (n=6) or no T cells at 
all (n=8). (d) Analysis of the survival of wild type (n=5) or let-7Tg (n=5) mice injected i.p. 
with 30X106 P815 cells. (e) Quantification of the number of P815 tumor cells remaining in 
the peritoneal cavity 7 days after i.p. injection of 20X106 cells into either wild type (n=6), 
or let-7Tg mice (n=5). n.s., not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P 
< 0.001, compared with wild type using two-tailed Student’s t-test (a, b, e) or one-tailed 
Student’s t-test (e). Data are from one experiment representative of three independent 
experiments (a, b; mean and s.e.m. of three experiments), two experiments (d, e), or one 
experiment (c). 
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Figure 2.5 Sorting strategy and let-7 expression in polyclonal CD8 T cells 
(a) Pre- sort and post- sort purities for naïve CD8 T cells from wild type, let-7Tg, and 
Lin28Tg mice. Cells were isolated from the lymph nodes of the indicated mice, and 
enriched for T cells using anti-mouse IgG magnetic beads. Next, to acquire naïve CD8 T 
cells, lymph node T cells were then stained for CD25, CD44, CD4, and CD8, and sorted 
as the CD25-CD44loCD4-CD8+ population. (b) Quantitative RT-PCR analysis of individual 
let-7 miRNAs in naïve and activated (day 5) polyclonal CD8 T cells from wild type, let-
7Tg, and Lin28Tg mice. Data are from one experiment representative of three independent 
experiments (b; mean and s.e.m. of technical triplicates). 
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Figure 2.6 let-7 miRNAs suppress the proliferation and metabolism of activated CD8 
T cells 
(a) Analysis of the proliferation of CellTrace Violet- labeled naïve CD8 T cells from the 
indicated mice 72 hours after activation with anti- CD3 mAbs. (b) Quantitative RT-PCR 
analysis of cell cycle regulators: Cdc25a (Cell division cycle 25A phosphatase), Ccnd2 
(Cyclin D2), Ccnf (Cyclin F), Cdk6 (Cyclin dependent kinase 6) in naïve and activated 
wild type, let-7Tg, and Lin28Tg CD8 T cells 3 days after anti-CD3 mAb stimulation, 
presented relative to the ribosomal protein Rpl13a. (c) Quantitative RT-PCR analysis of 
Myc and Tfap4 (Transcription factor AP-4) in CD8 T cells after stimulation with anti-CD3 
mAbs, presented relative to the ribosomal protein Rpl13a. Wild type, let-7Tg, and Lin28Tg 
CD8 T cells were stimulated with anti-CD3 mAbs and differentiated for the indicated time. 
(d) Quantitative RT-PCR analysis of the expression of genes involved in the metabolic 
switch: Glut1 (Glucose transporter 1), Glut3 (Glucose transporter 3), Gpd2 (Glycerol-3-
phosphate dehydrogenase 2), Pfk1 (Phosphofructokinase 1), Hk2 (Hexokinase 2), Tpi 
(Triose phosphate isomerase), Pkm (Pyruvate kinase muscle isozyme), Ldha (Lactate 
dehydrogenase A), Yars (Tyrosyl-tRNA synthetase) in wild type, let-7Tg, and Lin28Tg 
CD8 T cells three days after stimulation with anti-CD3 mAbs, presented relative to the 
ribosomal protein, Rpl13a. n.s., not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** 
P < 0.001, compared with wild type using two-tailed Student’s t-test. (a, b, c, d; one 
experiment representative of three independent experiments (a) or mean and s.e.m. of 
technical triplicates (b, c, d)). 
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Figure 2.7 let-7 miRNAs negatively regulate differentiation and acquisition of effector 
function in CTLs 
(a) Cytotoxicity assay of differentiated CTLs from P14+ wild type, P14+let-7Tg, and 
P14+Lin28Tg lymph nodes co-cultured with either LCMV gp33 or LCMV np396 peptide-
pulsed splenocytes for 4-5 hours. (b) Analysis of the internal complexity (FSC, forward 
scatter; SSC, side scatter) of effector (5 days after anti-CD3 mAb stimulation) CD8 T cells 
generated from wild type, let-7Tg, and Lin28Tg lymphocytes (left) and quantification of 
SSC of CD8 T cells normalized to wild type. (c) Quantification of Granzyme A and 
Granzyme B- positive granules in wild type, let-7Tg, and Lin28Tg CTLs via MilliPore 
Amnis ImageStream. (d) Quantitative RT-PCR analysis of effector molecule mRNA 
expression: Gzma (Granzyme A), Gzmb (Granzyme B), Prf1 (Perforin) in naïve and 
effector CD8 T cells from wild type, let-7Tg, and Lin28Tg lymph nodes, presented relative 
to expression of the ribosomal protein Rpl13a. (e) Staining (top, middle) and MFI (bottom) 
of Granzyme B, Interferon-γ, and Granzyme A in wild type, let-7Tg, and Lin28Tg effector 
CD8 T cells normalized to wild type. (f) Western blot analysis of lysates of wild type, let-
7Tg, and Lin28Tg effector CD8 T cells, probed with monoclonal antibodies against 
Perforin and actin. n.s., not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 
0.001, compared with wild type using two-tailed Student’s t-test. Data are from one 
experiment representative of three experiments (a, d, e; mean and s.e.m. of technical 
triplicates, b, e; mean and s.e.m of three experiments). 
 
 
  
 64 
 
 
Figure 2.8 Enhanced function of Lin28Tg CTLs is not due to a bystander effect of 
Lin28 expression 
(a) Cytotoxicity assay of differentiated CTLs from P14+ wild type (WT), or P14+let-
7Tg+Lin28Tg+Rag2-/- (4Tg) lymphocytes co-cultured with either LCMV gp33 or LCMV 
np396 peptide-pulsed splenocytes for 4-5 hours, either in the presence or absence of 
doxycycline. (b) Quantitative RT-PCR analysis of effector molecule mRNA expression: 
Prf1 (Perforin), Gzma (Granzyme A), Gzmb (Granzyme B) in effector CD8 T cells from 
P14+ wild type, or P14+let-7Tg+Lin28Tg+Rag2-/- (4Tg) lymph nodes cultured either in the 
presence or absence of Dox, presented as the fold change in expression, normalized to wild 
type. n.s., not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001, compared 
with wild type using two-tailed Student’s t-test. Data are from one experiment 
representative of three experiments (a) or one experiment (b) (a,b; mean and s.e.m. of 
technical triplicates). 
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Figure 2.9 let-7 miRNAs regulate Eomes expression in activated CD8 T cells 
(a, b) Quantitative RT-PCR analysis of Notch target genes: Hes1 (Hes family BHLH 
transcription factor 1), Hey1 (Hes related family BHLH transcription factor with YRPW 
motif 1), Heyl (Hes related family BHLH transcription factor with YRPW motif- like), 
Dtx1 (Deltex 1) (a) and transcription factors that control CD8 T cell differentiation: Zbtb32 
(Zinc finger and BTB domain containing 32), Prdm1 (Blimp-1), Runx3d (Runt related 
transcription factor 3 distal) Tbx21 (T-bet), and Eomes (b) in naïve and effector (5 days 
after anti-CD3 mAb stimulation) wild type, let-7Tg, and Lin28Tg CD8 T cells, presented 
relative to the expression of the ribosomal protein Rpl13a. (c) Staining of Eomes and T-bet 
(left) and MFI of Eomes and T-bet (right) in wild type, let-7Tg, and Lin28Tg effector CD8 
T cells, normalized to wild type. (d) Quantitative RT-PCR analysis of Eomes 
(Eomesodermin) mRNA in P14+ wild type, or P14+let-7Tg+Lin28Tg+Rag2-/- (4Tg) lymph 
nodes cultured either in the presence or absence of Dox, presented as the fold change in 
expression, normalized to wild type. n.s., not significant (P > 0.05), * P < 0.05, ** P < 
0.01, and *** P < 0.001, compared with wild type using two-tailed Student’s t-test. Data 
are from one experiment representative of three independent experiments (a, b, d; mean 
and s.e.m. of technical triplicates, or three experiments (c)). N.D., not determined. 
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Figure 2.10 let-7 miRNAs directly target the mRNA of Eomes in activated CD8 T cells 
(a) Eomes mRNA, including the 5’ and 3’ untranslated regions (UTR) and the open reading 
frame (ORF) within which one let-7 binding site was identified (top), sequence 
conservation between the mouse and human let-7 binding sites of Eomes is shown 
(middle). Mutated sequence of the let-7 binding site in the cDNA of mouse Eomes (bottom) 
used in the luciferase reporter assay. (b) Luciferase reporter assay of let-7 targeting of the 
Eomes ORF in NIH 3T3 fibroblasts transfected with a luciferase reporter containing either 
the intact or mutated sequence of the let-7 seed region from the mouse Eomes ORF; the 
activity of firefly luciferase was normalized to the Renilla luciferase control. (c) 
Quantitative RT-PCR analysis of individual let-7 miRNAs in NIH 3T3 fibroblasts, 
presented relative to results obtained for the small nuclear RNA (U6) (d) Expression 
analysis of three let-7 family members by luciferase reporter assay. A firefly luciferase 
reporter containing either intact or mutated let-7b, let-7g, or let-7i antisense seed regions 
were transfected into NIH 3T3 cells. The activity of firefly luciferase was normalized to 
the Renilla luciferase control. *** P < 0.001, compared with wild type using two-tailed 
Student’s t-test (b). Data are one experiment representative of three independent 
experiments (b, c, d; mean and s.e.m. of technical triplicates). 
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Figure 2.11 let-7 miRNAs control the differentiation of CTLs through Eomes-
dependent and independent mechanisms 
(a) Quantitative RT-PCR analysis of Eomes mRNA, presented as the fold change in 
expression, normalized to wild type (left) and MFI of Eomes protein expression, 
normalized to wild type (right), from CTLs generated from P14+CD4-Cre-Eomesfl/wt, 
P14+CD4-Cre-EomeswtLin28Tg, P14+CD4Cre+Eomesfl/wtLin28Tg, and 
P14+CD4Cre+Eomesfl/flLin28Tg CD8 T cells. (b) Quantitative RT-PCR analysis of GzmA 
(Granzyme A) and Prf1 (Perforin) mRNA in effector CTLs generated from the indicated 
mice, presented as the fold change in expression, normalized to wild type. (c) Staining of 
Granzyme A in CTLs generated from the indicated mice. (d) Staining of Granzyme B in 
CTLs generated from the indicated mice. (e) Cytotoxicity assay demonstrating specific 
target lysis of differentiated P14+ CTLs from the indicated mice, co-cultured with either 
LCMV gp33 or LCMV np396 peptide-pulsed splenocytes for 4-5 hours. n.s., not 
significant (P > 0.05), ** P < 0.01, and *** P < 0.001, compared with Lin28Tg (a, b, e) or 
4Tg without Dox compared with 4Tg with Dox (d) using two-tailed Student’s t-test. Data 
are from one experiment representative of two independent experiments (a, d; mean and 
s.e.m. of two experiments; b, e; mean and s.e.m. or technical triplicates). 
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Figure 2.12 Re-expression of Eomes enhances cytotoxic function of CTLs 
(a) Cytotoxicity assay demonstrating specific target lysis of LCMV gp33 or LCMV np396 
peptide-pulsed splenocytes by differentiated P14+CD4Cre+Eomesfl/flLin28Tg CTLs 
transduced with the indicated virus, cells were co-cultured for 4-5 hours. (b) Quantitative 
RT-PCR analysis of Eomes (Eomesodermin), Gzma (Granzyme A), Gzmb (Granzyme B), 
and Prf1 (Perforin) expression in CTLs described in a, presented as the fold change in 
expression, normalized to RV-Empty. (c) Visualization of the mutations made to the let-7 
binding motif in mouse Eomes ORF to generate the RV-EomesMUTANT (top), and 
cytotoxicity assay demonstrating specific target lysis of differentiated P14+let-7Tg CTLs 
transduced with the indicated virus, co-cultured with either LCMV gp33 or LCMV np396 
peptide-pulsed splenocytes for 4-5 hours (bottom). (d) Quantitative RT-PCR analysis of 
Eomes (Eomesodermin), Gzma (Granzyme A), Gzmb (Granzyme B), and Prf1 (Perforin) 
in effector CTLs from c, presented as the fold change in expression, normalized to RV-
Empty. n.s., not significant (P > 0.05), ** P <0.01, *** P < 0.001, RV-Eomes or RV-
EomesMUTANT compared with RV-Empty using two-tailed Student’s t-test (a, b, c, d). Data 
are from one experiment representative of two independent experiments (a, b, c, d; mean 
and s.e.m. of technical triplicates). 
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Figure 2.13 Model of let-7- mediated regulation of CD8 T cell differentiation 
(a) Upon TCR stimulation, let-7 miRNAs are rapidly down-regulated, in order to release 
the ‘molecular brake’ let-7 places on CD8 T cell differentiation in naïve cells. Our study 
suggests that let-7 miRNAs inhibit clonal expansion and metabolic reprogramming of 
activated CD8 T cells through inhibition of Myc and other cell cycle controlling factors. 
Further, our data indicates let-7 also suppresses the acquisition of effector function of CTLs 
through the direct targeting of Eomes mRNA. 
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CHAPTER 3 
LET-7 MIRNAS IN CD8 T CELLS PROMOTE MEMORY FORMATION BY 
RESTRAINING TERMINAL DIFFERENTIATION AND EXHAUSTION 
 
3.1 Introduction 
Antigen stimulation licenses CD8 T cells to rapidly differentiate into cytotoxic T 
lymphocytes (CTLs), the majority of which die during contraction following clearance of 
the antigen, while the surviving cells differentiate into highly protective long-lived memory 
cells (Kaech and Cui, 2012). Although terminal effector CTLs provide robust cytotoxic 
responses against the antigen, they do not contribute to the memory pool, and are cleared 
during contraction (Schluns et al., 2000; Kaech et al., 2003). In fact, as CD8 T cells 
progress further into the terminal effector program, they steadily lose the potential to 
differentiate into memory cells (Joshi et al., 2007; Kaech and Cui, 2012; Chang et al., 2014; 
Gray et al., 2017; Chen et al., 2018). Moreover, terminal effector cells express high levels 
of co-inhibitory receptors, such as PD-1, Tim-3, CD160, and 2B4, to prevent 
hyperactivation, and to scale the effector response to the demands of the infection (Wherry 
et al., 2007; Doering et al., 2012; Paley et al., 2012; Singer et al., 2016). However, in 
chronic infections and cancer, persistent antigen exposure results in sustained, and often 
heightened expression of inhibitory receptors, making the terminal effector population 
vulnerable to exhaustion (Wherry et al., 2007; Doering et al., 2012). Engagement of these 
receptors in immunosuppressive settings, such as the tumor microenvironment, re-routes 
terminal effector cells into an unresponsive, exhausted state (Wherry and Kurachi, 2015). 
Additionally, the chronic TCR stimulation which results from persistent antigen exposure 
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drives cells into a dysfunctional state by establishing irreversible epigenetic modifications 
(Schietinger et al., 2016; Yu et al., 2017).  
Interestingly, it was recently demonstrated that memory cells confer robust anti-
tumor protection (Geiger et al., 2016; Sahin et al., 2017; Herndler-Brandstetter et al., 2018). 
Although the exact mechanisms for these enhanced responses are not known, it is perhaps 
due to low inhibitory receptor expression and the enhanced survival program in memory 
CD8 T cells (Kaech et al., 2002), rendering these cells impervious to the 
immunosuppressive environments established during chronic infection and cancer. Thus, 
a more complete understanding of the molecular mechanisms that restrain CD8 T cell 
terminal differentiation, and in turn preserve memory potential in these cells is warranted, 
and would have therapeutic implications for both preventing exhaustion and promoting 
memory formation in immunosuppressive settings. As the differentiation of terminal 
effector and memory cells is regulated at multiple levels, it is that likely that a global 
molecular hub which can regulate multiple cellular process controls terminal effector and 
memory differentiation. Post-transcriptional regulation mediated by miRNAs provides 
robust sequence-specific regulation of gene expression in a tissue and context-dependent 
manner. Accordingly, miRNAs are strong candidates for controlling the differentiation of 
terminal effector and memory CD8 T cells. 
In fact, the involvement of miRNAs in terminal effector and memory CD8 T cell 
differentiation has been demonstrated, although the extent of their involvement is not fully 
understood. While roles for miR-31 (Moffett et al., 2017) and the miR-23-27-24 cluster 
(Cho et al., 2016) have been suggested, the miRNA most extensively studied in terminal 
effector and memory differentiation is miR-155 (Gracias et al., 2013; Lind et al., 2013; 
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Stelekati et al., 2018). Mir-155 expression is very dynamic in different CD8 T cell 
populations. It is expressed at low levels in naïve cells, is upregulated in terminal effector 
cells, becomes is highly expressed in exhausted CD8 T cells, and is lowly expressed in 
memory CD8 T cells (Gracias et al., 2013). A functional role for miR-155 in effector cells 
was identified by the compromised the effector CD8 T cell response in miR-155-deficienct 
mice, which was attributed to an impairment in CD8 T cell proliferation and expansion 
(Gracias et al., 2013; Lind et al., 2013). Consistent with high expression of miR-155 in 
exhausted cells, overexpression of miR-155 also compromised the proliferation and 
function of terminal effector CD8 T cells (Gracias et al., 2013; Stelekati et al., 2018). This 
was demonstrated to be a result of miR-155-mediated suppression of the Fosl2 component 
of the AP-1 transcription factor complex (Stelekati et al., 2018). Interestingly, miR-155 
expression was also demonstrated to be important for the long-term survival of exhausted 
CD8 T cells (Stelekati et al., 2018). The miR-17-72 cluster has also been demonstrated to 
modulate CD8 T cell differentiation. Similar to miR-155, the miR-17-92 cluster is strongly 
upregulated in effector cells and downregulated in memory cells (Wu et al., 2012). This 
miRNA cluster was demonstrated to support the proliferation of effector CD8 T cells by 
enhancing mTOR activity (Wu et al., 2012). Accordingly, failure to downregulate the miR-
17-92 cluster impaired memory formation, due to direct targeting of Id2 and Bcl-2 mRNAs 
(Wu et al., 2012; Khan et al., 2013). 
These studies provide strong, albeit limited, evidence that temporal modulation of 
miRNA expression has important consequences for CD8 T cell differentiation. Whether 
other miRNAs are involved in this process, and to what extent remains to be determined. 
Moreover, these studies have primarily focused on miRNAs which are upregulated during 
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activation, which may be a potential limitation in fully understanding the positive 
regulation by miRNAs during memory differentiation. We have previously demonstrated 
that the let-7 miRNAs are downregulated upon TCR stimulation as let-7 expression 
suppresses CTL differentiation (chapter 2; Wells et al., 2017). This study identified a 
surprising role for the let-7 miRNAs in determining the fate of CD8 T cells, and in doing 
so, we also describe a critical paradox in the study of CD8 T cell differentiation, where the 
in vitro function of CTLs does not necessarily predict the performance of cells in vivo. 
Specifically, it was determined that the absence of let-7 miRNAs drove cells into a terminal 
effector state characterized by high expression of inhibitory receptors. Accordingly, upon 
introduction into the immunosuppressive environment, these cells became functionally 
exhausted. Conversely, overexpression of let-7 improved tumor rejection due to an 
enhanced memory differentiation. This study has identified an important role for the let-7 
miRNAs in restraining terminal differentiation to maintain memory potential in 
differentiating CD8 T cells.  
 
3.2 Results 
3.2.1 let-7 expression in CTLs enhances tumor rejection 
To test the superior function of let-7-deficienct CTLs in anti-tumor responses, 
B16F10 mouse melanoma cells were genetically engineered using a retroviral vector which 
contains an IRES-GFP reporter, to express the gp33-41 peptide (Figure 3.1A, referred to 
as B16gp33) from the lymphocytic choriomeningitis virus (LCMV). Thus, tumor-specific 
lysis can be assessed using P14 TCR transgenic CD8 T cells which recognize this peptide 
in the context of MHC-I (H-2Db). P14 CTLs were generated from WT, Lin28Tg, or let-
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7Tg mice and the cytotoxic activity against B16gp33 cells was assessed in vitro. Lin28Tg 
CTLs killed B16gp33 cells with a much greater efficacy than WT CTLs, while let-7Tg CTLs 
demonstrated the least cytotoxic function (Figure 3.1B). These results indicated that P14 
CTLs can recognize B16gp33 tumors cells, and are consistent with the previously observed 
let-7-mediated control of in vitro cytotoxic function (Figure 2.7 A; Wells et al., 2017). 
However, upon adoptive transfer into B16gp33 tumor-bearing mice, Lin28Tg CTLs 
completely failed to control tumor growth. Rather, quite surprisingly, let-7Tg CTLs 
provided the most robust tumor protection in vivo, such that mice which received let-7Tg 
CTLs were the only mice that survived the study (Figure 3.2A-C). Importantly, tumors that 
did grow in these mice were found to be GFP-, indicating that outgrowth was due to a loss 
of gp33 expression (Figure 3.2D). Moreover, in a metastatic model of B16gp33, transfer of 
let-7Tg CTLs significantly reduced metastatic burden in the lung, while Lin28Tg CTLs 
conferred no improvement to the anti-tumor response (Figure 3.2E). Altogether, these 
results demonstrate that let-7Tg, rather than Lin28Tg CTLs improve tumor rejection, 
despite opposing cytotoxicity in vitro. 
 
3.2.2 Molecular characterization of let-7Tg and Lin28Tg CTLs 
 To explain the paradox between the in vitro and in vivo performances of Lin28Tg 
and let-7Tg CTLs, the transcriptomes of CTLs were generated for five days in vitro in the 
presence of IL-2, were analyzed. When compared to wild type CTLs, let-7Tg and Lin28Tg 
CTLs, differentially expressed 502 genes and 876 genes, respectively (Figure 3.3A). To 
characterize the signature of let-7Tg and Lin28Tg CTLs, their transcriptomes were 
analyzed for signatures of memory or terminal effector CD8 T cells (Kaech et al., 2002; 
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Doering et al., 2012). Gene set enrichment analysis revealed that let-7Tg CTLs express a 
memory signature, indicated by upregulation of genes highly expressed in memory cells 
generated in response to acute viral infection with LCMV Armstrong. Conversely, the gene 
signature of Lin28Tg CTLs is associated with genes expressed in terminal effector cells 
generated during chronic infection with LCMV clone 13, which results in persistent antigen 
exposure (Figure 3.3B) (Doering et al., 2012).  
Specifically, let-7Tg CTLs preferentially expressed memory markers such as the 
fate-specifying transcription factors Id3, Tcf7 (gene that encodes Tcf1) and Foxo1 (Ji et al., 
2011; Zhou et al., 2010). Let-7Tg CTLs upregulated expression of the secondary lymphoid 
homing receptors CD62L (encoded by the gene Sell) and Ccr7, which facilitate travel of 
memory CD8 T cells to the spleen and lymph nodes, the primary niches for memory CD8 
T cells (Kaech et al., 2003; Sallusto et al., 2004). Expression of the receptor for IL-7 
(CD127), an important cytokine for memory CD8 T cell homeostasis was also increased 
in let-7Tg CTLs (Schluns et al., 2000; Kaech et al., 2003; Sallusto et al., 2004). Further, 
let-7Tg CTLs increased expression of the anti-apoptotic protein Bcl-2 which helps promote 
the survival and longevity of memory CD8 T cells (Schluns et al., 2000; Hand et al., 2010) 
(Figure 3.3C). These results are particularly significant as let-7Tg CTLs were generated in 
conditions which do not typically support expression of memory-associated genes, 
suggesting let-7 miRNA expression maintains memory fate potential. 
In contrast, Lin28Tg CTLs expressed high levels of Id2, and Ikzf2 (gene that 
encodes Helios), two transcription factors associated with terminal differentiation and 
exhaustion (Cannarile et al., 2006; Doering et al., 2012). This is in addition to Eomes, 
which has been demonstrated to be regulated by let-7 (Figure 2.9A, B), and is highly 
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expressed in exhausted cells (Doering et al., 2012). Accordingly, expression of the 
inhibitory receptors Tim-3 (encoded by the gene Havcr2), PD-1 (encoded by the gene 
Pdcd1), CD160, and 2B4 (encoded by the gene Cd244) was upregulated in Lin28Tg CTLs 
(Wherry et al., 2007) (Figure 3.3D). Expression of the TNF costimulatory receptor 4-1BB 
(encoded by the gene Tnfrsf9) was also increased, consistent with its expression on strongly 
activated cells (Williams et al., 2017). Interestingly, OX-40 (encoded by the gene Tnfrsf4), 
another TNF costimulatory receptor, was downregulated (Figure 3.3D). This suggested the 
expression and function of these receptors in terminal effector differentiation may be more 
complex than is currently appreciated (Williams et al., 2017). Expression of Wnt10b 
(Trischler et al., 2016) was also elevated in Lin28Tg CTLs, in addition to the suppressive 
cytokine IL-10 (Brooks et al., 2006; Ejrnaes et al., 2006), which is a direct let-7 target 
(Figure 3.3D, E). These data suggest that the absence of let-7 miRNAs leads to the terminal 
differentiation, and potentially the exhaustion, of CD8 T cells. 
It is well established that terminal effector CD8 T cells are dependent on glycolysis 
to meet their high bioenergetic demands, and that the transition of memory cells back to a 
quiescent state is accompanied by reduced usage of glycolysis (Frauwirth et al., 2002; 
Wang et al., 2011; van der Windt and Pearce, 2012; O’Sullivan et al., 2018). To determine 
the extent to which the metabolism of let-7Tg and Lin28Tg CTLs reflects this feature of 
memory and terminal effector CD8 T cells, glycolytic usage was assessed. As glycolysis 
results in the release of lactate and H+, which acidify the cell culture media, the rate of 
glycolysis can be assessed by measuring the extracellular acidification rate (ECAR). In 
fact, let-7 regulated the extent to which CTLs used glycolysis, in a manner representative 
of differentiation into either a terminal effector, or memory state (Figure 3.3F). Ultimately, 
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these data strongly suggest that let-7 miRNAs control the differentiation of memory and 
terminal effector CD8 T cells. 
 
3.2.3 Maintenance of let-7 expression during activation supports memory T cell 
differentiation 
To directly assess the impact of the let-7 miRNAs in the generation of CD8 T cell 
memory, naïve P14+ CD8 T cells from WT, let-7Tg or Lin28Tg mice were adoptively 
transferred into congenic CD45.1+ hosts, which were then subsequently infected with 
Listeria monocytogenes expressing the LCMV peptide gp33 (LM-33) (Manjunath et al., 
2001; Shen et al., 1998). At the peak of the effector response (day nine), there was a higher 
frequency of memory precursor (CD44+CD62Lhi) P14 cells in the spleens of mice which 
received let-7Tg CD8 T cells, while nearly all donor Lin28Tg cells were effector CTLs 
(CD44+CD62Llo). These results are further supported by the distribution of 
KLRG1/CD127 expression on P14 cells (Figure 3.4A) (Kaech et al., 2003; Joshi et al., 
2007). Moreover, by day thirty, the few donor Lin28Tg cells that survived contraction 
retained an effector phenotype (CD44+CD62Llo) (Figure 3.4B). Consistent with previously 
described data, the maintenance of let-7 expression greatly inhibited the potential for let-
7Tg P14 cells to proliferate and expand in vivo (Figure 3.4B) (Chapter 2; Wells et al., 
2017), making long term analysis of this population difficult. To overcome this limitation, 
we used an established in vitro system for generating memory CD8 T cells in the presence 
of the memory cytokine IL-15 (Manjunath et al. 2001). As expected, WT CTLs upregulated 
the expression of Tcf7, Sell, Ccr7, and CD127 only in the presence of IL-15, whereas let-
7Tg CTLs displayed an enhanced memory phenotype regardless of the use of IL-2 or IL-
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15 (Figure 3.5A). Although IL-15 reduced expression of Id2, Havcr2, Pdcd1, and Cd244 
in Lin28Tg CTLs, the presence of IL-15 was not sufficient to induce expression of memory 
markers in Lin28Tg CTLs (Figure 3.5A). Thus, while IL-15 reduced exhaustion, it was 
unable to initiate the memory differentiation program in Lin28Tg CTLs. In addition, an in 
vitro assay which assesses T cell survival through immediate withdrawal of IL-2, 
demonstrated that let-7 expression determines CTL viability during cytokine withdrawal 
(Figure 3.5B) (Geiger et al., 2016). Ultimately, these studies indicate that let-7 programs 
the fate of the memory CD8 T cell population.  
It has been suggested that cues essential for the formation of memory cells occur 
throughout CD8 T cell differentiation (Badovinac et al., 2005; Kolumam et al., 2005; Joshi 
et al., 2007; Harty and Badovinac, 2008; Araki et al., 2009; Kaech and Cui, 2012). 
However, several reports also suggest that the memory fate is established during early 
activation (Kaech and Ahmed, 2001; Lauvau et al., 2001; Chang et al., 2007; King et al., 
2012; Kakaradov et al., 2016; Verbist et al., 2016; Wang et al., 2018). To determine if the 
timing of let-7 expression was important for its enhancement of memory formation, let-7 
expression was induced periodically during CTL differentiation using the doxycycline-
inducible transgene (Figure 3.5C). As previously demonstrated (Figure 3.3C), maintaining 
let-7 expression for all five days of CTL differentiation resulted in high levels of Tcf7, Sell, 
and Ccr7 expression, and downregulation of Id2, Cd244, and Havcr2 (Figure 3.5C). 
However, limiting let-7 overexpression to the first 48 hours of stimulation, also resulted in 
heightened expression of memory markers, accompanied by the downregulation of genes 
that contribute to terminal differentiation (Figure 3.5C). Consequently, inducing let-7 
expression after the first 48 hours of TCR stimulation was insufficient to enhance the 
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memory phenotype, and to downregulate expression of the terminal effector genes Id2 and 
Havcr2 to the same extent as cells with high levels of let-7 expression during activation 
(Figure 3.5C). Taken together, these results demonstrate that let-7 expression, specifically 
within the first few hours of activation, is necessary and sufficient for the generation of 
memory CD8 T cells. Additionally, this data provides a molecular mechanism to support 
earlier studies illustrating that the memory fate is established during antigen stimulation 
(Kaech and Ahmed, 2001; Lauvau et al., 2001; Chang et al., 2007; King et al., 2012; 
Kakaradov et al., 2016; Verbist et al., 2016; Wang et al., 2018). 
 
3.2.4 Downregulation of let-7 miRNAs leads to terminal differentiation  
Our previous data demonstrated that the maintenance and quiescence of naïve CD8 
T cells is negatively impacted by the absence of the let-7 miRNAs (Figure 2.2; Wells et 
al., 2017). To eliminate the possibility that the dysfunction of Lin28Tg CTLs is due to 
altered homeostasis of naïve CD8 T cells, mice expressing Lin28 with a GFP reporter 
downstream of a loxP flanked STOP cassette knocked into the Rosa26 locus (R26STOP-Lin28-
GFP) (Figure 3.6A), were crossed with mice that express Cre recombinase under the control 
of the granzyme B promoter (GzmbCre+), such that only activated T cells will express Lin28 
following Cre-mediated excision of the STOP cassette (GzmbCre+R26STOP-Lin28-GFP). These 
mice were then inoculated subcutaneously with the MC57 fibrosarcoma, which is 
controlled in healthy syngeneic C57BL/6 mice (Kundig et al., 1995; Schmits et al., 1996). 
Wild type mice were able completely clear the tumor by 13 days after the initial 
implantation (Figure 3.7A). However, this tumor rejection was compromised by depleting 
let-7 miRNAs in responding CD8 T cells (Figure 3.7A). These results demonstrate that loss 
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of let-7 expression upon activation is responsible for the dysfunction of Lin28Tg CTLs in 
vivo. 
We then hypothesized that the immunosuppressive tumor microenvironment 
engages the inhibitory receptors that are highly expressed on Lin28Tg CTLs (Figure 3.3D), 
thus driving dysfunction in let-7-deficient CTLs. To test this hypothesis, anti-PD-L1 was 
administered to EL-4gp33 tumor bearing mice upon transfer of Lin28Tg CTLs. Blocking 
engagement of the PD-1 inhibitory receptor via treatment with anti-PDL1 antibodies fully 
rescued Lin28Tg CTL function, enhancing anti-tumor responses to the level of let-7Tg 
CTLs (Figure 3.6B-D), indicating that Lin28Tg CTL dysfunction is due to functional 
exhaustion in the tumor microenvironment.  
To determine if the duration of let-7 downregulation is an important component in 
re-directing differentiating CTLs to a terminal effector fate, Lin28TgGFP mice were crossed 
to mice with a doxycycline inducible Cre (iCre+R26STOP-Lin28-GFP) (Figure 3.6B), such that 
permanent Lin28 expression can be induced at any point during CTL differentiation. 
Interestingly, regardless of how long let-7 expression was depleted, expression of the 
terminal effector genes Id2, Cd244, Havcr2, and Pdcd1 was upregulated, while expression 
of memory phenotypic markers (Tcf7, Sell, Ccr7) were reduced (Figure 3.7E). These 
results indicate that loss of let-7 expression drives cells into the terminal effector program, 
at the expense of memory potential, independent of the duration of let-7 depletion during 
differentiation. 
 
3.2.5 let-7 miRNAs regulate terminal differentiation through a complex 
transcriptional mechanism 
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Finally, to uncover the molecular machinery let-7 regulates to restrain terminal 
differentiation, we identified five genes that are direct let-7 targets (Figure 3.8A). These 
genes were also selected because they have been implicated in transcriptional regulation. 
All five candidates were individually overexpressed in let-7Tg CD8 T cells to assess the 
extent to which each gene could drive terminal differentiation in memory-like CD8 T cells.  
The first candidate, Nupr1, has a single eight-nucleotide let-7 binding site in its 3’ 
untranslated region (UTR), and has been demonstrated to be involved in various cellular 
stress responses. (Malicet et al., 2005; Malicet et al., 2006; Syn et al., 2017; Santofimia-
Castano et al., 2018). Consistent with no known function of Nupr1 in CD8 T cells, 
overexpression of Nupr1 had no effect in reversing the memory phenotype of let-7Tg CTLs 
(Figure 3.8B). The second candidate, Helios, has two seven-nucleotide let-7 binding sites 
in the 3’ UTR. Helios is a transcription factor frequently identified in gene profiles from 
exhausted and terminally differentiated CD8 T cells (Doering et al., 2012). While a specific 
role for Helios in driving terminal effector cell differentiation has yet to be determined, 
Helios has been demonstrated to support an immunosuppressive subset of T cells known 
as regulatory T cells (Tregs). Specifically, Helios is important for the development of Tregs 
in the thymus, and its expression is necessary to mediate the inhibitory functions of Tregs 
in the periphery (Thornton et al., 2010; Kim et al., 2015). However, despite being highly 
expressed in exhausted CD8 T cells, its re-expression into let-7Tg CD8 T cells had no 
significant impact during differentiation (Figure 3.8C). 
The expression of the third candidate, Hmga1, has a single seven-nucleotide let-7 
binding site in the 3’ UTR. Hmga1 has been demonstrated to be induced by TCR signaling, 
and consequently in driving expression of IL-2 and IFN- (Shannon et al., 1998; Chau et 
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al., 2005), suggesting its involvement in terminal effector differentiation (Figure 3.9A, B). 
Interestingly, while overexpression of Hmga1 was sufficient to modulate expression of 
inhibitory receptors, it had no effect on the production of IFN- (Figure 3.9A). Thus, 
although Hmga1 is involved in the regulation of terminal effector differentiation, its exact 
function is still unclear. 
Of the identified targets, the strongest candidate was Eomes, as it has already been 
demonstrated to be a functional target of let-7 due to a unique 10-nucleotide let-7 binding 
site in the open reading frame of the RNA. In addition, high levels of Eomes expression is 
associated with terminal effector differentiation, and may control a unique gene program 
to drive this state during chronic viral infection (Doering et al., 2012). Moreover, Eomes 
has been identified as a marker of the most severe stage of exhaustion in vivo (Wherry, 
2011). We found that overexpression of Eomes resulted in the upregulation of Tim-3, and 
modest upregulation of 2B4, while CD160 expression remained unchanged (Figure 3.9C, 
D). Eomes overexpression downregulated the memory marker CD62L, although this was 
not consistent at the RNA level (Figure 3.9C, D). To take the opposite approach, and assess 
if removal of Eomes from Lin28Tg cells could restrain terminal differentiation, CTLs 
generated from Lin28Tg mice with a T cell-specific deletion of Eomes 
(CD4Cre+Eomesfl/flLin28Tg) were analyzed. While deletion of Eomes in Lin28Tg CTLs 
had no effect on the expression of CD62L, PD-1, 2B4, or CD160, the expression of both 
Tim-3, and IL-10 was significantly reduced (Figure 3.9E). These results demonstrate that 
Eomes contributes to the terminal effector differentiation program by regulating expression 
of Tim-3 and IL-10. 
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The mRNA of the final candidate, Arid3a, contains five unique let-7 binding sites, 
three of which are in the 3’UTR, and two of which are in the open reading frame. This high 
number of let-7 binding sites indicative of functional suppression. In fact, Arid3a has 
previously been demonstrated to be a functional target of let-7 in fetal B cell development 
(Zhou et al., 2015), and in the regulation of specialized thymus-resident B cells in the adult 
organism (Xiao et al., 2018). Constitutive expression of Arid3a in B cells results in 
increased proliferation and autoantibody production, suggesting that in this population of 
immune cells its regulation is critical (Ratliff et al., 2014). However, there is no known 
function of Arid3a in CD8 T cells. When overexpressed in let-7Tg CTLs, Arid3a increased 
the frequency of cells expressing Tim-3, 2B4, and CD160, and the expression of PD-1 
more than doubled (Figure 3.9F, G). Conversely, Arid3a expression reduced the frequency 
of CD62L+ cells, while also downregulating the expression of Tcf7 and Ccr7 mRNA 
(Figure 3.9F, G). These results suggest that Arid3a may be another important contributing 
factor to let-7 mediated regulation of terminal effector differentiation. 
Together, these results suggested that while Arid3a, Eomes, and Hmga1 may 
contribute to the establishment of the terminal differentiation program, thus preventing 
memory formation, they are insufficient to do so independently. We speculate that a 
synergistic network of key factors is involved, and that the let-7 miRNAs act as a global 
regulator to suppress this network, thereby restraining terminal differentiation and in turn 
promoting the generation of memory CD8 T cells. Ultimately, this study identified let-7 
miRNAs as a unique therapeutic tool, where both its overexpression and deletion, when in 
combination with checkpoint blockade inhibitors, improve distinct components of CD8 T 
cell immunity. 
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3.3 Discussion 
 This study has identified a novel post-transcriptional mechanism involved in 
terminal effector and memory differentiation. Specifically, these results provide 
compelling data demonstrating an important role for the let-7 miRNAs suppress a complex 
transcriptional network to restrain terminal differentiation and thus preserve the memory 
potential of CD8 T cells. This was demonstrated primarily through the use of an aggressive 
B16 melanoma cancer model, in which expression of let-7Tg CTLs provided the most 
robust anti-tumor protection. However, if aided by checkpoint blockade inhibition, 
Lin28Tg terminal effector cells also efficiently eliminated tumors. These results directly 
implicate the let-7 miRNAs as a unique therapeutic tool. 
Transcriptome analysis revealed let-7Tg CTLs were highly enriched for the 
memory phenotype (Kaech et al., 2002). A functional role for let-7 miRNAs was in 
maintaining the memory phenotype was demonstrated in an in vitro memory differentiation 
model (Manjunath et al., 2001). Overexpression of let-7 miRNAs supported memory 
differentiation, even in conditions used to generate effector cells. On the other hand, 
Lin28Tg failed to generate memory cells, despite being cultured in memory-differentiating 
conditions. These data demonstrate that the let-7 miRNAs are sufficient to program cells 
into the memory fate, and that loss of let-7 expression irreparably damages the ability to 
initiate the memory differentiation program. Moreover, let-7 expression improved the 
survival of CD8 T cells upon IL-2 withdrawal. Accordingly, it will be important to follow 
up on the expression and function of pro- and anti-apoptotic proteins, including Bcl-2, that 
may contribute to the enhanced survival of let-7Tg CTLs. These results additionally 
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suggest that let-7 expression may be a contributing factor for the long-term maintenance 
of memory CD8 T cells. The let-7-mediated inhibition of proliferation prevented the 
investigation of the let-7 miRNAs in long-lived memory populations. As such, the role of 
let-7 miRNAs in the maintenance of memory CD8 T cells was not addressed. From these 
observations, it can be speculated that high let-7 expression may facilitate the maintenance 
of memory CD8 T cells by enhancing survival and reducing proliferation to preserve 
quiescence. This would be consistent with a role for the let-7 miRNAs in maintaining the 
quiescent state in naïve CD8 T cells (Chapter 2; Wells et al., 2017). 
The finding that let-7 expression during the first 48 hours of antigen stimulation is 
sufficient to generate cells with a memory phenotype provides critical insight into the 
mechanism which specifies the memory fate. Specifically, these results present evidence 
demonstrating that the most critical signal to generate memory cells is received during TCR 
stimulation. Based on this, and previous observations that let-7 expression is TCR-
dependent (chapter 2), it can be speculated that either weaker or shorter TCR signaling will 
yield a more plastic, stem-like CD8 T cell population with increased memory potential by 
keeping let-7 expression relatively high. Importantly, these results provide a molecular 
mechanism supporting studies which report a TCR-dependent model of memory 
differentiation (Chang et al., 2007; Zehn et al., 2009; King et al., 2012; Verbist et al., 2016). 
The data presented here also define a role for the let-7 miRNAs in terminal effector 
differentiation, and exhaustion, which was first identified by transcriptome analysis. 
Lin28Tg CTLs were highly enriched for a terminal effector/ exhausted signature. 
Expression of transcription factors, inhibitory receptors, and cytokines associated with 
terminal effector cells were all upregulated in Lin28Tg CTLs (Doering et al., 2012), with 
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the exception of the co-stimulatory receptors, of which OX-40 was upregulated in let-7Tg 
CTLs. It has primarily been thought that 4-1BB and OX-40 have similar functions in CD8 
T cell activation and effector differentiation (Croft et al., 2014). There is direct evidence 
that 4-1BB identifies exhausted cells (Williams et al., 2017; Horton et al., 2018), while 
such a role for OX-40 has not been as clearly defined (Croft et al., 2014). This data may 
indicate divergent roles for these two co-stimulatory receptors in effector and memory 
formation. Further elucidation of the distinct functions of costimulatory receptors 
belonging to the TNF receptor superfamily may thus have important implications for their 
therapeutic applications. 
This study also provides mechanistic insight into the establishment of exhaustion. 
Shortening the duration of let-7 depletion via excision of the STOP cassette from 
iCreR26STOP-Lin28-GFP CTLs progressively later in differentiation, demonstrated that the 
terminal effector program can be established at any point upon depletion of let-7 miRNAs, 
independent of the duration of let-7 depletion. Importantly, this came at the expense of 
memory differentiation, consistent with our data demonstrating Lin28Tg CTLs are unable 
to initiate the memory program. If extrapolated, this data could indicate that at any point 
during CD8 T cell differentiation, strong TCR signals can drive CD8 T cells into the 
terminal effector fate, and divert CD8 T cells away from the memory fate.  
 Although a single target responsible for the let-7-mediated restraint of terminal 
effector differentiation was not identified, several of the tested candidates did demonstrate 
moderate contributions to this process. Whether this is their primary function in CD8 T 
cells remains to be determined. Interestingly, every candidate gene which drove the 
effector phenotype in let-7Tg CLTs most significantly modulated Tim-3 expression. This 
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supports recent studies that have identified Tim-3 as having a more significant function in 
the differentiation of terminal effector cells, and their progression into exhaustion, than 
was originally appreciated (Jin et al., 2010; Singer et al., 2016; Kurtulus et al., 2019).  
It is improbable that let-7 would target one factor to restrain the entire terminal 
effector differentiation program. Let-7 is a very ancient miRNA, and accordingly its targets 
are numerous and highly conserved (Roush and Slack, 2008). Accordingly, let-7 and its 
targets would have co-evolved during the acquisition of the adaptive immune system, and 
there may be functional redundancies amongst its targets. Moreover, these candidates may 
need to cooperate together to exert their functions, which could be determined by 
combinatorial overexpression. Additionally, as cells enter into the exhaustion program, the 
epigenetic landscape is reconfigured (Schietinger et al., 2016; Yu et al., 2017). Further, the 
plasticity of memory CD8 T cell responses is associated with a ‘poised’ chromatin state 
(Gray et al., 2017; Akondy et al., 2017; Wang et al., 2018). Let-7 may play an important 
role in shaping the epigenetic landscape of differentiating CD8 T cells, and differing 
chromatin states in let-7Tg and Lin28Tg CTLs may mask the extent to which the tested 
candidates are involved in CD8 T cell differentiation. Thus, determining the chromatin 
landscapes of let-7Tg and Lin28Tg CTLs, and the role of let-7 miRNAs in regulating 
epigenetic modifications will be important.  
Future studies to determine the physiological expression of let-7 miRNAs in 
memory, terminal effector, and exhausted CD8 T cells will further elucidate their function 
in these populations. Asymmetric distribution of let-7 during antigen stimulation may 
explain the high let-7 expression required for memory cell differentiation, and the low let-
7 expression required for terminal effector differentiation. This would also provide a 
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molecular mechanism for the asymmetric division model of memory differentiation. 
Specifically, we would hypothesize the proximal daughter cell becomes a terminal effector 
cell due to downregulation of let-7 driven by stronger TCR stimulation. Conversely, the 
distal daughter CD8 T cell differentiates into a memory cell as it receives weaker TCR 
stimulation, and would thus retain let-7 expression (Chang et al., 2007; Verbist et al., 
2016). In regards to exhaustion, progressive downregulation of let-7 either by repeated 
TCR stimulation due to persistent antigen load might provide a mechanism for the gradual 
‘acquisition’ of exhaustion (Paley et al., 2012). Determining the direct mechanism by 
which TCR signaling regulates let-7 expression will be critical to the implementation of 
the let-7 miRNAs as a therapeutic tool.  
Differences in the temporal requirements for memory and terminal effector 
differentiation may be indicative of a central strategy used to generate effective CD8 T cell 
responses. Memory cells provide lifelong immunity, and may populate the effector 
population as it becomes exhausted during chronic infection and cancer (Im et al., 2016, 
Utzschneider et al., 2016; Siddiqui et al., 2019; Kurtulus et al., 2019). Specifying cells to 
the memory fate early during activation may be a mechanism by which to prioritize and 
guarantee their generation. The ability to then initiate the terminal effector differentiation 
program any point thereafter would allow the magnitude of the effector response to be 
scaled according to the severity of the infection. Thus, the persistence of antigen would 
determine the extent to which these cells are driven into the terminal effector program 
toward exhaustion (Wherry, 2011; Schietinger and Greenberg, 2014). This might further 
suggest that exhaustion may not be a negative bystander effect, but rather an intentional 
mechanism used to indirectly boost immune responses, supporting hypotheses which 
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propose CD8 T cell exhaustion is a strategy used by the immune system to drive neoantigen 
generation, and solicit ‘fresh’ and clonally diverse CD8 T cells to the tumor and site of 
infection to aid in clearing the unhealthy cells (Vezys et al., 2006; Wherry, 2011; 
Schietinger and Greenberg, 2014; Schietinger et al., 2016). This would also support 
evidence that exhaustion is an intentional program which aids in viral clearance, and 
prevents tissue damage during prolonged T cell responses (Vezys et al., 2006; Paley et al., 
2012; Cornberg et al., 2013). 
The data presented here suggests immense potential for manipulating let-7 miRNAs 
as a therapeutic approach. A mechanism by which to modulate let-7 expression could 
feasibly be integrated into the in vitro expansion phase of adoptive T cell therapy, and 
during CAR-T cell generation (Rosenberg and Restifo, 2015; Ramos et al., 2016). 
Moreover, these results may have implications for the improvement of vaccination 
strategies which rely on the formation of memory cells. Additionally, suppressing let-7 
miRNAs expression may be an effective therapeutic strategy in combating autoimmunity 
by intentionally ‘exhausting’ these autoreactive cells to inhibit their effector function 
against healthy host cells.  
Ultimately, this study has established a global role for the let-7 miRNAs in 
regulating CD8 T memory and terminal effector cell differentiation, and has identified the 
let-7 miRNAs as a unique therapeutic target for modulating CD8 T cell responses during 
chronic infection, cancer, and autoimmunity. 
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Figure 3.1 Generation of an antigen-specific tumor model 
(a) GFP expression on B16gp33 tumor cells which have transduced to express the LCMV 
gp33 antigen in an IREs-GFP retroviral vector. (b) Cytotoxicity assay of differentiated 
CTLs from P14+ wild type, P14+let-7Tg, and P14+Lin28Tg lymph nodes co-cultured with 
B16gp33 tumor cells for 14-16 hours. Data are from one experiment representative of two 
experiments (b; mean and s.e.m. of technical triplicates). 
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Figure 3.2 let-7 miRNA expression dramatically improves anti-tumor CTL responses 
in vivo 
(a, b) Tumor growth curves in mice inoculated s.c. with 0.25X106 B16gp33. Tumor-bearing 
mice received adoptive transfer of 1.5X106 CTLs generated from either P14+WT (n=5), 
P14+let-7Tg (n=5), P14+Lin28Tg (n=5) lymphocytes, or no CLTs at all (n=5). (c) Analysis 
of the survival of B16gp33 tumor bearing mice, which were received adoptive transfer of 
1.5X106 CTLs generated from either P14+WT (n=5), P14+let-7Tg (n=5), P14+Lin28Tg 
(n=5) lymphocytes, or no CLTs at all (n=5). (d) GFP expression on B16gp33 tumor cells 
before injection into the hos mouse and after cells were isolated from a mouse which 
received let-7Tg CTLs, and demonstrated tumor growth until the end point of the study. 
(e) Image (right) and quantification (left) of the number of metastatic nodes in the lungs of 
mice which received 0.2X106 B16gp33 tumor cells i.v. and received 1.5X106 CTLs 
generated from either P14+WT (n=5), P14+let-7Tg (n=5), P14+Lin28Tg (n=5) 
lymphocytes, or no CLTs at all (n=5). Data are from one experiment representative of two 
experiments (a,e; mean and s.e.m. of biological replicates (n=5)). 
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Figure 3.3 Molecular characterization of let-7Tg and Lin28Tg CTLs generated in 
vitro 
(a) Heat map illustratting differential gene expression between P14 WT, P14 let-7Tg, and 
P14 Lin28Tg CTLs. (b) Gene set enrichment analysis of the let-7 transcriptome aligned to 
the transcriptome of memory CD8 T cells generated in response to acute viral infection 
(left) and the Lin28Tg transcriptome aligned to the transcriptome of exhausted CD8 T cells 
generated in response to chronic viral infection. (c) Staining of CD62L and CD127 on P14 
WT, P14 let-7Tg, and P14 Lin28Tg CTLs (left) and quantitative RT-PCR analysis of 
mRNA expression: Id3, Tcf7 (Tcf1), Ccr7, Sell (Cd62L), and Bcl-2 in P14 WT, P14 let-
7Tg, and P14 Lin28Tg CTLs presented relative to expression of the ribosomal protein 
Rpl13a (right). (d) Staining of TIM-3, PD-1, CD160, and 2B4 on P14 WT, P14 let-7Tg, 
and P14 Lin28Tg CTLs (left) and quantitative RT-PCR analysis of mRNA expression: Id2, 
Ikzf2 (Helios), Havcr2 (TIM-3), Pdcd1 (PD-1), Tnfrsf9 (4-1BB), Cd160, Cd244 (2B4), 
Il10, Wnt10b, and Tnfrsf4 (OX-40) in P14 WT, P14 let-7Tg, and P14 Lin28Tg CTLs 
presented relative to expression of the ribosomal protein Rpl13a (right). (e) Intracellular 
staining of IL-10 in P14 WT, P14 let-7Tg, and P14 Lin28Tg CTLs. (f) Glycolytic rate assay 
of P14 WT, P14 let-7Tg, and P14 Lin28Tg CTLs. n.s., not significant (P > 0.05), * P < 
0.05, ** P < 0.01, and *** P < 0.001, **** P < 0.001 compared with wild type using two-
tailed Student’s t-test (c, d). Data from one experiment (a, b; mean of technical triplicates) 
or from one experiment representative of three experiments (c, d; mean and s.e.m. of 
technical triplicates.  
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Figure 3.4 let-7 miRNAs enhance the memory precursor phenotype during the 
effector response to LM-33 in vivo 
(a) Quantification of the frequency and staining of CD44hiCD62Lhi, CD44hiCD62Llo (top), 
KLRG1loCD127hi, KLRG1hiCD127lo (bottom) populations in the spleens of CD45.1+ host 
mice 9 days after adoptive transfer of 2X104 naïve CTLs from the indicated mice prior to 
infection with LM-33 (bottom left) (n=3). (b) Quantification of the number of donor 
(CD45.2+) CD8 T cells from P14 wild type (n=6), P14 let-7Tg mice (n=6), or P14 Lin28Tg 
mice in the spleens of congenic (CD45.1+) host mice 30 (n=3) and 31(n=3) days after cell 
transfer and LM-33 infection (left). Quantification of the frequency of CD44hiCD62Lhi, 
CD44hiCD62Llo populations in the spleens of mice 30-31 days after cell transfer and LM-
33 infection (right). n.s., not significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 
0.001, **** P < 0.001 compared with donor WT P14 cells using two-tailed Student’s t-test 
(c, d). Data are from one experiment (a, b; mean and s.e.m. of biological replicates). 
 
 
  
A
0
20
40
60
100
80
0
20
40
60
0
20
40
60
80
F
re
q
u
e
n
c
y
 o
f 
C
D
4
5
.2
+
c
e
lls
CD44hiCD62Lhi CD44hiCD62Llo
KLRG1hiCD127loKLRG1loCD127hi
Donor cells, 9 d.p.i
1
0
20
40
60
80
Day 9 CD62Lhi SPLN
WT
let-7Tg
B
1
0
20
40
60
80
100
Day 9 CD62Llo SPLN
WT
let-7Tg
B
1
0
20
40
60
80
Day 9, KLRG1loCD127hi SPLN
WT
let-7Tg
B+
1
0
20
40
60
80
Day 9 KLRG1hiCD127lo SPLN
WT
let-7Tg
B+
80
100101102103104105
0
103
104
105
CD62L
CD127
K
L
R
G
1
C
D
4
4
65.3% 34.0% 34.9% 65.1% 92.9% 5.36%
22.3% 24.1%
52.1%
25.5% 17.0%
47.2%
52.1% 25.1%
21.9%
WT let-7Tg Lin28Tg
100101102103104105
0
103
104
105
P14+ CD8 T cells: WT let-7Tg Lin28Tg
0
20
40
60
80
*
**
**
***
ns
ns
ns
**
1
50
60
70
80
90
100
Day 30, CD62L hi spln
WT
B
1
0
10
20
30
40
50
Day 30, CD62L lo spln
WT
B
N
u
m
b
e
r 
o
f 
c
e
lls
 (
x
1
0
4
)
Total CD45.2+ cells
F
re
q
u
e
n
c
y
 o
f 
C
D
4
5
.2
+
c
e
lls
0
20
40
60
100
80
CD44hiCD62Lhi CD44hiCD62Llo 
0
10
20
30
40
50
30 d.p.i 
1
0
500
1000
50000
100000
150000
200000
Day 30, let-7 donor recovery spln
WT
B
B
0
1
100
200
0.1
50
150
P14+ CD8 T cells:
WT
let-7Tg
Lin28Tg
B
****
********
****
 98 
 
 
 
 
 
 
 
  
A
Stimulate naïve 
P14+ T cells with 
aCD3+aCD28+IL-2:
WT, let-7Tg, Lin28Tg
Effector (CTL)
IL-2
3 days
IL-15
IL-2
3 days
Memory
0
50
100
150
200
0
50
100
150
0
50
100
150
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 (
n
o
rm
a
liz
e
d
 t
o
 R
p
l1
3
a
)
IL-2 IL-15 IL-2 IL-15 IL-2 IL-15IL-2 IL-15
Sell Ccr7 Cd127Tcf7
P14+ CD8 
T cells:
WT
let-7Tg
Lin28Tg
B
0 12 24
0
50
100
IL-2 withdrawal survival
WT
let- 7Tg
B+
Hours post-IL-2 withdrawal
0 12 24
S
u
rv
iv
a
l 
(%
)
0
50
0
Survival upon cytokine 
withdrawal
P14+ CD8 T cells: WT
let-7Tg
Lin28Tg
Dox induction of 
let-7 expression:
-2 0 2 3 4 5
Ag
Effector CTLs (day 5)
0
20
0
40
0
60
0
1
2
3
4
5
6
7
8
Id2
WT
let-7Tg
Id2
0 10 20 30 40
1
2
3
4
5
6
7
8
2B4
WT
let-7Tg
Cd244
0 5 10 15
1
2
3
4
5
6
7
8
Havcr2
WT
let-7Tg
Havcr2
0 200 400 600 0 10 20 30 40 5 10 150
0
20
0
40
0
60
0
80
0
1
2
3
4
5
6
7
8
Sell
WT
let-7Tg
0 50 10
0
15
0
20
0
25
0
1
2
3
4
5
6
7
8
Tcf7
WT
let-7Tg
0 50 10
0
15
0
1
2
3
4
5
6
7
8
Ccr7
WT
let-7Tg
SellTcf7 Ccr7
0 400 8000 50 150 250 50 100 1500200100 200 600
Ag
-2 0 2 3 4 5
Relative expression (normalized to Rpl13a)
P14+ CD8 T cells: WT let-7Tg
C
IL-
2
IL-
15
0
50
100
150
200
Sell IL2/IL15
WT
let-7Tg
B+
IL-
2
IL-
15
0
5
10
15
Cd127 IL2/IL15
WT
let-7Tg
B+
IL-
2
IL-
15
0
50
100
150
Ccr7 IL2/IL15
WT
let-7Tg
B+
IL-
2
IL-
15
0
50
100
150
Tcf7 IL2/IL15
WT
let-7Tg
B+
0
5
10
15
IL-
2
IL-
15
0
20
40
60
80
100
Havcr2 IL2/IL15
WT
let-7Tg
B+
IL
-2
IL
-1
5
0
5
10
15
Pdcd1 IL2/IL15
WT
let-7Tg
B+
IL-
2
IL-
15
0
100
200
300
400
500
Id2 IL2/IL15
WT
let-7Tg
B+
IL-
2
IL-
15
0
20
40
60
80
2B4 IL2/IL15
WT
let-7Tg
B+
IL-2 IL-15 IL-2 IL-15 IL-2IL-2 IL-15 IL-15
Id2 Havcr2 Pdcd1 Cd244
0
100
200
300
400
500
0
20
40
60
80
100
0
5
10
15
0
20
40
60
80
***
***
***
***
****
****
****
****
****
**** ****
****
****
****
**
****
****
****
****
****
****
****
****
**
****
****
***
***
*
****
****
****
****
****
****
****
A
c
ti
v
a
te
d
N
a
ïv
e
A
c
ti
v
a
te
d
N
a
ïv
e
***
n.s.
***
****
****
**
****
n.s.
*
***
***
****
****
****
****
***
n.s.
**
n.s.
****
****
***
n.s.
**
n.s.
**
n.s.
****
****
****
****
**
***
*
***
*
****
****
****
****
**
**
n.s.
****
****
****
****
****
 99 
Figure 3.5 Maintenance of let-7 expression during activation supports memory T cell 
differentiation 
(a) Quantitative RT-PCR analysis of mRNA expression presented relative to expression of 
the ribosomal protein Rpl13a: Tcf7 (Tcf1), Sell (CD62L), Ccr7, Cd127, Id2, Havcr2 (TIM-
3), Pdcd1 (PD-1), and Cd244 (2B4) in P14 WT, P14 let-7Tg, and P14 Lin28Tg CTLs 
stimulated and cultured for three days in IL-2, and for an additional three days in either IL-
2 or IL-15. (b) Analysis of survival 0, 12, and 24 hours after IL-2 withdrawal of P14 WT, 
P14 let-7Tg, P14 Lin28Tg CTLs which had been cultured in IL-2 for five days. (c) 
Quantitative RT-PCR analysis of mRNA expression: Tcf7 (Tcf1), Sell (CD62L), Ccr7, Id2, 
Havcr2 (TIM-3), and Cd244 (2B4) in P14 WT and P14 let-7Tg CTLs which received 
doxycycline either prior to stimulation or during the culture, as indicated (left, blue boxes), 
presented relative to the expression of the ribosomal protein Rpl13a. n.s., not significant 
(P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001, **** P < 0.001 compared with WT 
P14 cells from matched culture conditions using two-tailed Student’s t-test (a, b, c). Data 
are from one experiment representative of two experiments (a, b, c; mean and s.e.m. of 
technical triplicates).  
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Figure 3.6 Genetic schematics of R26STOP-Lin28-GFP and iCre mice 
(a) Cre deletes the STOP cassette to induce the expression of Lin28 and the GFP reporter. 
(b) Doxycycline- inducible Cre (iCre) is only expressed when doxycycline is present, such 
that when crossed with R26STOP-Lin28-GFP mice, cells will only express Lin28 and GFP in the 
presence of doxycycline. 
  
Lin28 is expressed ONLY in GzmbCre+ T cells
STOP GFPIRESLIN28FLAG
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+ Cre
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GFPIRESLIN28FLAG
R26STOP-Lin28-GFP:
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X
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Cre
 101 
 
 
Figure 3.7 Downregulation of let-7 miRNAs after activation leads to terminal 
differentiation 
(a) Tumor growth curves of MC57 (1X106, s.c.) in GzmbCreR26-(WT) (n=3) or 
GzmbCre+R26STOP-Lin28-GFP (n=3) mice. (b, d) Tumor growth curves of EL-4gp33 (0.25X106) 
tumors in host mice that received adoptive transfer of 1.5X106 CTLs generated from P14 
WT (n=5), P14 let-7Tg (n=5) , P14 Lin28Tg (n=5), P14 Lin28Tg+anti-PD-L1 (n=5), or no 
CTLs (n=5) at all. Mice which received anti-PD-L1 antibodies, were first treated (i.p.) 
immediately upon CTL adoptive transfer, and were injected (i.p.) every two days a total of 
four injections had been received. (c) Survival analysis of the mice in (b, d). (e) 
Quantitative RT-PCR analysis of mRNA expression presented relative to the expression of 
the ribosomal protein Rpl13a: Id2, Cd244 (2B4), Havcr2 (TIM-3), Pdcd1 (PD-1), Tcf7 
(Tcf1), Sell (CD62L), Ccr7 in iCre-R26- (WT) and iCreR26STOP-Lin28-GFP CTLs which 
received doxycycline for 48 hours at the indicated times (start of the green bar). The green 
bar represents Lin28 expression, rather than doxycycline treatment time. n.s., not 
significant (P > 0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001, **** P < 0.001 compared 
with EL-4gp33 tumor bearing mice receiving P14 WT CTLs (c) or iCre-R26- CTLs (e) using 
two-tailed Student’s t-test (c, e). Data are from one experiment (a, b, c, d (b; mean and 
s.e.m of biological replicates)) or one experiment representative of two independent 
experiments (e; mean and s.e.m of technical replicates). 
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Figure 3.8 let-7 miRNAs target several genes, but do not functionally regulate Nupr1 
or Ikzf2 in CD8 T cells 
(a) Quantitative RT-PCR analysis of mRNA expression presented relative to expression of 
the ribosomal protein Rpl13a: Nupr1 (Tcf1), Ikzf2 (Helios), Hmga1, Eomes, Arid3a, in P14 
WT, P14 let-7Tg, and P14 Lin28Tg CTLs (left). Schematics indicating the number and 
locations of let-7 binding sites in the tested candidate genes (right). (b, c) Staining of TIM-
3, 2b4, CD160, PD-1 and CD62L on P14 let-7Tg CD8 T cells transduced with either RV-
empty or RV-Nupr1 (b) or RV- empty or RV-Helios (c) which expresses a GFP reporter. 
Frequencies of protein-expressing cells (GFP, TIM-3, 2B-4, CD160, CD62L), cells with 
no protein expression (CD62L) and MFI of protein expression (PD-1) are indicated. * P < 
0.05, ** P < 0.01, and *** P < 0.001, **** P < 0.001 compared with P14 WT CTLs using 
two-tailed Student’s t-test (a). Data are from one experiment representative of two 
experiments.  
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Figure 3.9 let-7 miRNAs regulate terminal differentiation through a complex 
transcriptional mechanism involving Hmga1, Eomes, and Arid3a 
(a) Staining of TIM-3, 2B4, CD160, PD-1, and CD62L and intracellular staining of IFN- 
on P14 let-7Tg CD8 T cells transduced with either RV-empty or RV-Hmga1 which 
expresses a GFP reporter. Frequencies of protein-expressing cells (GFP, TIM-3, 2B-4, 
CD160, CD62L), cells with no protein expression (CD62L) and MFI of protein expression 
(PD-1, IFN-) are indicated. (b) Quantitative RT-PCR analysis of mRNA expression: 
Havcr2 (TIM-3), Pdcd1 (PD-1), Cd244 (2B4), Tcf7 (Tcf1), Sell (CD62L), and Ccr7 in 
sorted GFP+ let-7Tg CD8 T cells transduced with either RV-empty or RV-Hmga1, 
presented relative to the expression of the ribosomal protein Rpl13a. (c) Staining of TIM-
3, 2B4, CD160, PD-1, and CD62L on P14 let-7Tg CD8 T cells transduced with either RV-
empty or RV-Eomes which expresses a GFP reporter. Frequencies of protein-expressing 
cells (GFP, TIM-3, 2B-4, CD160, CD62L), cells with no protein expression (CD62L) and 
MFI of protein expression (PD-1) are indicated. (b) Quantitative RT-PCR analysis of 
mRNA expression: Havcr2 (TIM-3), Pdcd1 (PD-1), Cd244 (2B4), Cd160, Sell (CD62L), 
and Ccr7 in sorted GFP+ let-7Tg CD8 T cells transduced with either RV-empty or RV-
Eomes, presented relative to the expression of the ribosomal protein Rpl13a. (e) 
Quantitative RT-PCR of mRNA expression: Cd244 (2B4), Havcr2 (TIM-3), Pdcd1 (PD-
1), Cd160, Il10, Sell (CD62L), and Tcf7 (Tcf1) in CTLs generated from P14 CD4-Cre-
Eomesfl/fl, P14 CD4-Cre-Eomesfl/flLin28Tg, P14 CD4Cre+Eomesfl/flLin28Tg mice (top). 
Staining of TIM-3, PD-1, 2B4, CD160, and CD62L on CD8 T cells from the indicated 
mice (bottom). (f) Staining of TIM-3, 2B4, CD160, PD-1, and CD62L on P14 let-7Tg CD8 
T cells transduced with either RV-empty or RV-Arid3a which expresses a GFP reporter. 
Frequencies of protein-expressing cells (GFP, TIM-3, 2B-4, CD160, CD62L), cells with 
no protein expression (CD62L) and MFI of protein expression (PD-1) are indicated. (g) 
Quantitative RT-PCR analysis of mRNA expression: Havcr2 (TIM-3), Pdcd1 (PD-1), 
Cd244 (2B4), Tcf7 (Tcf1), Sell (CD62L), Ccr7, Prf1 (perforin), Gzma (Granzyme A), and 
Ifng in sorted GFP+ let-7Tg CD8 T cells transduced with either RV-empty or RV-Arid3a, 
presented relative to the expression of the ribosomal protein Rpl13a. not significant (P > 
0.05), * P < 0.05, ** P < 0.01, and *** P < 0.001, **** P < 0.001 compared with GFP+ 
let-7Tg CTLs transduced with RV-empty (a, b, c, d, f, g) or CTLs generated from P14 
CD4-Cre-Eomesfl/fl mice using two-tailed Student’s t-test. Data are from one experiment 
representative of two experiments (b, d, e, f, g; mean and s.e.m of technical triplicates). 
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Figure 3.10 let-7 miRNAs program CD8 T cell fate 
Model illustrating how let-7 miRNAs program the fate of CD8 T cells, where high let-7 
expression is necessary to maintain the quiescent state of naïve cells and promote 
memory differentiation. Conversely, let-7 miRNAs must be moderately downregulated to 
produce effective terminal effector CTL differentiation. It is important that let-7 
downregulation is moderate, as severe downregulation leads to exhaustion. 
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CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
4.1 Conclusions 
 Taken together, the results presented in this dissertation demonstrate that the let-7 
miRNAs are a molecular control hub that regulate the fate of CD8 T cells. First, it was 
determined that let-7 miRNAs are very highly expressed in naïve CD8 T cells and that their 
expression is downregulated through TCR signaling, in which both the duration and 
strength of signal control the expression of let-7. The high expression of let-7 miRNAs is 
necessary to maintain the quiescence of naïve CD8 T cells, as removal of let-7 expression 
in this population resulted in increased proliferation and expression of activation markers. 
Moreover, the downregulation of let-7 expression in activated cells is necessary for the 
acquisition of effector function, as overexpressing let-7 throughout CTL differentiation 
severely impaired the response to viral infection and the clearance of an allogeneic tumor. 
Specifically, the failure to downregulate let-7 impaired proliferation and important 
metabolic changes that occur during blastogenesis, likely through its regulation of Myc. 
Later in CTL differentiation, the downregulation of let-7 was necessary to express Eomes 
and acquire effector function. In fact, Eomes was identified as a novel direct target of let-
7. These data suggested that let-7 tunes the magnitude of CTL responses according to the 
strength of TCR signaling, where weak TCR signaling yields mild CTL responses due to 
retention of let-7 miRNA expression, and strong TCR signaling generates robust CTL 
responses as a result of strong downregulation of let-7 (Figure 2.13).  
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Further, a role for the let-7 miRNAs in regulating terminal effector and memory 
CD8 T cell differentiation was identified through the use of both bacterial infection and 
tumor models. Contrary to the cytotoxicity observed in vitro, let-7-deficiency did not 
improve anti-tumor CTL responses. Rather, CTLs in which let-7 was overexpressed 
mediated the most efficient tumor rejection. Molecular characterization of these cells 
revealed that overexpression of let-7 restrained the terminal differentiation program, which 
allowed these cells to differentiate into the memory fate. Consequently, depletion of let-7 
miRNAs pushed CTLs into a terminal effector state, which became functionally exhausted 
in the context of the immunosuppressive tumor microenvironment. Accordingly, the 
function of let-7-deficient CTLs was rescued through the use of checkpoint blockade 
inhibition. Although the exact let-7-mediated molecular mechanism was not fully 
characterized, several genes that let-7 targets to restrain terminal differentiation and 
preserve memory CD8 T cells were identified. Each of these factors likely contributes to a 
complex and synergistic transcriptional network regulated by let-7 (Figure 3.10). 
 
4.2 Future directions 
Much remains to be determined to better understand the role of the let-7 miRNAs 
in controlling CD8 T cell fate. There are several important points which remain to be 
addressed, including: (1) understanding better the mechanisms contributing to the 
paradoxical functions observed between the 2-dimensional in vitro setting and in 3-
dimensional in vivo environments; (2) determining the function of Arid3a and Hmga1 in 
CD8 T cells, which should further illuminate the importance of their regulation by let-7; 
(3) testing the function of the let-7 miRNAs in memory differentiation in vivo and how this 
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let-7-mediated mechanism fits into the proposed models of memory differentiation; (4) 
extrapolating upon this data to establish a role for the let-7 miRNAs in the differentiation 
and function of CD4 T cells; (5) identifying the molecular mechanism by which TCR 
signaling regulates the expression of the let-7 miRNAs.  
 
4.2.1 Characterizing the in vitro versus in vivo paradox 
The dramatic differences in the function of Lin28Tg and let-7Tg CTLs in vitro 
versus in vivo raises important questions regarding not only the method by which cells are 
cultured on 2-D plastic, but also the mechanism required to successfully transduce 
inhibitory signals to CD8 T cells. It is not known if the engagement of inhibitory receptors 
and immunosuppressive cytokine signaling alone are responsible for the exhaustion of CD8 
T cells, or if there are other environmental factors which are necessary for these signals to 
establish T cell exhaustion. It has been proposed that the stiff substrates drive cells into a 
more terminal effector state (O’Connor et al., 2012; Saitakis et al., 2017). Moreover, the 
inability to rescue exhausted CD8 T cells via checkpoint blockade immunotherapy has 
been documented (Wei et al., 2018). These two findings suggest that the ECM may have a 
previously unappreciated role in mediating signals through inhibitory receptors to promote 
exhaustion. 
In fact, we attempted to address the role of the ECM in driving CD8 T cell 
exhaustion by using tunable hydrogels, in which the gel can be manipulated to mimic the 
rigid ECM stiffnesses associated with the tumor microenvironment. Specifically, let-7Tg, 
Lin28Tg, and WT P14 CTLs were encapsulated in gels of either low or high stiffness, and 
the expression of inhibitory receptors was assessed, hypothesizing that high stiffness ECM 
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would increase expression of inhibitory receptors. However, encapsulation of activated 
CD8 T cells in the gels resulted in cell death, inhibiting the study of the ECM in 
contributing to CD8 T cell exhaustion (Figure 4.1). This does not mean that the ECM is 
not an important factor in establishing exhaustion or in the transduction of inhibitory 
signals, thus further investigation is warranted. Encapsulating T cells in a simpler gel 
system, such as poly(NIPAAm) may be useful to initially establish a role for a 3-
dimensional environment in promoting inhibitory receptor signaling (Haq et al., 2017). In 
this situation, performing an in vitro cytotoxicity assay in the gel versus on tissue culture 
plastic may be informative. If 3-dimensional interactions are necessary to transmit signals 
through the inhibitory receptors, it would be hypothesized that the high cytotoxic function 
of Lin28Tg CTLs against cancer cells on 2-dimensional plastic, would be reduced in the 
gel and more accurately represent the in vivo function of these cells. 
 
4.2.2 Identify the role of Hmga1 and Arid3a in CD8 T cell differentiation 
An important outcome of this research is the identification of the novel let-7 targets, 
Eomes, Hmga1, and Arid3a, which control the differentiation of CD8 T cells. As two of 
these factors, Hmga1 and Arid3a, have either been poorly characterized, or have no 
identified role in the differentiation of CD8 T cells, it will also be interesting to characterize 
their function in CD8 T cells independent of let-7. This can be accomplished by both gain 
of function and loss of function approaches. As this study focused only on the phenotype 
of in vitro differentiated cells transduced with cDNA that encodes these two factors, it will 
be very important to determine how they impact the function of CD8 T cells. The 
retroviruses used in this dissertation can be used to overexpress Hmga1 and Arid3a in CD8 
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T cells, that are transferred into mice which are subsequently infected with LM-33. The 
phenotype of donor cells overexpressing either Hmga1 or Arid3a can be assessed over time 
by analyzing circulating cells in the blood. This will provide insight into the differentiation 
of these cells in vivo, hypothesizing that overexpression of these factors would lead to the 
terminal differentiation of donor cells, and thus the inability to generate a robust long-lived 
memory population. At the end of the study, secondary lymphoid organs can be analyzed 
further to better characterize how memory CD8 T cell differentiation was affected by 
overexpression of these genes. The tumor models generated in this dissertation will also be 
useful in characterizing the function of Hmga1 and Arid3a in establishing the exhausted 
state in CD8 T cells. By monitoring tumor growth in mice with solid tumors which receive 
transfer of CTLs transduced with either of these factors, whether Hmga1 and Arid3a alone 
are sufficient to establish exhaustion in vivo can be determined. Moreover, loss of function 
approaches will also provide insight into the role of these factors in CD8 T cell 
differentiation. By introducing shRNAs against these factors into differentiating CD8 T 
cells, one would hypothesize memory differentiation might be enhanced. This can be tested 
in vivo again by transfer of CD8 T cells expressing these shRNAs into mice which are then 
infected with LM-33. It is important to note that in vitro, Hmga1, Arid3a, and even Eomes, 
only partially contributed to the terminal differentiation phenotype, with neither factor 
being able to entirely recapitulate the phenotype observed in Lin28Tg CTLs. Thus, it will 
also be interesting to introduce these factors into CD8 T cells in combination. This will 
provide insight into their cooperation and may explain why each factor individually only 
moderately skewed the differentiation of CD8 T cells. 
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The data presented in this dissertation suggests there is a role for Eomes, Hmga1, 
and Arid3a in directing differentiating CD8 T cells toward the terminal effector fate. To 
better understand how these transcriptional regulators accomplish this in an unbiased 
approach, performing ATAC-seq and ChIP-seq will generate global maps of the genetic 
targets of these factors. Moreover, RNA-seq can be performed on CD8 T cells in which  
these factors are either overexpressed or knocked down to identify which genes targeted 
by these factors are functionally relevant to CD8 T cell differentiation. 
 
4.2.3 Further characterization of let-7 miRNAs in memory differentiation 
Several challenges were encountered in attempting to study the role of the let-7 
miRNAs in memory P14 T cell differentiation in vivo through the adoptive transfer of naive 
let-7Tg CD8 T cells. Specifically, donor let-7Tg P14 T cells could not be identified in host 
spleens 30 days after vaccination with gp33, poly(I:C) and anti-CD40 monoclonal antibody 
(Figure 4.2A). Cells were properly activated as they could be recovered in equal numbers 
to WT P14 cells 48 hours after activation by LM-33 infection (Figure 4.2B). To overcome 
the let-7-mediated block on proliferation, 1X106 naïve let-7Tg P14 T cells, as opposed to 
2X104, were transferred to host mice prior to LM-33 infection, but only resulted in a mild 
improvement in cell recovery (Figure 4.2C). To address the possibility that let-7Tg P14 T 
cells preferentially become tissue-resident memory cells, the liver of vaccinated mice 
which received adoptive transfer of let-7Tg P14 T cells were analyzed, as this is a large 
reservoir for TRM cells. However, no let-7Tg P14 T cells were found (Figure 4.2D). It is 
also possible that although the mice from which let-7Tg P14 cells are isolated are restricted 
to MHC H-2Db, there may be differences in minor antigens that lead to allogeneic 
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responses against these cells upon transfer into host mice. To address this possibility, let-
7Tg P14 cells were transferred into Perforin deficient mice (Prf1-/-), such that T cells and 
natural killer cells cannot kill the MHC-mismatched cells. Yet, there was no improvement 
of recovery of let-7Tg cells in Prf1-/- mice (Figure 4.3E). These data suggested the let-7 
mediated block on proliferation may in part be responsible for the failure to identify let-
7Tg CD8 T cells during adoptive transfer experiments; however, it is not possible to rule 
out the possibility that differences in genetic background may also be a contributing factor, 
or that naïve let-7Tg CD8 T cells home to a unique peripheral site. There are several 
possibilities to address the latter two concerns.  
First, to completely rule out the possibility that let-7Tg cells are rejected from the 
host based on minor antigens, let-7Tg P14 T cells could be transferred into agouti mice 
(C57BL/6J-Aw-J/J) which should share any minor antigens, as let-7Tg mice were originally 
generated on the agouti background, thus eliminating rejection of the let-7Tg cells. 
However, to simply completely eliminate any differences in genetic background and still 
use the pure C57BL/6J genetic background on which all the other mouse models are based, 
DNA encoding the let-7 miRNAs can be cloned into a GFP-expressing retroviral vector 
that is transfected into WT P14 T cells which can be successfully transferred into host mice 
without any complications. In this way, both GFP positive (let-7 overexpressing) and 
negative (“wild type”) cells can be analyzed for their ability to differentiate into the 
memory fate. Further, in this model it may be possible that only GFP negative cells will be 
identified in secondary lymphoid organs, which would provide more insight into whether 
let-7 miRNAs direct the localization of memory cells to a unique niche. If this were the 
case, it would be prudent to check other tissues for the presence of let-7 transduced cells. 
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While the liver and gut are important niche for TRM cells, the skin, lung, white adipose 
tissue, and bone marrow also serve as reservoirs for TRM cells. Checking the presence of 
of GFP positive cells in these other organs may help not only in locating let-7-
overexpressing cells, but also may further illuminate the role of let-7 miRNAs in CD8 T 
cell differentiation. In fact, it was recently demonstrated that TCM cells (which are the 
memory population let-7Tg cells most resemble phenotypically) can seed the TRM 
population in the skin (Osborn et al., 2019). Thus, it will be important to analyze this organ 
for let-7Tg cells regardless of the results from the experiments described above. 
It will also be interesting to fit our data demonstrating that let-7 miRNAs promote 
memory CD8 T cell differentiation into the proposed models of this process. The 
observation that let-7 miRNA expression during the first 48 hours of activation is sufficient 
to generate memory CD8 T cells, would be consistent with the asymmetric division model. 
It would be interesting to sort the proximal and distal daughter cells generated as a result 
of T cell activation by antigen presenting cells, and assess let-7 expression in these two 
populations. We would hypothesize that let-7 expression would be higher in the distal 
daughter cell which received weaker TCR stimulation and will differentiate into a memory 
cell, as compared to the proximal daughter cell which would have lower let-7 expression 
due to stronger TCR stimulation. As a follow-up to these experiments, further dissection 
of the function of let-7 miRNAs within this 48-hour window will be enlightening. In fact, 
preliminary data in the lab suggests that let-7 makes critical ‘decisions’ to determine the 
fate of CD8 T cells as early as 12 hours after activation.  
 
4.2.4 Expansion of let-7 miRNA regulation of CD4 T cell differentiation and function 
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This study has focused primarily on CD8 T cells, but the let-7 miRNAs are also 
very abundantly expressed in naïve CD4 T cells, and have been shown by others in the lab 
to be downregulated by TCR signaling. Thus, the role of let-7 miRNAs during CD4 T cell 
differentiation should be examined. This is especially important because CD4 T cells are 
the primary mediators of autoimmune diseases. It will be interesting to test in vivo whether 
maintaining let-7 miRNAs or depleting let-7 miRNAs ameliorates autoimmune disease 
progression. Based on the in vitro data presented in this dissertation, one would hypothesize 
that expression of let-7 miRNAs would inhibit autoreactive cells from attacking healthy 
host cells, while depletion of let-7 miRNAs would expedite disease progression. This can 
easily be tested by using a mouse model of multiple sclerosis called experimental 
autoimmune encephalomyelitis in WT, let-7Tg, or Lin28Tg mice. In fact, this is an active 
area of investigation in the lab. CD4 T cells also have the unique ability to differentiate 
into distinct subsets of T helper cells based on the invading pathogen and cytokine milieu 
associated with the infection. It will be interesting to test whether modulation of let-7 
miRNAs is important to direct CD4 T cells into the different T helper subsets. Further, 
based on the cytokine milieu present during CD4 T cell differentiation, some of these 
helper subsets can also become pathogenic, contributing to autoimmune disease 
progression (Lee et al., 2012). Using the distinct cytokine conditions used to differentiate 
pathogenic CD4 T helper cells on WT, let-7Tg, and Lin28Tg CD4 T cells will help 
determine whether let-7 miRNAs negatively regulate the pathogenic differentiation of CD4 
T cells, and will also help to understand the role of let-7 miRNAs in CD4 T cell-mediated 
autoimmune diseases. 
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Moreover, it will be interesting to test the role of let-7 miRNAs in the development 
of CD4 T cell memory, which is less understood than CD8 T cell memory. As such, the 
importance of let-7 miRNAs in generating memory CD8 T cells presented here may 
provide important insight into the generation of memory CD4 T cells. First, WT, let-7Tg, 
and Lin28Tg mice can be crossed onto a SMARTA TCR background, in which SMARTA 
is a T cell receptor that recognizes the gp66-81 epitope from LCMV. This way, these cells 
can be transferred into mice which are subsequently infected with Listeria that express the 
target antigen (LM-66), in order to determine the extent to which let-7 expression directs 
memory CD4 T cell differentiation. However, it is entirely possible that these cells will 
also be rejected in the host. If this is the case, the previously generated retroviruses which 
encode let-7 miRNA can be used to overexpress let-7 in CD4 T cells to test the role of let-
7 in memory CD4 T cell differentiation. Moreover, the let-7 miRNAs are expressed 
throughout the immune system. Determining the function of let-7 miRNAs in other 
immune cell populations, and whether modulating let-7 expression in one immune cell may 
determine the effects of let-7 in another, will surely be illuminating. 
 
4.2.5 Identify the mechanism regulating let-7 miRNA expression 
As an important outcome of this research is the identification of the let-7 miRNAs 
as a therapeutic tool, it is extremely important to determine the molecular mechanism that 
controls the expression of these miRNAs in response to TCR signaling, as this might 
identify a means by which to artificially regulate let-7. Along these lines, it would be very 
interesting to perform bisulfite sequencing and ATACseq in memory, terminal effector, 
and exhausted CD8 T cells in genomic locations where let-7 miRNAs are found. One might 
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expect that as cells progress further into the terminal effector program, as let-7 expression 
decreases, there would be increased deposition of repressive marks, and closed chromatin 
in these areas. To perform these experiments, WT P14 CD8 T cells will be adoptively 
transferred into congenically marked host mice which are subsequently infected with either 
LCMV Armstrong to establish an acute infection, or LCMV clone 13 to establish a chronic 
infection. In this way, naïve, terminal effector cells, memory precursor cells, memory cells 
and exhausted cells can all be identified and sorted based on well-established phenotypic 
markers. Once these populations of CD8 T cells have been separated, they can be sent for 
bisulfite sequencing and ATAC-seq to determine the epigenetic landscapes of let-7 miRNA 
loci during the different stages of CD8 T cell differentiation, providing novel information 
regarding the regulation of let-7 miRNA expression. 
Moreover, the molecular mechanism mediated by TCR signaling to downregulate 
let-7 miRNA expression in activated CD8 T cells remains to be determined. First, whether 
let-7 miRNAs are downregulated by transcriptional or post-transcriptional mechanisms 
should be determined. To assess this, the relative levels of let-7 primary miRNAs and 
precursor miRNAs will be assessed. If the let-7 pri-miRNAs are dramatically 
downregulated upon TCR signaling, this would indicate strong transcriptional regulation, 
whereas downregulation of let-7 pre-miRNAs would be indicative of post-transcriptional 
regulation. This would be determined by northern blot, as probes for pri-miRNA and pre-
miRNA qPCR are limited. In the case of transcriptional regulation, some factor may bind 
to promoter or enhancer regions of let-7 genes to inhibit their expression. Analysis of 
chromatin accessibility around the promoters of let-7 genes and characterization of the 
binding sites in these regions of open chromatin will help to identify factors that bind to 
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promoters of let-7 miRNAs to inhibit their expression. Once several candidate factors have 
been identified, ChIP-seq can be used to determine if they do in fact bind to the promoters 
of let-7 genes. ChIP-seq data from activated versus naïve CD8 T cells could be compared. 
Proteins bound in activated, but not naïve CD8 T cells may negatively regulate let-7 
miRNA expression. In the case of post-transcriptional regulation, it is possible that the let-
7 miRNAs themselves are inhibited by some factor in a manner analogous to Lin28. To 
address the possibility of post-transcriptional regulation, immature let-7 miRNAs will be 
pulled down, such that any proteins bound to the immature let-7 miRNA are also pulled 
down. The proteins will be dissociated from the let-7 miRNA and sent for mass 
spectrometry to determine the identity of the bound proteins.  
Once these proteins have been identified, their function in regulating let-7 
expression can be tested by overexpressing the protein via retroviral vector in NIH 3T3 
cells, which have high endogenous let-7 expression, and assessing if let-7 expression is 
downregulated. Upon confirmation of a role in inhibiting let-7 expression, whether these 
proteins regulate let-7 expression in CD8 T cells can be tested by both gain and loss of 
function approaches. A potential loss of function approach would first be to generate 
shRNAs that prevent the expression of this protein. It would be hypothesized that by 
inhibiting expression of this protein, let-7 miRNAs will remain highly expressed upon TCR 
stimulation. Accordingly, determining the phenotype of CTLs generated in the absence of 
this protein will prove interesting. If inhibiting this protein maintained let-7 expression, 
one would hypothesize that these CD8 T cells would differentiate into the memory 
phenotype. If a phenotype is observed using shRNAs, generation of a conditional knockout 
mouse, in which the protein is deleted only in T cells, may be warranted for future studies. 
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In these studies, conditional knockout mice could be bred to a P14 TCR background, such 
that CD8 T cells from these mice could be transferred into host mice subsequently infected 
with LM-33 to study antigen specific responses. The differentiation of terminal effector, 
memory precursor, and memory populations would be assessed. Further, CTLs could be 
generated in vitro, and the extent to which they eliminate tumors in vivo could be 
determined.  Contrastingly, gain of function approaches could also be taken. In this 
situation, the previously generated retroviral vectors would be used to overexpress the 
protein in CD8 T cells. First, let-7 expression would be analyzed, expecting that it would 
be reduced in the presence of this protein. Further, analyzing the phenotype of these cells 
in vitro would demonstrate functional significance of the expression of this protein. It 
would be hypothesized that overexpressing this protein would drive cells into a terminal 
effector/ exhausted state due to downregulation of let-7. If a phenotype were observed, 
transgenic mice which constitutively overexpress this protein in T cells under the control 
of the human CD2 promoter (analogous to Lin28Tg mice) could be generated. These mice 
would also be crossed to a P14 background to study the ability of cells overexpressing this 
protein to generate memory cells in the LM-33 model and to eliminate tumors in the 
B16gp33 tumor model. These studies would identify novel candidates for manipulating let-
7 miRNAs therapeutically.  
In conclusion, our data demonstrate a novel role for the let-7 miRNAs in 
determining CD8 T cell fate, and has identified them as a unique therapeutic target. The 
further characterization of these miRNAs in CD8 T cells should prove fascinating and 
productive for manipulating immune responses to improve human health. 
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Figure 4.1 Encapsulation of T cells in hydrogels with different stiffnesses 
On day 3 after activation, 1X106 cells were encapsulated into functionalized hydrogels with 
either a 2kPa stiffness, representative of healthy tissues, an 8kPa stiffness, representative 
of a cancerous tissue, or cells were kept in suspension as usually cultured. Two days later, 
cells were analyzed by flow cytometry. Numbers indicate the frequency of live cells after 
isolation from the gels. Data are from one experiment, representative of two experiments. 
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Figure 4.2 Identification of let-7Tg cells in host mice 
(a) 2X104 naïve CD45.2 P14 or CD45.2 P14 let-7Tg CD8 T cells were transferred into 
CD45.1 host mice, and one day later vaccinated with gp33, poly(I:C), and anti-CD40 
monoclonal antibodies. The spleens of host mice were analyzed for donor cells 30 days 
after vaccination. (b) 1X106 naïve CD45.2 P14 or CD45.2 P14 let-7Tg CD8 T cells were 
transferred into CD45.1 host mice, and one day later infected with LM-33. The spleens of 
host mice were analyzed for host cells 48 hours after infection. (c) 2X104 naïve CD45.2 
P14, or either 2X104 or 1X106 naïve CD45.2 P14 let-7Tg CD8 T cells were transferred 
into CD45.1 host mice, and one day later infected with LM-33. The spleens of host mice 
were analyzed for host cells 48 hours after infection. (d) 2X104 naïve CD45.2 P14 or 
CD45.2 P14 let-7Tg CD8 T cells were transferred into CD45.1 host mice, and one day 
later vaccinated with gp33, poly(I:C), and anti-CD40 monoclonal antibodies. The livers 
of host mice were analyzed for donor cells 30 days after vaccination. (e) 2X104 naïve 
CD45.2 P14 or CD45.2 P14 let-7Tg CD8 T cells were transferred into Prf1-/- host mice, 
and one day later infected with LM-33. The spleens of host mice were analyzed for donor 
cells 12 days after infection, using a gp33 tetramer. Data are from one experiment, 
representative of one experiment.  
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CHAPTER 5 
MATERIALS AND METHODS 
 
5.1 Animals 
C57BL/6J (CD45.2+ wild type, stock no. 000664), B6.SJL- PtprcaPepcb/ BoyJ (CD45.1+ 
wild type, stock no. 002014), B6(Cg)- Rag2Tm1.1Cgn/J (Rag2-/-, stock no. 008449), B6 
Tg(CD4-cre)1Cwi/BfluJ (CD4-Cre, stock no. 017336), and B6.129S1 (Cg)- 
Eomestm1.1Bflu/J (Eomesfl/fl, stock no. 017293) were obtained from the Jackson Laboratory. 
B6.Cg- Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/J (let-7g, stock no. 023912) and B6.Cg- Gt(ROSA)26 
Sortm1(rtTA*M2)Jae/J (M2rtTA, stock no. 006965) were also obtained from the Jackson 
Laboratory and subsequently crossed to generate let-7Tg mice. Mice with the Lin28B 
transgene (Lin28Tg) driven under the control of the human CD2 promoter (Pobezinsky et 
al., 2015), and B6 Tg(TcrLCMV)327Sdz/JDvs/J (P14) mice were a generous gift from 
Alfred Singer (NCI, NIH). P14+ mice, and wild type C57Bl/6J mice on a Rag2-/- 
background were crossed to generate wild type P14 mice. let-7Tg mice, and P14+ mice 
were crossed on a Rag2-/- background to generate P14+ doxycycline- inducible let-7 
transgenic mice. Lin28B Tg mice were crossed with P14+ mice on a Rag2-/- background to 
generate P14+ Lin28Tg mice. let-7Tg, Lin28B Tg, P14+ mice were crossed on a Rag2-/- 
background to generate 4Tg mice. CD4-Cre and Eomesfl/fl mice were crossed to generate 
mice with a T cell- specific conditional knockout of Eomes. CD4-Cre, Eomesfl/fl Lin28B 
Tg, P14+ mice were crossed to generate Lin28Tg mice with a T cell- specific deletion of 
Eomes. R26STOP-Lin28-GFP mice were generated in collaboration with Alfred Singer, NCI) 
and Georg Hollander (University of Oxford). GzmbCre+R26STOP-Lin28-GFP were generated by 
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crossing R26STOP-Lin28-GFP mice with FVB-Tg(GZMB-cre)1 Jcb/J (GzmbCre) mice 
obtained from Jackson Labs (stock number: 003734). iCreR26STOP-Lin28-GFP mice were 
generated by crossing R26STOP-Lin28-GFP mice with Tg(tetO-cre)1Jaw/J (iCre) mice obtained 
from Jackson Labs (006224). Littermates or age and sex-matched mice were used as 
controls. All breedings were maintained at the University of Massachusetts, Amherst. This 
study was performed in accordance with the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health. All of the animals were 
handled according to approved institutional animal care and use committee (IACUC) 
protocols (#2014-0045, 2014-0065, 2015-0035) of the University of Massachusetts. 
 
5.2 Doxycycline-mediated induction of let-7 transgene expression 
Experimental mice including control animals (unless specifically stated otherwise) were 
fed with 2 mg/mL doxycycline in drinking water supplemented with 10 mg/mL sucrose for 
four days prior to the initiation of experimental procedures to ensure maximal induction of 
let-7g expression. Doxycycline drinking water was replaced every other day. In vitro, 
lymphocytes were cultured with 2 μg/mL doxycycline in CTL culture media (see cell 
sorting and in vitro culture below). 
 
5.3 In vivo BrdU labeling 
Mice were injected i.p. with 1 mg BrdU in PBS, and subsequently fed with 0.8 mg/mL 
BrdU in drinking water supplemented with 2% sucrose for four days. BrdU water was kept 
in the dark to eliminate light-sensitivity effects of BrdU and was replaced daily. 
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Incorporation of BrdU in CD8 T cells from the spleen and lymph nodes were analyzed by 
flow cytometry (see flow cytometry analysis below). 
 
5.4 Flow cytometry analysis 
Flow cytometry data were acquired on a BD Fortessa or a MilliPore Amnis ImageStream.  
For restimulation in vitro, 2x106 cells were stimulated with phorbol myristate acetate 
(PMA) and Ionomycin for 4 h at 37°C and Monensin A for 2 h at 37°C. Cells were first 
stained for surface proteins then fixed, permeablized, and stained for intracellular proteins 
according to the manufacturer’s instructions (BD Pharmingen, eBio).  
For LCMV studies, 2x106 cells were stimulated for 4 hr at 37°C with 2 μg/ mL of GP33-41 
or NP396-404 peptides, and 1 μl/ mL GolgiPlug (BD Pharmingen). Cells were first stained 
for surface proteins then fixed, permeablized, and stained for intracellular proteins 
according to the manufacturer’s instructions (BD Pharmingen). Flow cytometry data were 
acquired on a BD LSR II. All flow cytometry data was analyzed with FlowJo software 
(TreeStar; RRID:SCR_008520). MilliPore Amnis ImageStream data was analyzed with 
IDEAS software (EMD Millipore).  
The monoclonal antibodies used in these studies can be found in Table 5.1. 
 
5.5 Western blot analysis 
Cells were collected and lysed in M2 lysis buffer (20mM Tris, pH7.0, 0.5% NP40, 250mM 
NaCl, 3mM EDTA, 3mM EGTA, 2mM DTT, 05mM PMSF, 20mM β-glycerol phosphate, 
1mM sodium vanadate, 1μg/mL Leupeptin), then resolved by SDS-PAGE. Blots were 
probed with anti-Perforin (CB5.4, Abcam; RRID:AB_302236) and anti-actin (AC40, 
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Sigma; RRID:AB_2686923), and visualized using enhanced chemiluminescence 
(ThermoScientific) with horse-radish peroxidase conjugated anti-rat IgG (712-035-150, 
Jackson ImmunoResearch; RRID:AB_2340638) or anti-mouse IgG (401215, Calbiochem; 
RRID_AB:2686924). 
 
5.6 T cell isolation, sorting, and in vitro culture 
Lymph nodes were harvested and gently tweezed to remove lymphocytes. CD8 lymph node 
T cells were enriched for via antibody-mediated depletion of B cells using anti-mouse IgG 
magnetic beads (BioMag, Qiagen). CD4 T cells were removed via anti-rat IgG magnetic 
beads (BioMag, Qiagen) following incubation with anti-mouse CD4 antibodies conjugated 
with rat IgG (GK1.5). Lymphocytes were electronically sorted for the further purification 
of naïve CD8 T cells (CD44lo CD25loCD8+CD4-) (Figure 3—figure supplement 1A). 
Cells were stimulated either with irradiated splenocytes loaded with anti-CD3 mAbs (10 
μg/mL), or plate-bound anti-TCRβ mAbs (10 μg/mL) and anti-CD28 mAbs (5 μg/mL), 
then differentiated for five days in RPMI supplemented with 10% fetal bovine serum, 1% 
HEPES, 1% sodium pyruvate, 1% penicillin/ streptomycin, 1% L-glutamine, 1% non-
essential amino acids, 0.3% β-mercaptoethanol, 100 U/mL IL-2, 100 mg/mL gentamicin, 
and 2μg/mL doxycycline when necessary. When appropriate 100 U/mL IL-15 was used. 
 
5.7 Eomes site-directed mutagenesis  
Site-directed mutagenesis of the let-7 binding site in the Eomes ORF was performed using 
the Agilent QuikChange II Site-Directed Mutagenesis kit according to the manufacturer’s 
protocol. 
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5.8 Retroviral transduction of candidate genes 
Retrovirus expressing Eomes, EomesMUTANT, Nupr1, Helios, Hmga1, or Arid3a cDNA 
with a GFP reporter were produced from the transfection of PlatE cells using 
Lipofectamine plus (Invitrogen). For retroviral transduction, naïve lymphocytes were 
stimulated with irradiated splenocytes in the presence of anti-CD3 mAbs (10 μg/mL) for 
24 hours, then spin-fected (2000 RPM, 90 minutes, 30°C) with virus and polybrene (4 
μg/mL). Retrovirally transduced cells were obtained by sorting on the GFP+ population. 
 
Retrovirus expressing the gp33 minigene with a GFP reporter was produced from the 
transfection of PlatE cells using Lipofectamine plus (Invitrogen). For retroviral 
transduction, B16 and EL-4 cells were spin-fected (2000 RPM, 90 minutes, 30°C) with 
virus and polybrene (4 μg/mL). Retrovirally transduced cells were obtained by sorting on 
the GFP+ population. Antibodies used for flow cytometry are listed in Table 5.1. 
 
 
5.9 Prediction of miRNA targets 
Eomes was independently identified in an unbiased search of all ORFs in the mouse and 
humans genomes, for matches to an extended 9 bp let-7 seed, “TACTACCTC“. This search 
utilized a hashing algorithm as described in 81 and identified 119 genes in the mouse 
genome, and 159 genes in the human genome that have one or more matches to the 9 bp 
let-7 seed in their ORF sequences. Interestingly, humans have three splice variants of 
Eomes, one of which lacks the exon containing the match to let-7, thus opening the 
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possibility that Eomes may escape let-7 repression in some cells by alternative splicing of 
the target sequence. This may require further investigation. 
 
5.10 Luciferase assay 
NIH 3T3 cells (ATCC) were transfected with the pmirGLO vector (Promega) containing 
either the intact let-7 binding motif from Eomes, or a mutated version of this binding motif, 
or either intact antisense or mutated antisense seed regions of let-7b, let-7g, or let-7i using 
Lipofectamine and Plus reagent (Invitrogen). Luciferase activity was measured 48 hours 
later on a POLARstar Omega 96-well plate reader (BMG Labtech), using the Dual- 
Luciferase Reporter Assay System (Promega). 
 
5.11 IL-2 withdrawal assay 
P14+ CD8 T cells were stimulated with anti-TCRβ mAbs (10 μg/mL) and anti-CD28 mAbs 
(5 μg/mL) plate-bound antibodies, differentiated into CTLs for 5 days in the presence of 
IL-2, and 2 μg/mL doxycycline. On day 5, CTLs were washed twice with PBS to remove 
all cytokines from the cells. 5X104 CTLs were plated into cytokine-free media for up to 24 
hours. Survival was assessed by flow cytometry using propidium iodide.   
 
5.12 CellTrace Violet proliferation assay 
Electronically sorted naïve CD8 T cells were labeled with CellTrace Violet (Invitrogen) 
for 15 minutes at 37°C. Cells were stimulated using plate-bound anti-TCRβ mAbs (10 
μg/mL) and anti-CD28 mAbs (5 μg/mL), cultured for 72 hours, and analyzed by flow 
cytometry. 
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5.13 CellTrace Violet cytotoxicity assay 
P14+ CD8 T cells were stimulated with anti-TCRβ mAbs (10 μg/mL) and anti-CD28 mAbs 
(5 μg/mL) plate-bound antibodies, differentiated into CTLs for 5 days in the presence of 
IL-2, gentamicin, and 2 μg/mL doxycycline when appropriate. On day 5, live splenocytes 
were warmed for 10 minutes at 37°C, then labeled with CellTrace Violet (Invitrogen) at 
two different concentrations (CTVhigh or CTVlow) for 15 minutes at 37°C. CTVlow 
splenocytes were then loaded with either LCMV gp33-41 peptide (1 μM, GenScript) or 
LCMV np396-404 peptide (1 μM, GenScript) for 1 hour at 37°C, and are referred to below 
as “experimental splenocytes”. CTVhigh splenocytes remained peptide-free, and were used 
as a reference control, referred to below as “control splenocytes”. Equal amounts of both 
experimental and control splenocytes were co-cultured with CTLs at different ratios for 
four to five hours. Cytotoxicity was assessed by flow cytometry using propidium iodide. 
Measured as the percent target lysis of live experimental splenocytes loaded with either 
target (gp33-41) or control (np396-404) peptide from the lymphocytic choriomeningitis 
virus. The following formula was used to calculate the percent target lysis: 
(1 − (
𝐴
𝐵
𝑋
𝐶
𝐷
))X 100 
A- frequency of live experimental splenocytes co-cultured with CTLs; B- frequency of live 
control splenocytes co-cultured with CTLs; C- frequency of live control splenocytes 
incubated in the absence of CTLs; D- frequency of live experimental splenocytes incubated 
in the absence of CTLs. 
 
5.14 Tumor cytotoxicity assay 
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P14+ CD8 T cells were stimulated with anti-TCRβ mAbs (10 μg/mL) and anti-CD28 mAbs 
(5 μg/mL) plate-bound antibodies, differentiated into CTLs for 5 days in the presence of 
IL-2, and 2 μg/mL doxycycline. On day 5, titrated amounts of CTLs were added to 1X106 
B16gp33 adherent tumor cells plated one day prior. Cells were co-cultured for 12-16 hours. 
Cytotoxicity was assessed by propidium iodide in GFP+ tumor cells by flow cytometry.  
 
5.15 Lymphocytic choriomeningitis virus infection and T cell adoptive transfer 
10X103 CD45.2+ P14+ donor cells from the indicated mice were transferred i.v. into 
CD45.1+ congenic hosts. Mice were inoculated with 5X104 p.f.u. of LCMV Armstrong i.p.. 
Spleens were harvested and processed 7 days post- infection. 
 
5.16 L. monocytogenesgp33 bacterial infection and T cell adoptive transfer 
2X104 CD45.2+ P14+ donor cells from the indicated mice were transferred i.v. into 
CD45.1+ congenic hosts. Mice were inoculated with 6X106 c.f.u. LM-33 grown to log 
phase in TSB with 50 g/mL streptomycin. 
 
5.17 Isolation of RNA and quantitative PCR 
RNA was isolated according to the manufacturer’s instructions (QIAGEN miRNeasy), and 
genomic DNA removed using the DNA-free DNA removal kit (Ambion). mRNA- 
encoding cDNA was synthesized using the SuperScript III Reverse Transcriptase kit 
(Invitrogen), while miRNA- encoding cDNA was synthesized using the Taqman 
MicroRNA Reverse Transcription kit (Applied Biosystems). SYBR Green quantitative 
PCR was performed using the Bioline SensiFAST SYBR Lo-Rox kit and Taqman 
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quantitative PCR was performed using the Bioline SensiFAST Lo-Rox kit. Both SYBR 
Green and Taqman amplification primers (Integrated DNA Technologies, or Applied 
Biosystems) are listed in Tables 5.2 and 5.3.  
 
5.18 Generation of gp33-expressing tumor cell lines 
Retrovirus expressing the gp33 minigene with a GFP reporter was produced from the 
transfection of PlatE cells using Lipofectamine plus (Invitrogen). For retroviral 
transduction, B16 and EL-4 cells were spin-fected (2000 RPM, 90 minutes, 30°C) with 
virus and polybrene (4 μg/mL). Retrovirally transduced cells were obtained by sorting on 
the GFP+ population. To select for tumor cells which grow in syngeneic hosts, 0.5X106 
sorted gp33-expressing cells were injected into C57BL/6J mice. Solid tumors were 
homogenized, and single cells were isolated and cultured in vitro. Mouse-passaged cells 
were sorted on the GFP+ again before considering the tumor cell line established. 
 
5.19 P815 and MC57 tumor transplantation 
For P815 (ATCC; RRID:CVCL_2124) survival studies, 30X106 tumor cells were injected 
i.p. into host mice. For P815 tumor burden studies, 20X106 tumor cells were injected i.p. 
into host mice. Seven days post-injection, tumor burden was assessed by washing the 
peritoneum with cold PBS and counting the collected cells. For studies involving let-7Tg 
mice, all mice were fed with doxycycline for the duration of the study. For studies 
involving adoptive CD8 T cell transfer, 10X106 naïve CD8 T cells were injected i.v. into 
P14+Rag2-/- mice, concurrently with i.p. tumor injection. The P815 cell line was 
authenticated by analyzing H-2Kd expression via flow cytometry.  
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For MC57 tumor growth studies 1X106 cells were injected s.c. into host mice. Tumors were 
measured by caliper every other day. Once tumor sizes reached 3000 mm3, mice were 
euthanized. 
 
5.20 B16gp33 and EL-4gp33 tumor transplantation and CTL adoptive transfer 
For solid tumor studies, 0.25X106 B16gp33 or EL-4gp33 were injected s.c. into host mice that 
had been sub-lethally irradiated (300 rad) 24 hours prior. Seven days later, 1.5X106 P14 
CTLs were injected i.v. into host mice. Tumors were measured by caliper every other day. 
For survival studies, once tumor sizes reached 3000 mm3, mice were euthanized and 
considered to not have survived the study. For metastatic tumor studies, 0.2X106 B16gp33 
were injected i.v. into host mice. Two days later, 1.5X106 P14 CTLs were injected i.v. into 
host mice. Fourteen day after adoptive transfer of CTLs, tumor burden was assessed by 
lung perfusion and counting metastatic nodes. For studies involving let-7Tg CTL transfer, 
all mice were fed with doxycycline for the duration of the study. For studies involving anti-
PD-L1 antibody treatment, mice were injected i.p. with 200 g anti-PD-L1 antibodies 
(BioXCell, clone: 10F.9G2). Treatments were scheduled according to the study design. 
 
5.21 Seahorse glycolytic rate assay 
CTLs were plated in XF media and the ECAR was measured using the Seahorse XF 
glycolytic rate assay kit (Agilent; Catalog #:103344-100), on an XFe96. 
 
5.22 RNA-seq analysis 
5.22.1 Data Analysis 
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Downstream analysis was performed using a combination of programs including Bowtie2, 
Tophat2, HTseq, Cufflink and our wrapped scripts. Alignments were parsed using Tophat 
program and differential expressions were determined through DESeq2/DEGseq. GO and 
KEGG enrichment were implemented by the GOseq R package and KOBAS. Gene fusion 
and difference of alternative splicing event were detected by MISO and TopHatfusion 
software. 
 
5.22.2 Reads mapping to the reference genome 
Reference genome and gene model annotation files were downloaded from genome 
website browser (NCBI/UCSC/Ensembl) directly. Indexes of the reference genome were 
built using Bowtie v2.0.6 and paired-end clean reads were aligned to the reference genome 
using TopHat v2.0.9. Bowtie uses a BWT(Burrows-Wheeler Transformer) algorithm for 
mapping reads to the genome and Tophat can generate a database of splice junctions based 
on the gene model annotation file and thus achieve a better mapping result than other non-
splice mapping tools. 
 
5.22.3 Quantification of gene expression level 
HTSeq v0.6.1 was used to count the read numbers mapped of each gene. And then RPKM 
of each gene was calculated based on the length of the gene and reads count mapped to this 
gene. RPKM, Reads Per Kilobase of exon model per Million mapped reads, considers the 
effect of sequencing depth and gene length for the reads count at the same time, and is 
currently the most commonly used method for estimating gene expression levels 
(Mortazavi et al., 2008). 
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5.22.4 Differential expression analysis 
(For DESeq2 with biological replicates) Differential expression analysis between two 
conditions/groups (two biological replicates per condition) was performed using the 
DESeq2 R package (2_1.6.3). DESeq2 provide statistical routines for determining 
differential expression in digital gene expression data using a model based on the negative 
binomial distribution. The resulting P-values were adjusted using the Benjamini and 
Hochberg’s approach for controlling the False Discovery Rate(FDR). Genes with an 
adjusted P-value <0.05 found by DESeq2 were assigned as differentially expressed. (For 
DEGSeq without biological replicates) Prior to differential gene expression analysis, for 
each sequenced library, the read counts were adjusted by edgeR program package through 
one scaling normalized factor. Differential expression analysis of two conditions was 
performed using the DEGSeq R package (1.12.0). The P values were adjusted using the 
Benjamini & Hochberg method. Corrected P-value of 0.005 and log2(Fold change) of 1 
were set as the threshold for significantly differential expression. 
 
5.22.5 Correlations 
To allow for log adjustment, genes with 0 RPKM are assigned a value of 0.001. Correlation 
were determined using the cor.test function in R with options set alternative =”greater” and 
method = “Spearman”. 
 
5.22.6 Clustering 
 133 
To identify the correlation between difference, we clustered different samples using 
expression level RPKM to see the correlation using hierarchical clustering distance method 
with the function of heatmap, SOM(Self-organization mapping) and kmeans using 
silhouette coefficient to adapt the optimal classification with default parameter in R. 
 
5.23 Statistical analysis 
P-values were determined using a two-tailed Student’s t-test, or one-tailed Student’s t-test 
where indicated. 
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Table 5.1: Antibodies used for flow cytometry 
 
 
  
Target protein Clone Company
CD8a 53-6.7 eBioscience
5H10 Invitrogen
CD8b YTS156.7.7 BioLegend
CD4 RM4-5 BioLegend
BrdU 3D4 BioLegend
CD44 IM7 BD Pharmingen
CD25 PC61 BioLegend
PC61.5 eBiosceince
CD122 TM-b1 BioLegend
Granzyme A 3G8.5 BioLegend
Granzyme B GB11 BioLegend
IFN-g XMG1.2 eBioScience
Eomes Dan11mag eBioScience
Ki67 SolA15 eBioScience
Tbet O4-46 BD Pharmingen
PE-Streptavadin BioLegend
APC-Streptavadin BioLegend
CD45.1 A20 BD Pharmingen
CD45.2 104 BD Pharmingen
KLRG1 2F1 BD Pharmingen
TNF-a MP6-XT22 BD Pharmingen
CD62L MEL-14 BioLegend
CD127 A7R34 BioLegend
TIM-3 RMT3-23 BioLegend
PD-1 29F.A12 BioLegend
CD160 CNX46-3 eBioscience
2B4 m2B4 BioLegend
IL-10 JES5-16E3 eBioscience
GFP FM264G BioLegend
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Table 5.2: Taqman primers used for qRT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
IDT Taq Assay
Eomes Mm.PT.58. 32833544
Tbx21 Mm.PT.58. 5261453
Gzma Mm.PT.58. 43238753
Gmzb Mm.PT.58. 42155916
Ifng Mm.PT.58. 30096391
Prf1 Mm.PT.58. 41904164
Rpl13a Mm.PT.58. 43547045.g
AB Taqman Assay
Hes1 Mm01342805_m1
Hey1 Mm00468865_m1
Heyl Mm00516558_m1
Dtx1 Mm00492297_m1
Ldha Mm01612132_g1
Yars Mm00460301_m1
let-7a 377
let-7b 378
let-7c 379
let-7d 2283
let-7e 2406
let-7f 382
let-7g 2282
let-7i 2221
U6 1973
 136 
Table 5.3: Primers used for qRT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
SYBR primers Forward Reverse
Cdc25a ACAGCAGTCTACAGAGAATGGG GATGAGGTGAAAGGTGTCTTGG
Ccnd2 GAGTGGGAACTGGTAGTGTTG CGCACAGAGCGATGAAGGT
Ccnf GTAGGCGATAGGTCATACGGA ACAATGGATCACTACCCCGTG
Cdk6 GGCGTACCCACAGAAACCATA AGGTAAGGGCCATCTGAAAACT
Glut1 CAGTTCGGCTATAACACTGGTG GCCCCCGACAGAGAAGATG
Glut3 ATGGGGACAACGAAGGTGAC GTCTCAGGTGCATTGATGACTC
Gpd2 GAAGGGGACTATTCTTGTGGGT GGATGTCAAATTCGGGTGTGT
Pfk1 GGAGGCGAGAACATCAAGCC CGGCCTTCCCTCGTAGTGA
Hk2 TGATCGCCTGCTTATTCACGG AACCGCCTAGAAATCTCCAGA
Tpi CCAGGAAGTTCTTCGTTGGGG CAAAGTCGATGTAAGCGGTGG
Pkm GCCGCCTGGACATTGACTC CCATGAGAGAAATTCAGCCGAG
Myc AGTGCTGCATGAGGAGACAC GGTTTGCCTCTTCTCCACAG
Tfap4 GGAGAAGCTAGAGCGGGAAC TTTTGCCGGGATGTAGAGAC
Zbtb32 CCCACTCCAGGATCTTTTCCC TGACTCACACAGGTTGCCAG
Prdm1 GACGGGGGTACTTCTGTTCA GGCATTCTTGGGAACTGTGT
Runx3d GCGACATGCCTTCCAACAGC CTTAGCGCGCCGCTGTTCTCGC
Id3 CTGTCGGAACGTAGCCTGG GTGGTTCATGTCGTCCAAGAG
Tcf7 NA NA
Ccr7 NA NA
Sell TACATTGCCCAAAAGCCCTTAT CATCGTTCCATTTCCCAGAGTC
Bcl2 CACCCCTGGCATCTTCTCCTTC CATCTCCCTGTTGACGCTCTCC
Id2 ATGAAAGCCTTCAGTCCGGTG AGCAGACTCATCGGGTCGT
Ikzf2 CCGTACCTGGTCATCACAGAG CAGTCTCGAAGCTCGATGGC
Havcr2 TCAGGTCTTACCCTCAACTGTG GGCATTCTTACCAACCTCAAACA
Pdcd1 ACCCTGGTCATTCACTTGGG CATTTGCTCCCTCTGACACTG
Cd160 GGGGCTAATACTCTTCTGGTGC CTTTTCAGTGATGCCATCTGTCT
Cd244 AGCCCTGGACTAATGGGACTT GCTGGCGTCAATCTGGTTCT
Il10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG
Wnt10b GAAGGGTAGTGGTGAGCAAGA GGTTACAGCCACCCCATTCC
Cd127 GGATGGAGACCTAGAAGATG GAGTTAGGCATTTCACTCGT
Arid3a GCTTGGGACATCCGTCCTC CAAATGCCTATCTCCCTCAGC
Nupr1 CCCTTCCCAGCAACCTCTAAA TCTTGGTCCGACCTTTCCGA
Hmga1 GGTCGGGAGTCAGAAAGAGC ATTCTTGCTTCCCTTTGGTCG
Tnfrsf9 CCTTGCAGGTCCTTACCTTGT GTTGCTTGAATATGTGGGGGA
Tnfrsf4 ATGTCATCCGTGTGAGACTGG CCACTTCGATGGTTGCACTGT
RPL13a CGAGGCATGCTGCCCCACAA AGCAGGGACCACCATCCGCT
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